Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors

Information

  • Patent Application
  • 20180360041
  • Publication Number
    20180360041
  • Date Filed
    August 24, 2018
    6 years ago
  • Date Published
    December 20, 2018
    6 years ago
Abstract
The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.
Description
DESCRIPTION

The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.


Qo inhibitor fungicides, often referred to as strobilurin-type fungicides (Sauter 2007: Chapter 13.2. Strobilurins and other complex III inhibitors. In: Krämer, W.; Schirmer, U. (Ed.)—Modern Crop Protection Compounds. Volume 2. Wiley-VCH Verlag 457-495), are conventionally used to control a number of fungal pathogens in crops. Qo inhibitors typically work by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex (electron transport complex III) in mitochondria. Said oxidation center is located on the outer side of the inner mitochrondrial membrane. A prime example of the use of Qo inhibitors includes the use of, for example, strobilurins on wheat for the control of Septoria tritici (also known as Mycosphaerella graminicola), which is the cause of wheat leaf blotch. Unfortunately, widespread use of such Qo inhibitors has resulted in the selection of mutant pathogens which are resistant to such Qo inhibitors (Gisi et al., Pest Manag Sci 56, 833-841, (2000). Resistance to Qo inhibitors has been detected in several phytopathogenic fungi such as Blumeria graminis, Mycosphaerella fijiensis, Pseudoperonspora cubensis or Venturia inaequalis. Although several resistance mechanisms have been detected meanwhile (e.g. Jabs et al. Phytomedizin 31, 15-16 (2001); Olaya et al., Pestic Sci 54, 230-236 (1998), the major part of resistance to Qo inhibitors in agricultural uses has been attributed to pathogens containing a single amino acid residue substitution G143A in the cytochrome b gene for their cytochrome bc1 complex, the target protein of Qo inhibitors. See, for example, Lucas, Pestic Outlook 14(6), 268-70 (2003); and Fraaije et al., Phytopathol 95(8), 933-41 (2005), (which both are expressly incorporated by reference herein). Thus, new methods and compositions are desirable for controlling pathogen induced diseases in crops comprising plants subjected to pathogens that are resistant to Qo inhibitors. Furthermore, in many cases, in particular at low application rates, the fungicidal activity of the known fungicidal strobilurin analogue compounds is unsatisfactory, especially in case that a high proportion of the fungal pathogens contain a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors. Based on this, it was also an object of the present invention to provide compounds having improved activity and/or a broader activity spectrum against phytopathogenic harmful fungi.


“Qo inhibitor,” as used herein, includes any substance that is capable of diminishing and/or inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. The oxidation center is typically located on the outer side of the inner mitochrondrial membrane.


From WO 2009/155095, the use of a Qi inhibitor UK2A of formula




embedded image


is known for combating phytopathogenic fungi that are resistant to Qo inhibitors. Qi inhibitors typically work by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bcl complex in mitochondria, the said oxidation center being located on the inner side of the inner mitochrondrial membrane.


The strobilurin-analogue compounds according to the present invention differ from those described in the abovemention publication by the specific formula I and by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bcl complex in mitochondria which defines them as Qo inhibitors. Besides the strobilurin analogue-specific structural elements R4, these compounds contain two specific carbon atoms bound by a double bond wherein the groups R1 and R2 are cis-oriented or the R1 and R2 together with the abovementioned two carbon atoms linking them form a phenyl ring if R4 is 4-methyl-1,4-dihydro-tetrazol-5-on-1-yl.


BRIEF DESCRIPTION OF THE INVENTION

Accordingly, the present invention relates to the use of compounds of formula I




embedded image


wherein:

  • R1, R2 independently of each other are hydrogen, halogen, C1-C4-alkyl, C1-C4-alkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-cycloalkyl-C1-C4-alkyl, wherein the groups R1 and R2 are cis-oriented, or
    • R1 and R2 together with the two carbon atoms linking them form a phenyl ring provided
    • that R4 is 4-methyl-1,4-dihydro-tetrazol-5-one-1-yl (formula R4-7), and
      • wherein the aliphatic moieties of R1 and/or R2 or the abovementioned phenyl ring may carry 1, 2, 3 or up to the maximum number of identical or different groups Ra which independently of one another are selected from:
    • Ra halogen, CN, nitro, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl and C1-C4-haloalkoxy;
  • Y is a direct bond or a divalent group selected from —OCH2—, —CH2—, —CH2CH2—, —C(Z)═N—O—CH2—, —CHZ—C(Z)═N—O—CH2—, —O—N═C(Z)—C(Z)═N—O—CH2—, —C(═O)—C(Z)═N—O—CH2— and —C(═N—O—Z)—C(Z)═N—O—CH2—,
    • where the bond depicted on the left side of the divalent group Y is attached to R3, and the bond depicted on the right side is attached to the carbon atom being substituted by R2, and
    • Z, which may be the same or different to any other Z, is hydrogen, C1-C4-alkyl or C1-C4-haloalkyl;
  • R3 is phenyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl wherein the ring member atoms of the heterocyclyl include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S;
    • wherein the cyclic groups R3 may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb which independently of one another are selected from:
    • Rb, which may be the same or different to any other Rb, is amino, halogen, hydroxyl, oxo, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C2-C6-alkenyloxy, C3-C6-alkynyloxy, C1-C6-alkoxyimino-C1-C4alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of N, O and S as ring members; and wherein the aforementioned phenyl and heterocyclyl groups Rb are attached via a direct bond, an oxygen or sulfur atom, and
    • two radicals Rb that are bound to adjacent ring member atoms of the cyclic group R3 may form together with said ring member atoms a fused 5-, 6- or 7-membered saturated, partially unsaturated or aromatic cycle, which may be a carbocycle or heterocycle, wherein the ring member atoms of the heterocycle include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S,
    • and
    • where the aliphatic or cyclic groups Rb for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rc:
    • Rc, which may be the same or different to any other Rc, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C6-alkoxyimino-, C2-C6-alkenyloxyimino-, C2-C6-alkynyloxyimino-, C2-C6-haloalkenyloxyimino-, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, phenyl or a 5-membered saturated, partially unsaturated or aromatic heterocyclyl which, in addition to carbon atoms, contains one to three heteroatoms from the group consisting of N, O and S as ring members; wherein the aforementioned cyclic groups Rc are attached via a direct bond, an oxygen or sulfur atom, and where the aliphatic or cyclic groups Rc for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rd:
    • Rd, which may be the same or different to any other Rd, is halogen, C1-C4-alkyl or C1-C4-haloalkyl;
    • or


      R3 is —CRA═N—O—RB, wherein
    • RA is amino, hydroxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C2-C6-alkenyloxy, C3-C6-alkynyloxy, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, phenyl-C1-C4-alkyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members; and wherein the aforementioned cyclic RA are attached via a direct bond, an oxygen or sulfur atom;
    • RB is C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C4-alkoxycarbonyl, phenyl, phenyl-C1-C4-alkyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members;
      • where the aliphatic or cyclic groups RA and/or RB for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Re:
      • Re, which may be the same or different to any other Re, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;


        R4 is a monovalent group selected from formulae R4-1 to R4-7




embedded image




    • wherein the jagged line defines the point of attachment, and

    • X is a direct bond or a divalent group CH2, 0 or NH,

    • R5 is C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl, C1-C4-haloalkoxy or C3-C6-cycloalkyl,

    • R6 is C1-C4-alkyl or C1-C4-haloalkyl;


      and the N-oxides and the agriculturally acceptable salts thereof, for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors.





Furthermore, the present invention also relates to methods for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors using the abovementioned compounds of formula I.


Certain strobilurin type compounds of formula I, wherein R4 is 1-methoxycarbonyl-2-methoxy-ethen-1-yl (defined as R4-2 herein, wherein X is O) and R1 is CF3, are mentioned in WO 1998/021174: (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(4-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (CAS No. 207852-99-1); (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (207853-00-7); (E)-2-[1-methoxy-meth-(E)-ylidene]-4-methyl-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester; and (E)-5,5,5-trifluoro-2-[1-methoxy-meth-(E)-ylidene]-3-methyl-4-(4-phenoxy-phenoxymethyl)-pent-3-enoic acid methyl ester. However, it is not mentioned that the strobilurine type compounds inhibit fungal pathogens containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors. II


Further, preparation of the compound (2E,3Z)-2-(ethylidene)-5-phenyl-3-pentenoic acid methyl ester (CAS-No. 681026-20-0) has been described in J Organomet Chem 689, 575-584 (2004).


Further, certain strobilurin type compounds, wherein R1 and R2 together with the two carbon atoms linking them form a phenyl ring and wherein R4 is 1-methyl-1,4-dihydro-tetrazole-5-one-4-yl (R4-7) are known inter alia from WO 1996/036229, WO 1999/046246 and DE 199 00 571 A1.


The compounds according to the present invention differ from those described in the abovementioned publications that R1 and R2 do not form with the two carbon atoms linking them a phenyl ring, and that (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(4-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (207852-99-1); (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (207853-00-7); (E)-2-[1-methoxy-meth-(E)-ylidene]-4-methyl-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester; (E)-5,5,5-trifluoro-2-[1-methoxy-meth-(E)-ylidene]-3-methyl-4-(4-phenoxy-phenoxymethyl)-pent-3-enoic acid methyl ester; and (2E,3Z)-2-(ethylidene)-5-phenyl-3-pentenoic acid methyl ester (CAS-No. 681026-20-0) are excluded.


Therefore, according to a second aspect, the invention provides compounds of formula I which are represented by formula I




embedded image


wherein:

  • R1, R2 independently of each other are hydrogen, halogen, C1-C4-alkyl, C1-C4-alkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-cycloalkyl-C1-C4-alkyl,
    • wherein the groups R1 and R2 are cis-oriented,
    • wherein the aliphatic moieties of R1 and/or R2 may carry 1, 2, 3 or up to the maximum number of identical or different groups Ra which independently of one another are selected from:
    • Ra halogen, CN, nitro, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl and C1-C4-haloalkoxy;
  • Y is a direct bond or a divalent group selected from —OCH2—, —CH2—, —CH2CH2—, —C(Z)═N—O—CH2—, —CHZ—C(Z)═N—O—CH2—, —O—N═C(Z)—C(Z)═N—O—CH2—, —C(═O)—C(Z)═N—O—CH2— and —C(═N—O—Z)—C(Z)═N—O—CH2—,
    • where the bond depicted on the left side of the divalent group Y is attached to R3, and the bond depicted on the right side is attached to the carbon atom being substituted by R2, and
    • Z, which may be the same or different to any other Z, is C1-C4-alkyl or C1-C4-haloalkyl;
  • R3 is phenyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl wherein the ring member atoms of the heterocyclyl include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S;
    • wherein the cyclic groups R3 may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb which independently of one another are selected from:
    • Rb, which may be the same or different to any other Rb, is amino, halogen, hydroxyl, oxo, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4alkoxy, C1-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C2-C6-alkenyloxy, C3-C6-alkynyloxy, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl or which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of N, O and S as ring members; and wherein the aforementioned phenyl and heterocyclyl groups Rb are attached via a direct bond, an oxygen or sulfur atom;
      • and
      • two radicals Rb that are bound to adjacent ring member atoms of the cyclic group R3 may form together with said ring member atoms a fused 5-, 6- or 7-membered saturated, partially unsaturated or aromatic cycle, which may be a carbocycle or heterocycle, wherein the ring member atoms of the fused heterocycle include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S, and where the aliphatic or cyclic groups Rb for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rc:
      • Rc, which may be the same or different to any other Rc, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C6-alkoxyimino-C1-C4-alkyl, C2-C6-alkenyloxyimino-C1-C4-alkyl, C2-C6-alkynyloxyimino-C1-C4-alkyl, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C6-alkoxyimino-, C2-C6-alkenyloxyimino-, C2-C6-alkynyloxyimino-, C2-C6-haloalkenyloxyimino-, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, phenyl or a 5-membered saturated, partially unsaturated or aromatic heterocyclyl which, in addition to carbon atoms, contains one to three heteroatoms from the group consisting of N, O and S as ring members; wherein the aforementioned cyclic groups Rc are attached via a direct bond, an oxygen or sulfur atom and where the aliphatic or cyclic groups Rc for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rd:
      • Rd, which may be the same or different to any other Rd, is halogen, C1-C4-alkyl or C1-C4-haloalkyl;
    • or


      R3 is —CRA═N—O—RB, wherein
    • RA is amino, hydroxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C2-C6-alkenyloxy, C3-C6-alkynyloxy, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, phenyl-C1-C4-alkyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members; and wherein the aforementioned cyclic RA are attached via a direct bond, an oxygen or sulfur atom;
    • RB is C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C4-alkoxycarbonyl, phenyl, phenyl-C1-C4-alkyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members;
      • where the aliphatic or cyclic groups RA and/or RB for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Re:
      • Re, which may be the same or different to any other Re, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy;


        R4 is a monovalent group selected from formulae R4-1 to R4-7




embedded image




    • wherein the jagged line defines the point of attachment, and where

    • X is a divalent group O or NH,

    • R5 is C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl, C1-C4-haloalkoxy or C3-C6-cycloalkyl,

    • R6 is C1-C4-alkyl or C1-C4-haloalkyl;


      and the N-oxides and the agriculturally acceptable salts thereof, except for (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(4-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (207852-99-1), (E)-2-[1-methoxy-meth-(E)-ylidene]-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester (207853-00-7); (E)-2-[1-methoxy-meth-(E)-ylidene]-4-methyl-5-(3-phenoxy-phenoxy)-3-trifluoromethyl-pent-3-enoic acid methyl ester, (E)-5,5,5-trifluoro-2-[1-methoxy-meth-(E)-ylidene]-3-methyl-4-(4-phenoxy-phenoxymethyl)-pent-3-enoic acid methyl ester, and


      (2E,3Z)-2-(ethylidene)-5-phenyl-3-pentenoic acid methyl ester (CAS-No. 681026-20-0).








BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1: The commercially available strobilurin analogue compound Pyraclostrobin modelled into an artificial cytochrome bc1 complex Qo-binding site displays steric clash of the phenyl ring with the 143A methyl group as indicated by arrow in the upper right part of the picture (see left picture). Compound I-6 according to the present invention does not show a steric clash (see right picture).





DETAILED DESCRIPTION OF THE INVENTION

The term “compounds I” refers to compounds of formula I. Likewise, this terminology applies to all sub-formulae, e. g. “compounds I.2” refers to compounds of formula I.2 or “compounds V” refers to compounds of formula V, etc.


The compounds I can be obtained by various routes in analogy to prior art processes known (e.g. WO 1998/021174, J Organomet Chem 689, 575-584 (2004), WO 1996/036229) and, advantageously, by the synthesis shown in the following schemes and in the experimental part of this application.


A suitable method to prepare compounds I is illustrated in scheme 1. It starts with the reduction of an acetylene compound II with a reducing agent like lithium aluminium hydride preferably in the presence of a solvent. Suitable solvents are inert against the reducing agent used and preferably selected from cyclic or aliphatic ethers like diethyl ether, tetrahydrofurane (THF), 1,4-dioxane, and methyl-tert.-butyl ether (MTBE). The reaction temperature can be between −40° C. and 100° C., preferably −20 to 60° C. After a reduced intermediate has been formed, a tin compound of formula III, wherein Alk defines a suitable alkyl residue like methyl, ethyl, n-propyl, or n-butyl and wherein L is a leaving group such as halogen, ethoxy and methoxy, in particular methoxy, is added. The resulting intermediate IV is a stable compound which can be isolated and purified with the usual methods (for example extraction and chromatography).


Compound IV is further reacted with compound V to yield the intermediate VI applying the usual methods for coupling aliphatic alcohols with hydroxyl compounds IV. The Mitsonobu reaction has proven especially useful.


Compound VI is then coupled with compound VII, wherein LG is a leaving group, preferably being halogen (except fluoro) or a sulfonyloxy group such as triflate, preferably in the presence of a suitable catalyst such as known transition metal catalysts, more preferably palladium catalysts, wherein the ligand may be trifurylphoshine, triphenyl phosphine, tritolyl phosphine or bidentate phosphine ligands. The. Copper compounds, such as CuI2 can be added to improve the reaction. A wide variety of solvents is possible here, with THF, 1,4-dioxane and amides like dimethylformamide (DMF) being preferred. The reaction temperatures can be −20 to 150° C., preferably 20 to 120° C.


The resulting compounds I, wherein Y is —OCH2— and R2 is H, can be further modified. For example, if R4 contains an ester group, VIII can be transformed into a methyl amide by reaction with methyl amine.




embedded image


Another general method to prepare compounds I is illustrated in scheme 2. The starting materials VIII are either known or can be prepared analogous to known compounds. The Wittig-Homer reaction of compounds VIII with compounds IX illustrated here (see also Tetrahedron Lett. 1988, 29, 3361) can be replaced by the Wittig reaction if this results in better yields. These reactions as well as the reaction conditions are well known. A specific problem is the E/Z-ratio in the newly formed double bond. The desired isomer is usually accompanied by some undesired isomer, which has to be removed by purification known in the art (e. g. chromatography, distillation, crystallization, etc.).




embedded image


A route to compounds I, wherein R4 is of formula R4-4, is illustrated in scheme 3. The compound X can be obtained for example from compound VI by direct reaction with iodine. The iodine in compounds X may be replaced by other suitable leaving groups, for example by bromine, chlorine or triflate. The sodium atom in the salt VII can be replaced by other suitable metal atoms, for example potassium, lithium, magnesium, calcium, etc. The coupling reaction of X and XI is performed preferably in the presence of a transition metal catalyst being preferably copper in the presence of a nitrogen containing ligand system (see e.g.: Tetrahedron Lett 2008, 49 (26), 4196-4199; Org Lett. 2004, 6 (11), 1809-1812).




embedded image


If individual compounds I cannot be obtained by the routes described above, they can be prepared by derivatization of other compounds I.


If the synthesis yields mixtures of isomers in the case of oximes, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (e. g. under the action of light, acids or bases). Such conversions may also take place after use, e. g. in the treatment of plants in the treated plant, or in the harmful fungus to be controlled.


In the definitions of the variables given above, collective terms are used which are generally representative for the substituents in question. The term “Cn-Cm” indicates the number of carbon atoms possible in each case in the substituent or substituent moiety in question.


The term “halogen” refers to fluorine, chlorine, bromine and iodine.


The term “C1-C6-alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, e.g. methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl (isobutyl), 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methyl pentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl. Likewise, the term “C1-C4-alkyl” refers to a straight-chained or branched alkyl group having 1 to 4 carbon atoms.


The term “C1-C4-haloalkyl” refers to a straight-chained or branched alkyl group having 1 to 4 carbon atoms (as defined above), wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above, for example chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 2-bromopropyl, 3-bromopropyl, 3,3,3-trifluoropropyl, 3,3,3-trichloropropyl, CH2—C2F5, CF2—C2F5, CF(CF3)2, 1-(fluoromethyl)-2-fluoroethyl, 1-(chloromethyl)-2-chloroethyl, 1-(bromomethyl)-2-bromoethyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl or nonafluorobutyl. Likewise, the term “C1-C6-haloalkyl” refers to a straight-chained or branched alkyl group having 1 to 6 carbon atoms.


The term “C1-C6-alkoxy” refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkyl group, e.g. OCH3, OCH2CH3, O(CH2)2CH3, 1-methylethoxy, O(CH2)3CH3, 1-methyl¬propoxy, 2-methylpropoxy or 1,1-dimethylethoxy, O(CH2)4CH3 or O(CH2)5CH3. Likewise, the term “C1-C4-alkoxy” refers to a straight-chain or branched alkyl group having 1 to 4 carbon atoms which is bonded via an oxygen, at any position in the alkyl group.


The term “C1-C4-haloalkoxy” refers to a C1-C4-alkoxy group as defined above, wherein some or all of the hydrogen atoms may be replaced by halogen atoms as mentioned above, for example, OCH2F, OCHF2, OCF3, OCH2Cl, OCHCl2, OCCl3, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloro¬ethoxy, 0C2F5, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoro¬propoxy, 2-chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromo¬propoxy, 3-bromopropoxy, 3,3,3-trifluoropropoxy, 3,3,3-trichloropropoxy, OCH2—C2F5, OCF2—C2F5, 1-(CH2F)-2-fluoroethoxy, 1-(CH2Cl)-2-chloroethoxy, 1-(CH2Br)-2-bromo¬ethoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy. Likewise, the term “C1-C6-haloalkoxy” refers to a C1-C6-alkoxy group as defined above, wherein some or all of the hydrogen atoms may be replaced by halogen atoms as mentioned above.


The term “C1-C4-alkoxy-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms, wherein one hydrogen atom of the alkyl radical is replaced by a C1-C4-alkoxy group. Likewise, the term “C1-C6-alkoxy-C1-C6-alkyl” refers to alkyl having 1 to 6 carbon atoms, wherein one hydrogen atom of the alkyl radical is replaced by a C1-C6-alkoxy group.


The term “C1-C4-alkylamino” refers to an amino radical carrying one C1-C4-alkyl group as substituent, e.g. methylamino, ethylamino, propylamino, 1-methylethylamino, butylamino, 1-methylpropylamino, 2-methylpropylamino, 1,1-dimethylethylamino and the like. Likewise, the term “C1-C6-alkylamino” refers to an amino radical carrying one C1-C6-alkyl group as substituent.


The term “di(C1-C4-alkyl)amino” refers to an amino radical carrying two identical or different C1-C4-alkyl groups as substituents, e. g. dimethylamino, diethylamino, di-n-propylamino, diisopropylamino, N-ethyl-N-methylamino, N-(n-propyl)-N-methylamino, N-(isopropyl)-N methylamino, N-(n-butyl)-N-methylamino, N-(2-butyl)-N methylamino, N-(isobutyl)-N-methylamino, and the like. Likewise, the term “di(C1-C6-alkyl)amino” refers to an amino radical carrying two identical or different C1-C6-alkyl groups as substituents.


The term “C1-C4-alkoxyimino” refers to a divalent imino radical (C1-C4-alkyl-O—N═) carrying one C1-C4-alkoxy group as substituent, e.g. methylimino, ethylimino, propylimino, 1-methylethylimino, butylimino, 1-methylpropylimino, 2-methylpropylimino, 1,1-dimethylethylimino and the like.


The term “C1-C6-alkoxyimino-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein two hydrogen atoms of one carbon atom of the alkyl radical are replaced by a divalent C1-C6-alkoxyimino radical (C1-C6-alkyl-O—N═) as defined above.


The term “C2-C6-alkenyloxyimino-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein two hydrogen atoms of one carbon atom of the alkyl radical are replaced by a divalent C2-C6-alkenyloxyimino radical (C2-C6-alkenyl-O—N═).


The term “C2-C6-alkynyloxyimino-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein two hydrogen atoms of one carbon atom of the alkyl radical are replaced by a divalent C2-C6-alkynyloxyimino radical (C2-C6-alkynyl-O—N═).


The term “C1-C4-alkylcarbonyl” refers to a C1-C4-alkyl radical which is attached via a carbonyl group. The term “(C1-C6-alkoxy)carbonyl” refers to a C1-C6-alkoxy radical which is attached via a carbonyl group.


The term “C1-C6-alkylaminocarbonyl” refers to a C1-C6-alkylamino radical which is attached via a carbonyl group. Likewise, the term “di(C1-C6-alkyl)aminocarbonyl” refers to a di(C1-C6)alkylamino radical which is attached via a carbonyl group.


The term “C2-C4-alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 4 carbon atoms and a double bond in any position, e.g. ethenyl, 1-propenyl, 2-propenyl (allyl), 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl. Likewise, the term “C2-C6-alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and a double bond in any position.


The term “C2-C4-alkynyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 4 carbon atoms and containing at least one triple bond, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl. Likewise, the term “C2-C6-alkynyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and at least one triple bond.


The term “C3-C6-cycloalkyl” refers to monocyclic, bicyclic, saturated hydrocarbon radicals having 3 to 6 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.


Likewise, the term “C3-C6-cycloalkenyl” refers to unsaturated hydrocarbon radicals having 3 to 6 carbon ring members and a double bond in any position, such as cyclopropenyl, cyclobutenyl, cyclopentenyl or cyclohexenyl.


The term “C3-C6-cycloalkyl-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a cycloalkyl radical having 3 to 6 carbon atoms.


The term “phenyl-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a phenyl radical.


Agriculturally acceptable salts of compounds I encompass especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, have no adverse effect on the fungicidal action of the compounds I. Suitable cations are thus in particular the ions of the alkali metals, preferably sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, of the transition metals, preferably manganese, copper, zinc and iron, and also the ammonium ion which, if desired, may carry one to four C1-C4-alkyl substituents and/or one phenyl or benzyl substituent, preferably diisopropylammonium, tetramethylammonium, tetrabutylammonium, trimethylbenzylammonium, furthermore phosphonium ions, sulfonium ions, preferably tri(C1-C4-alkyl)sulfonium, and sulfoxonium ions, preferably tri(C1-C4-alkyl)sulfoxonium. Anions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of C1-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting a compound of formula I with an acid of the corresponding anion, preferably of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.


The compounds of formula I can be present in atropisomers arising from restricted rotation about a single bond of asymmetric groups. They also form part of the subject matter of the present invention.


Depending on the substitution pattern, the compounds of formula I and their N-oxides may have one or more centers of chirality, in which case they are present as pure enantiomers or pure diastereomers or as enantiomer or diastereomer mixtures. Both, the pure enantiomers or diastereomers and their mixtures are subject matter of the present invention.


In respect of the variables, the embodiments of the intermediates correspond to the embodiments of the compounds I.


Preference is given to those compounds I and where applicable also to compounds of all sub-formulae provided herein, e. g. formulae I.1 and I.2, and to the intermediates such as compounds II, III, IV and V, wherein the substituents and variables (such as k, R1, R2, R3, R4, R5, R6, X, Y, Z, RA, RB, Ra, Rb Rc, Rd and Re) have independently of each other or more preferably in combination (any possible combination of 2 or more substituents as defined herein) the following meanings:


Preference is also given to the uses, methods, mixtures and compositions, wherein the definitions (such as phytopathogenic fungi, treatments, crops, compounds II, further active ingredients, solvents, solid carriers) have independently of each other or more preferably in combination the following meanings and even more preferably in combination (any possible combination of 2 or more definitions as provided herein) with the preferred meanings of compounds I herein:


According to one embodiment of the invention, the invention also relates to a method for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, comprising: treating the phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors with an effective amount of at least one compound I, or a composition comprising it thereof.


The term “phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors” is to be understood that at least 10% of the fungal isolates to be controlled contain a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, more preferably at least 30%, even more preferably at least 50%, and most preferably at least 75% of the fungi, in particular between 90 and 100%.


It has been observed under field conditions that populations of phytopathogenic fungi apparently consisting of non-resistant strains can readily develop resistance. The compounds can be applied under such conditions, too, in order to prevent the formation of resistance and the spread of resistant strains altogether. In this regard it is useful that they have strong activity against non-resistant phytopathogenic fungi also.


According to another embodiment, the method for combating phytopathogenic fungi, comprises: a) identifying the phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi as defined herein, and b) treating said fungi or the materials, plants, the soil or seeds with an effective amount of at least one compound I, or a composition comprising it thereof.


According to another embodiment of the invention, the invention also relates to a method for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, comprising: treating the phytopathogenic fungi whereof at least 10% contain a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors with an effective amount of at least one compound I, or a composition comprising it thereof; more preferably at least 30%, even more preferably at least 50%, and most preferably at least 75% of the fungi contain a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors.


According to one embodiment of the use and the method for combating phytopathogenic fungi, wherein the mutation in the mitochondrial cytochrome b gene of the phytopathogenic fungi is G143A.


According to another embodiment, the phytopathogenic fungi are selected from the group consisting of basidomycetes, ascomycetes, and oomycetes.


According to a further embodiment, the phytopathogenic fungi are selected from the group consisting of Alternaria alternata, Blumeria graminis, Pyricularia oryzae (also known as Magnaporthe grisea), Septoria tritici (also known as Mycosphaerella graminicola), Mycosphaerella fijiensis, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis and Plasmopara viticola, in particular Septoria tritici.


One embodiment of the invention relates to compounds I, wherein R1 is halogen, C1-C4-alkyl, C1-C4-alkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-cycloalkyl-C1-C4-alkyl, wherein the aliphatic moieties of R1 may carry 1, 2, 3 or up to the maximum number of identical or different groups Rb which independently of one another are selected from halogen, CN, nitro, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl and C1-C4-haloalkoxy; more preferably R1 is halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl or C1-C4-haloalkoxy-C1-C4-alkyl; even more preferably R1 is halogen, C1-C4-alkyl, C1-C4-chloroalkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl or C1-C4-haloalkoxy-C1-C4-alkyl; in particular C1-C4-alkyl.


According to another embodiment, if R4 is 1-methoxycarbonyl-2-methoxy-ethen-1-yl (R4-2, wherein X is O), R1 cannot be CF3.


According to a further embodiment, R2 is hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl or C1-C4-haloalkoxy-C1-C4-alkyl; more preferably R2 is hydrogen, halogen, C1-C4-alkyl, C1-C4-alkoxy, or C1-C4-alkoxy-C1-C4-alkyl; even more preferably R2 is hydrogen, C1-C4-alkyl or C1-C4-alkoxy; in particular hydrogen.


According to a further embodiment, R2 is halogen, C1-C4-alkyl, C1-C4-alkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-cycloalkyl-C1-C4-alkyl, wherein the aliphatic moieties of R2 may carry 1, 2, 3 or up to the maximum number of identical or different groups Ra which independently of one another are selected from halogen, CN, nitro, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl and C1-C4-haloalkoxy.


According to a further embodiment, Z is hydrogen or methyl, in particular methyl.


According to a further embodiment, Y is a divalent group selected from —OCH2—, —CH2—, —CH2CH2—, —C(CH3)═N—O—CH2—, —O—N═C(CH3)—C(CH3)═N—O—CH2— and —C(═N—O—CH3)—C(CH3)═NO—CH2—; preferably —OCH2—, —CH2CH2—, —C(CH3)═N—O—CH2—, —O—N═C(CH3)—C(CH3)═N—O—CH2— or —C(═N—O—CH3)—C(CH3)═N—O—CH2—, where the bond depicted on the left side of the divalent group Y is attached to R3, and the bond depicted on the right side is attached to the carbon atom being substituted by R2; in particular Y is —OCH2, which compounds are of formula I.1:




embedded image


According to a further embodiment, Y is —CH2—, which compounds are of formula I.2:




embedded image


According to a further embodiment, Y is —CH2CH2—, which compounds are of formula I.3:




embedded image


According to a further embodiment, Y is —C(CH3)═N—O—CH2—, which compounds are of formula I.4:




embedded image


According to a further embodiment, Y is —O—N═C(CH3)—C(CH3)═N—O—CH2—, which compounds are of formula I.5:




embedded image


According to a further embodiment, Y is —C(═N—O—CH3)—C(CH3)═N—O—CH2—, which compounds are of formula I.6:




embedded image


Particularly preferred embodiments of the invention relate to compounds I, wherein the group Y is one of the following radicals Y-1 to Y-10, where the bond depicted on the left side of the divalent group Y is attached to R3, and the bond depicted on the right side is attached to the carbon atom being substituted by R2:
















No.
Y









Y-1
—OCH2



Y-2
—CH2



Y-3
—CH2CH2



Y-4
—C(CH3)═N—O—CH2



Y-5
—O—N═C(CH3)—C(CH3)═N—O—CH2



Y-6
—C(═N—O—CH3)—C(CH3)═N—O—CH2



Y-7
—CH2—C(CH3)═N—O—CH2



Y-8
—C(═O)—C(CH3)═N—O—CH2



Y-9
—CH2OCH2



Y-10
—CH═N—O—CH2










Particularly preferred embodiments of the invention relate to compounds I, wherein the group Y is —OCH2—.


According to a further embodiment, R3 is phenyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl wherein the ring member atoms of the heterocyclyl include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S, wherein R3 may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb as defined herein; more preferably said 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl is a 5- to 6-membered heteroaryl wherein the ring member atoms of the heteroaryl include besides carbon atoms 1, 2 or 3 heteroatoms selected from the group of N, O and S.


According to a further embodiment, R3 is phenyl, wherein the phenyl may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb as defined herein.


According to a further embodiment, R3 is a 5-membered-heteroaryl, wherein the ring member atoms of the heterocyclyl include besides carbon atoms 1, 2 or 3 heteroatoms selected from the group of N, O and S, wherein the heteroaryl may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb as defined herein; more preferably said heteroaryl is pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl or 1,2,4-thiadiazolyl.


According to a further embodiment, R3 is pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl or 1,2,4-thiadiazolyl, which is substituted by phenyl, wherein said phenyl may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rc, which may be the same or different to any other Rc, wherein Rc is halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkoxyimino-C1-C4-alkyl, phenyl or a 5-membered saturated, partially unsaturated or aromatic heterocyclyl which, in addition to carbon atoms, contains one to three heteroatoms from the group consisting of N, O and S as ring members; and wherein the aforementioned heterocyclyl groups Rc are attached via a direct bond, an oxygen or sulfur atom and for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rd as defined herein.


According to a further embodiment, R3 is a 6-membered-heteroaryl, wherein the ring member atoms of the heterocyclyl include besides carbon atoms 1, 2 or 3 heteroatoms selected from the group of N, O and S, wherein the heteroaryl may carry 1, 2, 3, 4 or up to the maximum possible number of identical or different groups Rb as defined herein; more preferably said heteroaryl is pyridinyl or pyrimidinyl.


According to a further embodiment, R3 carries 1, 2 or 3 identical or different groups Rb.


According to a further embodiment, Rb independently of one another are selected from carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members; and wherein the aforementioned phenyl and heterocyclyl groups Rb are attached via a direct bond, an oxygen or sulfur atom.


According to a further embodiment, the aliphatic or cyclic groups Rb for their part carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rc, which, may be the same or different to any other Rc, selected from halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy and C1-C4-haloalkoxy; more preferably Rb for their part carry 1, 2 or 3 identical or different groups Rc.


According to a further embodiment, Rc, which, may be the same or different to any other Rc, is halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxyimino-C1-C4-alkyl, phenyl or a 5-membered saturated, partially unsaturated or aromatic heterocyclyl which, in addition to carbon atoms, contains one to three heteroatoms from the group consisting of N, O and S as ring members; wherein the aforementioned cyclic groups Rc are attached via a direct bond, an oxygen or sulfur atom and for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rd as defined herein.


According to a further embodiment, two radicals Rb that are bound to adjacent ring member atoms of the cyclic group R3 form together with said ring member atoms a fused 5-, 6- or 7-membered saturated, partially unsaturated or aromatic cycle, which may be a carbocycle or heterocycle, wherein the ring member atoms of the fused heterocycle include besides carbon atoms 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S.


According to a further embodiment, R3 is —CRA═N—O—RB, wherein RA is amino, hydroxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C2-C6-alkenyloxy, C3-C6-alkynyloxy, C1-C4-alkoxyimino-C1-C4-alkyl, C1-C4-alkylamino, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyloxy, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members; and wherein the aforementioned phenyl and heterocyclyl groups RA are attached via a direct bond, an oxygen or sulfur atom, where the aliphatic or cyclic groups RA may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Re, which may be the same or different to any other Re, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy.


According to a further embodiment, R3 is —CRA═N—O—RB, wherein RB is hydroxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C1-C4-alkoxyimino-C1-C4-alkylC1-C4-alkoxycarbonyl, phenyl, naphthyl or a 3- to 10-membered saturated, partially unsaturated or aromatic mono- or bicyclic heterocyclyl which, in addition to carbon atoms, contains one to four heteroatoms from the group consisting of O, N and S as ring members, where the aliphatic or cyclic groups RB may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Re, which may be the same or different to any other Re, is halogen, hydroxyl, nitro, CN, carboxyl, C1-C4-alkyl, C2-C4-alkenyl, C2-C8-alkynyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy.


More preferably RA and RB, independently of each other, are C1-C4-alkyl which may carry 1, 2, 3 or up to the maximum possible number of identical or different halogen; in particular RA and RB are methyl.


According to a further embodiment, the aliphatic or cyclic groups RA and/or RB for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Re, more preferably they carry 0, 1 or 3 identical or different groups Re.


According to a further embodiment, Re, which may be the same or different to any other Re, is halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy.


According to a further embodiment, R4 is —C(═NOCH3)—CONHCH3, —C(═NOCH3)—COOCH3, —C(═CHOCH3)—COOCH3, —C(═CHOCH3)—CONHCH3, —N(OCH3)—COOCH3, —N(CH3)—COOCH3 or —N(CH2CH3)—COOCH3


According to a further embodiment, R4 is R4-1 as defined herein, wherein X is O.


According to a further embodiment, R4 is R4-1 as defined herein, wherein X is NH.


According to a further embodiment, R4 is R4-2 as defined herein, wherein X is O.


According to a further embodiment, R4 is R4-2 as defined herein, wherein X is NH.


According to a further embodiment, R4 is R4-3 as defined herein, wherein X is O.


According to a further embodiment, R4 is R4-3 as defined herein, wherein X is NH.


According to a further embodiment, R4 is R4-4 as defined herein, wherein X is O.


According to a further embodiment, R4 is R4-4 as defined herein, wherein X is NH.


According to a further embodiment, R5 is C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy, more preferably C1-C2-alkyl or C1-C2-alkoxy, even more preferably methyl, ethyl or methoxy.


According to a further embodiment, R4 is R4-4 as defined herein, wherein X is O and wherein R5 is methyl, ethyl or methoxy.


According to a further embodiment, R4 is R4-5 as defined herein, wherein X is O.


According to a further embodiment, R4 is R4-5 as defined herein, wherein X is NH.


According to a further embodiment, R4 is R4-6 as defined herein.


According to a further embodiment, R4 is R4-7 as defined herein.


Further embodiments of the invention relate to compounds I, wherein the group R3 is one of the following radicals R3-A to R3-B, wherein # indicates the point of attachment to the linker moiety Y:
















Line
R3









R3-A


embedded image









R3-B


embedded image












Particularly preferred embodiments of the invention relate to compounds I, wherein the group R3 is one of the following radicals R3-1 to R3-195, wherein # indicates the point of attachment to the linker moiety Y:










TABLE A





Line
R3







R3-1


embedded image







R3-2


embedded image







R3-3


embedded image







R3-4


embedded image







R3-5


embedded image







R3-6


embedded image







R3-7


embedded image







R3-8


embedded image







R3-9


embedded image







R3-10


embedded image







R3-11


embedded image







R3-12


embedded image







R3-13


embedded image







R3-14


embedded image







R3-15


embedded image







R3-16


embedded image







R3-17


embedded image







R3-18


embedded image







R3-19


embedded image







R3-20


embedded image







R3-21


embedded image







R3-22


embedded image







R3-23


embedded image







R3-24


embedded image







R3-25


embedded image







R3-26


embedded image







R3-27


embedded image







R3-28


embedded image







R3-29


embedded image







R3-30


embedded image







R3-31


embedded image







R3-32


embedded image







R3-33


embedded image







R3-34


embedded image







R3-35


embedded image







R3-36


embedded image







R3-37


embedded image







R3-38


embedded image







R3-39


embedded image







R3-40


embedded image







R3-41


embedded image







R3-42


embedded image







R3-43


embedded image







R3-44


embedded image







R3-45


embedded image







R3-46


embedded image







R3-47


embedded image







R3-48


embedded image







R3-49


embedded image







R3-50


embedded image







R3-51


embedded image







R3-52


embedded image







R3-53


embedded image







R3-54


embedded image







R3-55


embedded image







R3-56


embedded image







R3-57


embedded image







R3-58


embedded image







R3-59


embedded image







R3-60


embedded image







R3-61


embedded image







R3-62


embedded image







R3-63


embedded image







R3-64


embedded image







R3-65


embedded image







R3-66


embedded image







R3-67


embedded image







R3-68


embedded image







R3-69


embedded image







R3-70


embedded image







R3-71


embedded image







R3-72


embedded image







R3-73


embedded image







R3-74


embedded image







R3-75


embedded image







R3-76


embedded image







R3-77


embedded image







R3-78


embedded image







R3-79


embedded image







R3-80


embedded image







R3-81


embedded image







R3-82


embedded image







R3-83


embedded image







R3-84


embedded image







R3-85


embedded image







R3-86


embedded image







R3-87


embedded image







R3-88


embedded image







R3-89


embedded image







R3-90


embedded image







R3-91


embedded image







R3-92


embedded image







R3-93


embedded image







R3-94


embedded image







R3-95


embedded image







R3-96


embedded image







R3-97


embedded image







R3-98


embedded image







R3-99


embedded image







R3-100


embedded image







R3-101


embedded image







R3-102


embedded image







R3-103


embedded image







R3-104


embedded image







R3-105


embedded image







R3-106


embedded image







R3-107


embedded image







R3-108


embedded image







R3-109


embedded image







R3-110


embedded image







R3-111


embedded image







R3-112


embedded image







R3-113


embedded image







R3-114


embedded image







R3-115


embedded image







R3-116


embedded image







R3-117


embedded image







R3-118


embedded image







R3-119


embedded image







R3-120


embedded image







R3-121


embedded image







R3-122


embedded image







R3-123


embedded image







R3-124


embedded image







R3-125


embedded image







R3-126


embedded image







R3-127


embedded image







R3-128


embedded image







R3-129


embedded image







R3-130


embedded image







R3-131


embedded image







R3-132


embedded image







R3-133


embedded image







R3-134


embedded image







R3-135


embedded image







R3-136


embedded image







R3-137


embedded image







R3-138


embedded image







R3-139


embedded image







R3-140


embedded image







R3-141


embedded image







R3-142


embedded image







R3-143


embedded image







R3-144


embedded image







R3-145


embedded image







R3-146


embedded image







R3-147


embedded image







R3-148


embedded image







R3-149


embedded image







R3-150


embedded image







R3-151


embedded image







R3-152


embedded image







R3-153


embedded image







R3-154


embedded image







R3-155


embedded image







R3-156


embedded image







R3-157


embedded image







R3-158


embedded image







R3-159


embedded image







R3-160


embedded image







R3-161


embedded image







R3-162


embedded image







R3-163


embedded image







R3-164


embedded image







R3-165


embedded image







R3-166


embedded image







R3-167


embedded image







R3-168


embedded image







R3-169


embedded image







R3-170


embedded image







R3-171


embedded image







R3-172


embedded image







R3-173


embedded image







R3-174


embedded image







R3-175


embedded image







R3-176


embedded image







R3-177


embedded image







R3-178


embedded image







R3-179


embedded image







R3-180


embedded image







R3-181


embedded image







R3-182


embedded image







R3-183


embedded image







R3-184


embedded image







R3-185


embedded image







R3-186


embedded image







R3-187


embedded image







R3-188


embedded image







R3-189


embedded image







R3-190


embedded image







R3-191


embedded image







R3-192


embedded image







R3-193


embedded image







R3-194


embedded image







R3-195


embedded image












wherein # indicates the point of attachment to the linker moiety Y.


Preferred embodiments of the invention relate to compounds I, wherein the group R3 is R3-A, in particular R3-1 (1-(4-chlorophenyl)-pyrazol-3-yl).


The compounds I and the compositions according to the invention, respectively, are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.


The compounds I and the compositions according to the invention are particularly important in the control of a multitude of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruits or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; energy and raw material plants, such as corn, soybean, rape, sugar cane or oil palm; corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e. g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.


Preferably, compounds I and compositions thereof, respectively are used for controlling a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamentals; or vegetables, such as cucumbers, tomatoes, beans or squashes.


The term “plant propagation material” is to be understood to denote all the generative parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g. potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil. These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.


Preferably, treatment of plant propagation materials with compounds I and compositions thereof, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton and soybeans.


The term “cultivated plants” is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech products on the market or in development (cf. cf. http://cera-gmc.org/, see GM crop database therein). Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant. Such genetic modifications also include but are not limited to targeted posttranslational modification of protein(s), oligo- or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties.


The compounds I and compositions thereof, respectively, are particularly suitable for controlling the following plant diseases:



Albugo spp. (white rust) on ornamentals, vegetables (e. g. A. candida) and sunflowers (e. g. A. tragopogonis); Alternaria spp. (Alternaria leaf spot) on vegetables, rape (A. brassicola or brassicae), sugar beets (A. tenuis), fruits, rice, soybeans, potatoes (e. g. A. solani or A. alternata), tomatoes (e. g. A. solani or A. alternata) and wheat; Aphanomyces spp. on sugar beets and vegetables; Ascochyta spp. on cereals and vegetables, e. g. A. tritici(anthracnose) on wheat and A. hordei on barley; Bipolaris and Drechslera spp. (teleomorph: Cochliobolus spp.), e. g. Southern leaf blight (D. maydis) or Northern leaf blight (B. zeicola) on corn, e. g. spot blotch (B. sorokiniana) on cereals and e.g. B. oryzae on rice and turfs; Blumeria (formerly Elysiphe) graminis (powdery mildew) on cereals (e. g. on wheat or barley); Botrytis cinerea (teleomorph: Botryotinia fuckeliana: grey mold) on fruits and berries (e. g. strawberries), vegetables (e. g. lettuce, carrots, celery and cabbages), rape, flowers, vines, forestry plants and wheat; Bremia lactucae (downy mildew) on lettuce; Ceratocystis (syn. Ophiostoma) spp. (rot or wilt) on broad-leaved trees and evergreens, e. g. C. ulmi (Dutch elm disease) on elms; Cercospora spp. (Cercospora leaf spots) on corn (e.g. Gray leaf spot: C. zeae-maydis), rice, sugar beets (e. g. C. beticola), sugar cane, vegetables, coffee, soybeans (e. g. C. sojina or C. kikuchii) and rice; Cladosporium spp. on tomatoes (e. g. C. fulvum: leaf mold) and cereals, e. g. C. herbarum (black ear) on wheat; Claviceps purpurea (ergot) on cereals; Cochliobolus (anamorph: Helminthosporium of Bipolaris) spp. (leaf spots) on corn (C. carbonum), cereals (e. g. C. sativus, anamorph: B. sorokiniana) and rice (e. g. C. miyabeanus, anamorph: H. oryzae); Colletotrichum (teleomorph: Glomerella) spp. (anthracnose) on cotton (e. g. C. gossypii), corn (e. g. C. graminicola: Anthracnose stalk rot), soft fruits, potatoes (e. g. C. coccodes: black dot), beans (e. g. C. lindemuthianum) and soybeans (e. g. C. truncatum or C. gloeosporioides); Corticium spp., e. g. C. sasakii (sheath blight) on rice; Corynespora cassiicola (leaf spots) on soybeans and ornamentals; Cycloconium spp., e. g. C. oleaginum on olive trees; Cylindrocarpon spp. (e. g. fruit tree canker or young vine decline, teleomorph: Nectria or Neonectria spp.) on fruit trees, vines (e. g. C. liriodendri, teleomorph: Neonectria liriodendri: Black Foot Disease) and ornamentals; Dematophora (teleomorph: Rosellinia) necatrix (root and stem rot) on soybeans; Diaporthe spp., e. g. D. phaseolorum (damping off) on soybeans; Drechslera (syn. Helminthosporium, teleomorph: Pyrenophora) spp. on corn, cereals, such as barley (e. g. D. teres, net blotch) and wheat (e. g. D. tritici-repentis: tan spot), rice and turf; Esca (dieback, apoplexy) on vines, caused by Formitiporia (syn. Phellinus) punctata, F. mediterranea, Phaeomoniella chlamydospora (earlier Phaeoacremonium chlamydosporum), Phaeoacremonium aleophilum and/or Botryosphaeria obtusa; Elsinoe spp. on pome fruits (E. pyri), soft fruits (E. veneta: anthracnose) and vines (E. ampelina: anthracnose); Entyloma oryzae (leaf smut) on rice; Epicoccum spp. (black mold) on wheat; Erysiphe spp. (powdery mildew) on sugar beets (E. betae), vegetables (e. g. E. pisi), such as cucurbits (e. g. E. cichoracearum), cabbages, rape (e. g. E. cruciferarum); Eutypa lata (Eutypa canker or dieback, anamorph: Cytosporina lata, syn. Libertella blepharis) on fruit trees, vines and ornamental woods; Exserohilum (syn. Helminthosporium) spp. on corn (e. g. E. turcicum); Fusarium (teleomorph: Gibberella) spp. (wilt, root or stem rot) on various plants, such as F. graminearum or F. culmorum (root rot, scab or head blight) on cereals (e. g. wheat or barley), F. oxysporum on tomatoes, F. solani on soybeans and F. verticillioides on corn; Gaeumannomyces graminis (take-all) on cereals (e. g. wheat or barley) and corn; Gibberella spp. on cereals (e. g. G. zeae) and rice (e. g. G. fujikuroi: Bakanae disease); Glomerella cingulata on vines, pome fruits and other plants and G. gossypii on cotton; Grainstaining complex on rice; Guignardia bewellii (black rot) on vines; Gymnosporangium spp. on rosaceous plants and junipers, e. g. G. sabinae (rust) on pears; Helminthosporium spp. (syn. Drechslera, teleomorph: Cochliobolus) on corn, cereals and rice; Hemileia spp., e. g. H. vastatrix (coffee leaf rust) on coffee; Isariopsis clavispora (syn. Cladosporium vitis) on vines; Macrophomina phaseolina (syn. phaseoli) (root and stem rot) on soybeans and cotton; Microdochium (syn. Fusarium) nivale (pink snow mold) on cereals (e. g. wheat or barley); Microsphaera diffusa (powdery mildew) on soybeans; Monilinia spp., e. g. M. laxa, M. fructicola and M. fructigena (bloom and twig blight, brown rot) on stone fruits and other rosaceous plants; Mycosphaerella spp. on cereals, bananas, soft fruits and ground nuts, such as e. g. M. graminicola (anamorph: Septoria tritici, Septoria blotch) on wheat or M. fijiensis (black Sigatoka disease) on bananas; Peronospora spp. (downy mildew) on cabbage (e. g. P. brassicae), rape (e. g. P. parasitica), onions (e. g. P. destructor), tobacco (P. tabacina) and soybeans (e. g. P. manshurica); Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans; Phialophora spp. e. g. on vines (e. g. P. tracheiphila and P. tetraspora) and soybeans (e. g. P. gregata: stem rot); Phoma lingam (root and stem rot) on rape and cabbage and P. betae (root rot, leaf spot and damping-off) on sugar beets; Phomopsis spp. on sunflowers, vines (e. g. P. viticola: can and leaf spot) and soybeans (e. g. stem rot: P. phaseoli, teleomorph: Diaporthe phaseolorum); Physoderma maydis (brown spots) on corn; Phytophthora spp. (wilt, root, leaf, fruit and stem root) on various plants, such as paprika and cucurbits (e. g. P. capsici), soybeans (e. g. P. megasperma, syn. P. sojae), potatoes and tomatoes (e. g. P. infestans: late blight) and broad-leaved trees (e. g. P. ramorum: sudden oak death); Plasmodiophora brassicae (club root) on cabbage, rape, radish and other plants; Plasmopara spp., e. g. P. viticola (grapevine downy mildew) on vines and P. halstedii on sunflowers; Podosphaera spp. (powdery mildew) on rosaceous plants, hop, pome and soft fruits, e. g. P. leucotricha on apples; Polymyxa spp., e. g. on cereals, such as barley and wheat (P. graminis) and sugar beets (P. betae) and thereby transmitted viral diseases; Pseudocercosporella herpotrichoides (eyespot, teleomorph: Tapesia yallundae) on cereals, e. g. wheat or barley; Pseudoperonospora (downy mildew) on various plants, e. g. P. cubensis on cucurbits or P. humili on hop; Pseudopezicula tracheiphila (red fire disease or ‘rotbrenner’, anamorph: Phialophora) on vines; Puccinia spp. (rusts) on various plants, e. g. P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. hordei (dwarf rust), P. graminis (stem or black rust) or P. recondita (brown or leaf rust) on cereals, such as e. g. wheat, barley or rye, P. kuehnii (orange rust) on sugar cane and P. asparagi on asparagus; Pyrenophora (anamorph: Drechslera) tritici-repentis (tan spot) on wheat or P. teres (net blotch) on barley; Pyricularia spp., e. g. P. oryzae (teleomorph: Magnaporthe grisea, rice blast) on rice and P. grisea on turf and cereals; Pythium spp. (damping-off) on turf, rice, corn, wheat, cotton, rape, sunflowers, soybeans, sugar beets, vegetables and various other plants (e. g. P. ultimum or P. aphanidermatum); Ramularia spp., e. g. R. collo-cygni (Ramularia leaf spots, Physiological leaf spots) on barley and R. beticola on sugar beets; Rhizoctonia spp. on cotton, rice, potatoes, turf, corn, rape, potatoes, sugar beets, vegetables and various other plants, e. g. R. solani (root and stem rot) on soybeans, R. solani (sheath blight) on rice or R. cerealis (Rhizoctonia spring blight) on wheat or barley; Rhizopus stolonifer (black mold, soft rot) on strawberries, carrots, cabbage, vines and tomatoes; Rhynchosporium secalis (scald) on barley, rye and triticale; Sarocladium oryzae and S. attenuatum (sheath rot) on rice; Sclerotinia spp. (stem rot or white mold) on vegetables and field crops, such as rape, sunflowers (e. g. S. sclerotiorum) and soybeans (e. g. S. rolfsii or S. sclerotiorum); Septoria spp. on various plants, e. g. S. glycines (brown spot) on soybeans, S. tritici(Septoria blotch) on wheat and S. (syn. Stagonospora) nodorum (Stagonospora blotch) on cereals; Uncinula (syn. Erysiphe) necator (powdery mildew, anamorph: Oidium tuckeri) on vines; Setospaeria spp. (leaf blight) on corn (e. g. S. turcicum, syn. Helminthosporium turcicum) and turf; Sphacelotheca spp. (smut) on corn, (e. g. S. reiliana: head smut), sorghum and sugar cane; Sphaerotheca fuliginea (powdery mildew) on cucurbits; Spongospora subterranea (powdery scab) on potatoes and thereby transmitted viral diseases; Stagonospora spp. on cereals, e. g. S. nodorum (Stagonospora blotch, teleomorph: Leptosphaeria [syn. Phaeosphaeria] nodorum) on wheat; Synchytrium endobioticum on potatoes (potato wart disease); Taphrina spp., e. g. T. deformans (leaf curl disease) on peaches and T. pruni (plum pocket) on plums; Thielaviopsis spp. (black root rot) on tobacco, pome fruits, vegetables, soybeans and cotton, e. g. T. basicola (syn. Chalara elegans); Tilletia spp. (common bunt or stinking smut) on cereals, such as e. g. T. tritici (syn. T. caries, wheat bunt) and T. controversa (dwarf bunt) on wheat; Typhula incarnata (grey snow mold) on barley or wheat; Urocystis spp., e. g. U. occulta (stem smut) on rye; Uromyces spp. (rust) on vegetables, such as beans (e. g. U. appendiculatus, syn. U. phaseoli) and sugar beets (e. g. U. betae); Ustilago spp. (loose smut) on cereals (e. g. U. nuda and U. avaenae), corn (e. g. U. maydis: corn smut) and sugar cane; Venturia spp. (scab) on apples (e. g. V. inaequalis) and pears; and Verticillium spp. (wilt) on various plants, such as fruits and ornamentals, vines, soft fruits, vegetables and field crops, e. g. V. dahliae on strawberries, rape, potatoes and tomatoes.


The compounds I and compositions thereof, respectively, may be used for improving the health of a plant. The invention also relates to a method for improving plant health by treating a plant, its propagation material and/or the locus where the plant is growing or is to grow with an effective amount of compounds I and compositions thereof, respectively.


The term “plant health” is to be understood to denote a condition of the plant and/or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased biomass and/or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and/or greener leaves (“greening effect”)), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and/or biotic stress. The above identified indicators for the health condition of a plant may be interdependent or may result from each other.


The compounds of formula I can be present in different crystal modifications whose biological activity may differ. They are likewise subject matter of the present invention.


The compounds I are employed as such or in form of compositions by treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms by the fungi.


Plant propagation materials may be treated with compounds I as such or a composition comprising at least one compound I prophylactically either at or before planting or transplanting.


The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I according to the invention.


An agrochemical composition comprises a fungicidally effective amount of a compound I. The term “effective amount” denotes an amount of the composition or of the compounds I, which is sufficient for controlling harmful fungi on cultivated plants or in the protection of materials and which does not result in a substantial damage to the treated plants. Such an amount can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated cultivated plant or material, the climatic conditions and the specific compound I used.


The compounds I, their N-oxides and salts can be converted into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. CS, ZC), pastes, pastilles, wettable powders or dusts (e.g. WP, SP, WS, DP, DS), pressings (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG, GG, MG), insecticidal articles (e.g. LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e.g. GF). These and further compositions types are defined in the “Catalogue of pesticide formulation types and international coding system”, Technical Monograph No. 2, 6th Ed. May 2008, CropLife International.


The compositions are prepared in a known manner, such as described by Mollet and Grubemann, Formulation technology, Wiley VCH, Weinheim, 2001; or Knowles, New developments in crop protection product formulation, Agrow Reports DS243, T&F Informa, London, 2005.


Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.


Suitable solvents and liquid carriers are water and organic solvents, such as mineral oil fractions of medium to high boiling point, e.g. kerosene, diesel oil; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, e. g. toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, e.g. ethanol, propanol, butanol, benzylalcohol, cyclohexanol; glycols; DMSO; ketones, e.g. cyclohexanone; esters, e.g. lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, e.g. N-methylpyrrolidone, fatty acid dimethylamides; and mixtures thereof.


Suitable solid carriers or fillers are mineral earths, e.g. silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, e.g. cellulose, starch; fertilizers, e.g. ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; products of vegetable origin, e.g. cereal meal, tree bark meal, wood meal, nutshell meal, and mixtures thereof.


Suitable surfactants are surface-active compounds, such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Examples of surfactants are listed in McCutcheon's, Vol. 1: Emulsifiers & Detergents, McCutcheon's Directories, Glen Rock, USA, 2008 (International Ed. or North American Ed.).


Suitable anionic surfactants are alkali, alkaline earth or ammonium salts of sulfonates, sulfates, phosphates, carboxylates, and mixtures thereof. Examples of sulfonates are alkylarylsulfonates, diphenylsulfonates, alpha-olefin sulfonates, lignine sulfonates, sulfonates of fatty acids and oils, sulfonates of ethoxylated alkylphenols, sulfonates of alkoxylated arylphenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl- and tridecylbenzenes, sulfonates of naphthalenes and alkylnaphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of fatty acid esters. Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, and carboxylated alcohol or alkylphenol ethoxylates.


Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters which have been alkoxylated with 1 to 50 equivalents. Ethylene oxide and/or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar-based surfactants are sorbitans, ethoxylated sorbitans, sucrose and glucose esters or alkylpolyglucosides. Examples of polymeric surfactants are home- or copolymers of vinylpyrrolidone, vinylalcohols, or vinylacetate.


Suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkylbetains and imidazolines. Suitable block polymers are block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide, or of the A-B-C type comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are polyacids or polybases. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinylamines or polyethyleneamines.


Suitable adjuvants are compounds, which have a neglectable or even no pesticidal activity themselves, and which improve the biological performance of the compound I on the target. Examples are surfactants, mineral or vegetable oils, and other auxiliaries. Further examples are listed by Knowles, Adjuvants and additives, Agrow Reports DS256, T&F Informa UK, 2006, chapter 5.


Suitable thickeners are polysaccharides (e.g. xanthan gum, carboxymethylcellulose), anorganic clays (organically modified or unmodified), polycarboxylates, and silicates.


Suitable bactericides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones.


Suitable anti-freezing agents are ethylene glycol, propylene glycol, urea and glycerin.


Suitable anti-foaming agents are silicones, long chain alcohols, and salts of fatty acids.


Suitable colorants (e.g. in red, blue, or green) are pigments of low water solubility and water-soluble dyes. Examples are inorganic colorants (e.g. iron oxide, titan oxide, iron hexacyanoferrate) and organic colorants (e.g. alizarin-, azo- and phthalocyanine colorants).


Suitable tackifiers or binders are polyvinylpyrrolidons, polyvinylacetates, polyvinyl alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers.


Examples for composition types and their preparation are:


i) Water-Soluble Concentrates (SL, LS)

10-60 wt % of a compound I and 5-15 wt % wetting agent (e.g. alcohol alkoxylates) are dissolved in water and/or in a water-soluble solvent (e.g. alcohols) ad 100 wt %. The active substance dissolves upon dilution with water.


ii) Dispersible Concentrates (DC)

5-25 wt % of a compound I and 1-10 wt % dispersant (e. g. polyvinylpyrrolidone) are dissolved in organic solvent (e.g. cyclohexanone) ad 100 wt %. Dilution with water gives a dispersion.


iii) Emulsifiable Concentrates (EC)


15-70 wt % of a compound I and 5-10 wt % emulsifiers (e.g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in water-insoluble organic solvent (e.g. aromatic hydrocarbon) ad 100 wt %. Dilution with water gives an emulsion.


iv) Emulsions (EW, EO, ES)

5-40 wt % of a compound I and 1-10 wt % emulsifiers (e.g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in 20-40 wt % water-insoluble organic solvent (e.g. aromatic hydrocarbon). This mixture is introduced into water ad 100 wt % by means of an emulsifying machine and made into a homogeneous emulsion. Dilution with water gives an emulsion.


v) Suspensions (SC, OD, FS)

In an agitated ball mill, 20-60 wt % of a compound I are comminuted with addition of 2-10 wt % dispersants and wetting agents (e.g. sodium lignosulfonate and alcohol ethoxylate), 0.1-2 wt % thickener (e.g. xanthan gum) and water ad 100 wt % to give a fine active substance suspension. Dilution with water gives a stable suspension of the active substance. For FS type composition up to 40 wt % binder (e.g. polyvinylalcohol) is added.


vi) Water-Dispersible Granules and Water-Soluble Granules (WG, SG)

50-80 wt % of a compound I are ground finely with addition of dispersants and wetting agents (e.g. sodium lignosulfonate and alcohol ethoxylate) ad 100 wt % and prepared as water-dispersible or water-soluble granules by means of technical appliances (e. g. extrusion, spray tower, fluidized bed). Dilution with water gives a stable dispersion or solution of the active substance.


vii) Water-Dispersible Powders and Water-Soluble Powders (WP, SP, WS)


50-80 wt % of a compound I are ground in a rotor-stator mill with addition of 1-5 wt % dispersants (e.g. sodium lignosulfonate), 1-3 wt % wetting agents (e.g. alcohol ethoxylate) and solid carrier (e.g. silica gel) ad 100 wt %. Dilution with water gives a stable dispersion or solution of the active substance.


viii) Gel (GW, GF)


In an agitated ball mill, 5-25 wt % of a compound I are comminuted with addition of 3-10 wt % dispersants (e.g. sodium lignosulfonate), 1-5 wt % thickener (e.g. carboxymethylcellulose) and water ad 100 wt % to give a fine suspension of the active substance. Dilution with water gives a stable suspension of the active substance.


iv) Microemulsion (ME)

5-20 wt % of a compound I are added to 5-30 wt % organic solvent blend (e.g. fatty acid dimethylamide and cyclohexanone), 10-25 wt % surfactant blend (e.g. alcohol ethoxylate and arylphenol ethoxylate), and water ad 100%. This mixture is stirred for 1 h to produce spontaneously a thermodynamically stable microemulsion.


iv) Microcapsules (CS)

An oil phase comprising 5-50 wt % of a compound I, 0-40 wt % water insoluble organic solvent (e.g. aromatic hydrocarbon), 2-15 wt % acrylic monomers (e.g. methylmethacrylate, methacrylic acid and a di- or triacrylate) are dispersed into an aqueous solution of a protective colloid (e.g. polyvinyl alcohol). Radical polymerization initiated by a radical initiator results in the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50 wt % of a compound I according to the invention, 0-40 wt % water insoluble organic solvent (e.g. aromatic hydrocarbon), and an isocyanate monomer (e.g. diphenylmethene-4,4′-diisocyanate) are dispersed into an aqueous solution of a protective colloid (e.g. polyvinyl alcohol). The addition of a polyamine (e.g. hexamethylenediamine) results in the formation of polyurea microcapsules. The monomers amount to 1-10 wt %. The wt % relate to the total CS composition.


ix) Dustable Powders (DP, DS)

1-10 wt % of a compound I are ground finely and mixed intimately with solid carrier (e.g. finely divided kaolin) ad 100 wt %.


x) Granules (GR, FG)

0.5-30 wt % of a compound I is ground finely and associated with solid carrier (e.g. silicate) ad 100 wt %. Granulation is achieved by extrusion, spray-drying or fluidized bed.


xi) Ultra-Low Volume Liquids (UL)

1-50 wt % of a compound I are dissolved in organic solvent (e.g. aromatic hydrocarbon) ad 100 wt %.


The compositions types i) to xi) may optionally comprise further auxiliaries, such as 0.1-1 wt % bactericides, 5-15 wt % anti-freezing agents, 0.1-1 wt % anti-foaming agents, and 0.1-1 wt % colorants.


The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, and in particular between 0.5 and 75%, by weight of active substance. The active substances are employed in a purity of from 90% to 100%, preferably from 95% to 100% (according to NMR spectrum).


Solutions for seed treatment (LS), Suspoemulsions (SE), flowable concentrates (FS), powders for dry treatment (DS), water-dispersible powders for slurry treatment (WS), water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC) and gels (GF) are usually employed for the purposes of treatment of plant propagation materials, particularly seeds. The compositions in question give, after two-to-tenfold dilution, active substance concentrations of from 0.01 to 60% by weight, preferably from 0.1 to 40%, in the ready-to-use preparations. Application can be carried out before or during sowing. Methods for applying compound I and compositions thereof, respectively, on to plant propagation material, especially seeds include dressing, coating, pelleting, dusting, soaking and in-furrow application methods of the propagation material. Preferably, compound I or the compositions thereof, respectively, are applied on to the plant propagation material by a method such that germination is not induced, e. g. by seed dressing, pelleting, coating and dusting.


When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 0.9 kg per ha, and in particular from 0.1 to 0.75 kg per ha.


In treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching seed, amounts of active substance of from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kilogram of plant propagation material (preferably seeds) are generally required.


When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are 0.001 g to 2 kg, preferably 0.005 g to 1 kg, of active substance per cubic meter of treated material.


Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and further pesticides (e.g. herbicides, insecticides, fungicides, growth regulators, safeners) may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1.


The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area.


According to one embodiment, individual components of the composition according to the invention such as parts of a kit or parts of a binary or ternary mixture may be mixed by the user himself in a spray tank and further auxiliaries may be added, if appropriate.


Mixing the compounds I or the compositions comprising them in the use form as fungicides with other fungicides results in many cases in an expansion of the fungicidal spectrum of activity being obtained or in a prevention of fungicide resistance development. Furthermore, in many cases, synergistic effects are obtained.


The following list of active substances, in conjunction with which the compounds I can be used, is intended to illustrate the possible combinations but does not limit them:

  • A) Respiration inhibitors
    • Inhibitors of complex III at Qo site (e.g. strobilurins): azoxystrobin, coumethoxystrobin, coumoxystrobin, dimoxystrobin, enestroburin, fenaminstrobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, trifloxystrobin, 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneaminooxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, fenamidone;
    • inhibitors of complex III at Qi site: cyazofamid, amisulbrom, [(3S,6S,7R,8R)-8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[(3-isobutoxycarbonyloxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-benzodioxol-5-ylmethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate; (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate
    • inhibitors of complex II (e. g. carboxamides): benodanil, benzovindiflupyr, bixafen, boscalid, carboxin, fenfuram, fluopyram, flutolanil, fluxapyroxad, furametpyr, isopyrazam, mepronil, oxycarboxin, penflufen, penthiopyrad, sedaxane, tecloftalam, thifluzamide, N-(4′-trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(2-(1,3,3-trimethyl-butyl)-phenyl)-1,3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(difluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide;
    • other respiration inhibitors (e.g. complex I, uncouplers): diflumetorim, (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluoromethylpyridin-2-yloxy)-phenyl]-ethyl}-amine; nitrophenyl derivates: binapacryl, dinobuton, dinocap, fluazinam; ferimzone; organometal compounds: fentin salts, such as fentin-acetate, fentin chloride or fentin hydroxide; ametoctradin; and silthiofam;
  • B) Sterol biosynthesis inhibitors (SBI fungicides)
    • C14 demethylase inhibitors (DMI fungicides): triazoles: azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, diniconazole-M, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, 1-[rel-(2S;3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-oxiranylmethyl]-5-thiocyanato-1H-[1,2,4]triazole, 2-[rel-(2S;3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiranylmethyl]-2H-[1,2,4]triazole-3-thiol; imidazoles: imazalil, pefurazoate, prochloraz, triflumizol; pyrimidines, pyridines and piperazines: fenarimol, nuarimol, pyrifenox, triforine;
    • Delta14-reductase inhibitors: aldimorph, dodemorph, dodemorph-acetate, fenpropimorph, tridemorph, fenpropidin, piperalin, spiroxamine;
    • Inhibitors of 3-keto reductase: fenhexamid;
  • C) Nucleic acid synthesis inhibitors
    • phenylamides or acyl amino acid fungicides: benalaxyl, benalaxyl-M, kiralaxyl, metalaxyl, metalaxyl-M (mefenoxam), ofurace, oxadixyl;
    • others: hymexazole, octhilinone, oxolinic acid, bupirimate, 5-fluorocytosine, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine;
  • D) Inhibitors of cell division and cytoskeleton
    • tubulin inhibitors, such as benzimidazoles, thiophanates: benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate-methyl; triazolopyrimidines: 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine
    • other cell division inhibitors: diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone, pyriofenone;
  • E) Inhibitors of amino acid and protein synthesis
    • methionine synthesis inhibitors (anilino-pyrimidines): cyprodinil, mepanipyrim, pyrimethanil;
    • protein synthesis inhibitors: blasticidin-S, kasugamycin, kasugamycin hydrochloride-hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, validamycin A;
  • F) Signal transduction inhibitors
    • MAP/histidine kinase inhibitors: fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, fludioxonil;
    • G protein inhibitors: quinoxyfen;
  • G) Lipid and membrane synthesis inhibitors
    • Phospholipid biosynthesis inhibitors: edifenphos, iprobenfos, pyrazophos, isoprothiolane;
    • lipid peroxidation: dicloran, quintozene, tecnazene, tolclofos-methyl, biphenyl, chloroneb, etridiazole;
    • phospholipid biosynthesis and cell wall deposition: dimethomorph, flumorph, mandipropamid, pyrimorph, benthiavalicarb, iprovalicarb, valifenalate and N-(1-(1-(4-cyano-phenyl)ethanesulfonyl)-but-2-yl) carbamic acid-(4-fluorophenyl) ester;
    • compounds affecting cell membrane permeability and fatty acids: propamocarb, propamocarb-hydrochlorid
    • fatty acid amide hydrolase inhibitors: 1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone
  • H) Inhibitors with Multi Site Action
    • inorganic active substances: Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride, basic copper sulfate, sulfur;
    • thio- and dithiocarbamates: ferbam, mancozeb, maneb, metam, metiram, propineb, thiram, zineb, ziram;
    • organochlorine compounds (e.g. phthalimides, sulfamides, chloronitriles): anilazine, chlorothalonil, captafol, captan, folpet, dichlofluanid, dichlorophen, flusulfamide, hexachlorobenzene, pentachlorphenole and its salts, phthalide, tolylfluanid, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide;
    • guanidines and others: guanidine, dodine, dodine free base, guazatine, guazatine-acetate, iminoctadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), dithianon, 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone;
  • I) Cell wall synthesis inhibitors
    • inhibitors of glucan synthesis: validamycin, polyoxin B; melanin synthesis inhibitors: pyroquilon, tricyclazole, carpropamid, dicyclomet, fenoxanil;
  • J) Plant defence inducers
    • acibenzolar-S-methyl, probenazole, isotianil, tiadinil, prohexadione-calcium; phosphonates: fosetyl, fosetyl-aluminum, phosphorous acid and its salts;
  • K) Unknown mode of action
    • bronopol, chinomethionat, cyflufenamid, cymoxanil, dazomet, debacarb, diclomezine, difenzoquat, difenzoquat-methylsulfate, diphenylamin, fenpyrazamine, flumetover, flusulfamide, flutianil, methasulfocarb, nitrapyrin, nitrothal-isopropyl, oxathiapiprolin, oxin-copper, proquinazid, tebufloquin, tecloftalam, triazoxide, 2-butoxy-6-iodo-3-propylchromen-4-one, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, N′-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanylpropoxy)-phenyl)-N-ethyl-N-methyl formamidine, methoxy-acetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl ester, 3-[5-(4-methylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (pyrisoxazole),
    • N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxylic acid amide, 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole, 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxy-phenyl)-isoxazol-5-yl]-2-prop-2-ynyloxy-acetamide;
  • L) Antifungal biocontrol agents, plant bioactivators: Ampelomyces quisqualis (e.g. AQ 10® from Intrachem Bio GmbH & Co. KG, Germany), Aspergillus flavus (e.g. AFLAGUARD® from Syngenta, CH), Aureobasidium pullulans (e.g. BOTECTOR® from bio-ferm GmbH, Germany), Bacillus pumilus (e.g. NRRL Accession No. B-30087 in SONATA® and BALLAD® Plus from AgraQuest Inc., USA), Bacillus subtilis (e.g. isolate NRRL-Nr. B-21661 in RHAPSODY®, SERENADE® MAX and SERENADE® ASO from AgraQuest Inc., USA), Bacillus subtilis var. amyloliquefaciens FZB24 (e.g. TAEGRO® from Novozyme Biologicals, Inc., USA), Candida oleophila I-82 (e.g. ASPIRE® from Ecogen Inc., USA), Candida saitoana (e.g. BIOCURE® (in mixture with lysozyme) and BIOCOAT® from Micro Flo Company, USA (BASF SE) and Arysta), Chitosan (e.g. ARMOUR-ZEN from BotriZen Ltd., NZ), Clonostachys rosea f. catenulata, also named Gliocladium catenulatum (e.g. isolate J1446: PRESTOP® from Verdera, Finland), Coniothyrium minitans (e.g. CONTANS® from Prophyta, Germany), Cryphonectria parasitica (e.g. Endothia parasitica from CNICM, France), Cryptococcus albidus (e.g. YIELD PLUS® from Anchor Bio-Technologies, South Africa), Fusarium oxysporum (e.g. BIOFOX® from S.I.A.P.A., Italy, FUSACLEAN® from Natural Plant Protection, France), Metschnikowia fructicola (e.g. SHEMER® from Agrogreen, Israel), Microdochium dimerum (e.g. ANTIBOT® from Agrauxine, France), Phlebiopsis gigantea (e.g. ROTSOP® from Verdera, Finland), Pseudozyma flocculosa (e.g. SPORODEX® from Plant Products Co. Ltd., Canada), Pythium oligandrum DV74 (e.g. POLYVERSUM® from Remeslo SSRO, Biopreparaty, Czech Rep.), Reynoutria sachlinensis (e.g. REGALIA® from Marrone BioInnovations, USA), Talaromyces flavus V117b (e.g. PROTUS® from Prophyta, Germany), Trichoderma asperellum SKT-1 (e.g. ECO-HOPE® from Kumiai Chemical Industry Co., Ltd., Japan), T. atroviride LC52 (e.g. SENTINEL® from Agrimm Technologies Ltd, NZ), T. harzianumT-22 (e.g. PLANTSHIELD® der Firma BioWorks Inc., USA), T. harzianum TH 35 (e.g. ROOT PRO® from Mycontrol Ltd., Israel), T. harzianum T-39 (e.g. TRICHODEX® and TRICHODERMA 2000® from Mycontrol Ltd., Israel and Makhteshim Ltd., Israel), T. harzianum and T. viride (e.g. TRICHOPEL from Agrimm Technologies Ltd, NZ), T. harzianum ICC012 and T. viride ICC080 (e.g. REMEDIER® WP from Isagro Ricerca, Italy), T. polysporum and T. harzianum (e.g. BINAB® from BINAB Bio-Innovation AB, Sweden), T. stromaticum (e.g. TRICOVAB® from C.E.P.L.A.C., Brazil), T. virens GL-21 (e.g. SOILGARD® from Certis LLC, USA), T. viride (e.g. TRIECO® from Ecosense Labs. (India) Pvt. Ltd., Indien, BIO-CURE® F from T. Stanes & Co. Ltd., Indien), T. viride TV1 (e.g. T. viride TV1 from Agribiotec srl, Italy), Ulocladium oudemansii HRU3 (e.g. BOTRY-ZEN® from Botry-Zen Ltd, NZ);
  • M) Growth regulators


    abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassinolide, butralin, chlormequat (chlormequat chloride), choline chloride, cyclanilide, daminozide, dikegulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat (mepiquat chloride), naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium), prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-iodobenzoic acid, trinexapac-ethyl and uniconazole;
  • N) Herbicides
    • acetamides: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, metolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, thenylchlor;
    • amino acid derivatives: bilanafos, glyphosate, glufosinate, sulfosate;
    • aryloxyphenoxypropionates: clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, haloxyfop, metamifop, propaquizafop, quizalofop, quizalofop-P-tefuryl;
    • Bipyridyls: diquat, paraquat;
    • (thio)carbamates: asulam, butylate, carbetamide, desmedipham, dimepiperate, eptam (EPTC), esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyributicarb, thiobencarb, triallate;
    • cyclohexanediones: butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim;
    • dinitroanilines: benfluralin, ethalfluralin, oryzalin, pendimethalin, prodiamine, trifluralin;
    • diphenyl ethers: acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, oxyfluorfen;
    • hydroxybenzonitriles: bomoxynil, dichlobenil, ioxynil;
    • imidazolinones: imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr;
    • phenoxy acetic acids: clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, Mecoprop;
    • pyrazines: chloridazon, flufenpyr-ethyl, fluthiacet, norflurazon, pyridate;
    • pyridines: aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, picloram, picolinafen, thiazopyr;
    • sulfonyl ureas: amidosulfuron, azimsulfuron, bensulfuron, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metazosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, 1-((2-chloro-6-propyl-imidazo[1,2-b]pyridazin-3-yl)sulfonyl)-3-(4,6-dimethoxy-pyrimidin-2-yl)urea;
    • triazines: ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, metamitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam;
    • ureas: chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, tebuthiuron;
    • other acetolactate synthase inhibitors: bispyribac-sodium, cloransulam-methyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, penoxsulam, propoxycarbazone, pyribambenz-propyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, pyroxsulam;
    • others: amicarbazone, aminotriazole, anilofos, beflubutamid, benazolin, bencarbazone, benfluresate, benzofenap, bentazone, benzobicyclon, bicyclopyrone, bromacil, bromobutide, butafenacil, butamifos, cafenstrole, carfentrazone, cinidon-ethyl, chlorthal, cinmethylin, clomazone, cumyluron, cyprosulfamide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanid, fenoxasulfone, fentrazamide, flumiclorac-pentyl, flumioxazin, flupoxam, flurochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, quinclorac, quinmerac, mesotrione, methyl arsonic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefone, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazoxyfen, pyrazolynate, quinoclamine, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, topramezone, (3-[2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-phenoxy]-pyridin-2-yloxy)-acetic acid ethyl ester, 6-amino-5-chloro-2-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-chloro-3-(2-cyclopropyl-6-methyl-phenoxy)-pyridazin-4-ol, 4-amino-3-chloro-6-(4-chloro-phenyl)-5-fluoro-pyridine-2-carboxylic acid, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)pyridine-2-carboxylic acid methyl ester, and 4-amino-3-chloro-6-(4-chloro-3-dimethylamino-2-fluoro-phenyl)-pyridine-2-carboxylic acid methyl ester.
  • O) Insecticides
    • organo(thio)phosphates: acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phosphamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon;
    • carbamates: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, fenoxycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, triazamate;
    • pyrethroids: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin;
    • insect growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, cyramazin, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spirotetramat;
    • nicotinic receptor agonists/antagonists compounds: clothianidin, dinotefuran, flupyradifurone, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1-2-chloro-thiazol-5-ylmethyl)-2-nitrimino-3,5-dimethyl-[1,3,5]triazinane;
    • GABA antagonist compounds: endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, 5-amino-1-(2,6-dichloro-4-methyl-phenyl)-4-sulfinamoyl-1H-pyrazole-3-carbothioic acid amide;
    • macrocyclic lactone insecticides: abamectin, emamectin, milbemectin, lepimectin, spinosad, spinetoram;
    • mitochondrial electron transport inhibitor (METI) I acaricides: fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, flufenerim;
    • METI II and III compounds: acequinocyl, fluacyprim, hydramethylnon;
    • Uncouplers: chlorfenapyr;
    • oxidative phosphorylation inhibitors: cyhexatin, diafenthiuron, fenbutatin oxide, propargite;
    • moulting disruptor compounds: cryomazine;
    • mixed function oxidase inhibitors: piperonyl butoxide;
    • sodium channel blockers: indoxacarb, metaflumizone;
    • others: benclothiaz, bifenazate, cartap, flonicamid, pyridalyl, pymetrozine, sulfur, thiocyclam, flubendiamide, chlorantraniliprole, cyazypyr (HGW86), cyenopyrafen, flupyrazofos, cyflumetofen, amidoflumet, imicyafos, bistrifluron, and pyrifluquinazon.


The present invention furthermore relates to agrochemical compositions comprising a mixture of at least one compound I (component 1) and at least one further active substance useful for plant protection, e. g. selected from the groups A) to O) (component 2), in particular one further fungicide, e. g. one or more fungicide from the groups A) to L), as described above, and if desired one suitable solvent or solid carrier. Those mixtures are of particular interest, since many of them at the same application rate show higher efficiencies against harmful fungi. Furthermore, combating harmful fungi with a mixture of compounds I and at least one fungicide from groups A) to L), as described above, is more efficient than combating those fungi with individual compounds I or individual fungicides from groups A) to L). By applying compounds I together with at least one active substance from groups A) to O) a synergistic effect can be obtained, i.e. more then simple addition of the individual effects is obtained (synergistic mixtures). This can be obtained by applying the compounds I and at least one further active substance simultaneously, either jointly (e. g. as tank-mix) or separately, or in succession, wherein the time interval between the individual applications is selected to ensure that the active substance applied first still occurs at the site of action in a sufficient amount at the time of application of the further active substance(s). The order of application is not essential for working of the present invention.


In binary mixtures, i.e. compositions according to the invention comprising one compound I (component 1) and one further active substance (component 2), e. g. one active substance from groups A) to O), the weight ratio of component 1 and component 2 generally depends from the properties of the active substances used, usually it is in the range of from 1:100 to 100:1, regularly in the range of from 1:50 to 50:1, preferably in the range of from 1:20 to 20:1, more preferably in the range of from 1:10 to 10:1 and in particular in the range of from 1:3 to 3:1.


In ternary mixtures, i.e. compositions according to the invention comprising one compound I (component 1) and a first further active substance (component 2) and a second further active substance (component 3), e. g. two active substances from groups A) to O), the weight ratio of component 1 and component 2 depends from the properties of the active substances used, preferably it is in the range of from 1:50 to 50:1 and particularly in the range of from 1:10 to 10:1, and the weight ratio of component 1 and component 3 preferably is in the range of from 1:50 to 50:1 and particularly in the range of from 1:10 to 10:1.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group A) (component 2) and particularly selected from azoxystrobin, dimoxystrobin, fluoxastrobin, kresoxim-methyl, orysastrobin, picoxystrobin, pyraclostrobin, trifloxystrobin; famoxadone, fenamidone; benzovindiflupyr, bixafen, boscalid, fluopyram, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane; ametoctradin, cyazofamid, fluazinam, fentin salts, such as fentin acetate.


Preference is given to mixtures comprising a compound of formula I (component 1) and at least one active substance selected from group B) (component 2) and particularly selected from cyproconazole, difenoconazole, epoxiconazole, fluquinconazole, flusilazole, flutriafol, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, prochloraz, fenarimol, triforine; dodemorph, fenpropimorph, tridemorph, fenpropidin, spiroxamine; fenhexamid.


Preference is given to mixtures comprising a compound of formula I (component 1) and at least one active substance selected from group C) (component 2) and particularly selected from metalaxyl, (metalaxyl-M) mefenoxam, ofurace.


Preference is given to mixtures comprising a compound of formula I (component 1) and at least one active substance selected from group D) (component 2) and particularly selected from benomyl, carbendazim, thiophanate-methyl, ethaboxam, fluopicolide, zoxamide, metrafenone, pyriofenone.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group E) (component 2) and particularly selected from cyprodinil, mepanipyrim, pyrimethanil.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group F) (component 2) and particularly selected from iprodione, fludioxonil, vinclozolin, quinoxyfen.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group G) (component 2) and particularly selected from dimethomorph, flumorph, iprovalicarb, benthiavalicarb, mandipropamid, propamocarb.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group H) (component 2) and particularly selected from copper acetate, copper hydroxide, copper oxychloride, copper sulfate, sulfur, mancozeb, metiram, propineb, thiram, captafol, folpet, chlorothalonil, dichlofluanid, dithianon.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group I) (component 2) and particularly selected from carpropamid and fenoxanil.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group J) (component 2) and particularly selected from acibenzolar-S-methyl, probenazole, tiadinil, fosetyl, fosetyl-aluminium, H3PO3 and salts thereof.


Preference is also given to mixtures comprising a compound I (component 1) and at least one active substance selected from group K) (component 2) and particularly selected from cymoxanil, proquinazid and N-methyl-2-{1-[(5-methyl-3-trifluoromethyl-1H-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-thiazolecarboxamide.


Preference is also given to mixtures comprising a compound 1 (component 1) and at least one active substance selected from group L) (component 2) and particularly selected from Bacillus subtilis strain NRRL No. B-21661, Bacillus pumilus strain NRRL No. B-30087 and Ulocladium oudemansii.


Accordingly, the present invention furthermore relates to compositions comprising one compound I (component 1) and one further active substance (component 2), which further active substance is selected from the column “Component 2” of the lines B-1 to B-369 of Table B.


A further embodiment relates to the compositions B-1 to B-369 listed in Table B, where a row of Table B corresponds in each case to a fungicidal composition comprising one of the in the present specification individualized compounds of formula I (component 1) and the respective further active substance from groups A) to O) (component 2) stated in the row in question. Preferably, the compositions described comprise the active substances in synergistically effective amounts.









TABLE B







Composition comprising one indiviualized compound I


and one further active substance from groups A) to O)









Mixture
Component 1
Component 2





B-1
one individualized compound I
Azoxystrobin


B-2
one individualized compound I
Coumethoxystrobin


B-3
one individualized compound I
Coumoxystrobin


B-4
one individualized compound I
Dimoxystrobin


B-5
one individualized compound I
Enestroburin


B-6
one individualized compound I
Fenaminstrobin


B-7
one individualized compound I
Fenoxystrobin/Flufenoxystrobin


B-8
one individualized compound I
Fluoxastrobin


B-9
one individualized compound I
Kresoxim-methyl


B-10
one individualized compound I
Metominostrobin


B-11
one individualized compound I
Orysastrobin


B-12
one individualized compound I
Picoxystrobin


B-13
one individualized compound I
Pyraclostrobin


B-14
one individualized compound I
Pyrametostrobin


B-15
one individualized compound I
Pyraoxystrobin


B-16
one individualized compound I
Pyribencarb


B-17
one individualized compound I
Trifloxystrobin


B-18
one individualized compound I
Triclopyricarb/Chlorodincarb


B-19
one individualized compound I
2-[2-(2,5-dimethyl-phenoxy-methyl)-




phenyl]-3-methoxy-acrylic acid methyl




ester


B-20
one individualized compound I
2-(2-(3-(2,6-dichlorophenyl)-1-methyl-




allylideneaminooxymethyl)-phenyl)-




2-methoxyimino-N-methyl-acetamide


B-21
one individualized compound I
Benalaxyl


B-22
one individualized compound I
Benalaxyl-M


B-23
one individualized compound I
Benodanil


B-24
one individualized compound I
Benzovindiflupyr


B-25
one individualized compound I
Bixafen


B-26
one individualized compound I
Boscalid


B-27
one individualized compound I
Carboxin


B-28
one individualized compound I
Fenfuram


B-29
one individualized compound I
Fenhexamid


B-30
one individualized compound I
Flutolanil


B-31
one individualized compound I
Fluxapyroxad


B-32
one individualized compound I
Furametpyr


B-33
one individualized compound I
Isopyrazam


B-34
one individualized compound I
Isotianil


B-35
one individualized compound I
Kiralaxyl


B-36
one individualized compound I
Mepronil


B-37
one individualized compound I
Metalaxyl


B-38
one individualized compound I
Metalaxyl-M


B-39
one individualized compound I
Ofurace


B-40
one individualized compound I
Oxadixyl


B-41
one individualized compound I
Oxycarboxin


B-42
one individualized compound I
Penflufen


B-43
one individualized compound I
Penthiopyrad


B-44
one individualized compound I
Sedaxane


B-45
one individualized compound I
Tecloftalam


B-46
one individualized compound I
Thifluzamide


B-47
one individualized compound I
Tiadinil


B-48
one individualized compound I
2-Amino-4-methyl-thiazole-5-carboxylic




acid anilide


B-49
one individualized compound I
N-(4′-trifluoromethylthiobiphenyl-2-yl)-




3-difluoromethyl-1-methyl-1H-pyrazole-




4-carboxamide


B-50
one individualized compound I
N-(2-(1,3,3-trimethyl-butyl)-phenyl)-




1,3-dimethyl-5-fluoro-1H-pyrazole-




4-carboxamide


B-51
one individualized compound I
3-(difluoromethyl)-1-methyl-N-(1,1,3-tri-




methylindan-4-yl)pyrazole-4-carboxamide


B-52
one individualized compound I
3-(trifluoromethyl)-1-methyl-N-(1,1,3-tri-




methylindan-4-yl)pyrazole-4-carboxamide


B-53
one individualized compound I
1,3-dimethyl-N-(1,1,3-trimethylindan-




4-yl)pyrazole-4-carboxamide


B-54
one individualized compound I
3-(trifluoromethyl)-1,5-dimethyl-




N-(1,1,3-trimethylindan-4-yl)pyrazole-




4-carboxamide


B-55
one individualized compound I
3-(difluoromethyl)-1,5-dimethyl-




N-(1,1,3-trimethylindan-4-yl)pyrazole-




4-carboxamide


B-56
one individualized compound I
1,3,5-trimethyl-N-(1,1,3-trimethylindan-




4-yl)pyrazole-4-carboxamide


B-57
one individualized compound I
Dimethomorph


B-58
one individualized compound I
Flumorph


B-59
one individualized compound I
Pyrimorph


B-60
one individualized compound I
Flumetover


B-61
one individualized compound I
Fluopicolide


B-62
one individualized compound I
Fluopyram


B-63
one individualized compound I
Zoxamide


B-64
one individualized compound I
Carpropamid


B-65
one individualized compound I
Diclocymet


B-66
one individualized compound I
Mandipropamid


B-67
one individualized compound I
Oxytetracyclin


B-68
one individualized compound I
Silthiofam


B-69
one individualized compound I
N-(6-methoxy-pyridin-3-yl) cyclopro-




panecarboxylic acid amide


B-70
one individualized compound I
Azaconazole


B-71
one individualized compound I
Bitertanol


B-72
one individualized compound I
Bromuconazole


B-73
one individualized compound I
Cyproconazole


B-74
one individualized compound I
Difenoconazole


B-75
one individualized compound I
Diniconazole


B-76
one individualized compound I
Diniconazole-M


B-77
one individualized compound I
Epoxiconazole


B-78
one individualized compound I
Fenbuconazole


B-79
one individualized compound I
Fluquinconazole


B-80
one individualized compound I
Flusilazole


B-81
one individualized compound I
Flutriafol


B-82
one individualized compound I
Hexaconazol


B-83
one individualized compound I
Imibenconazole


B-84
one individualized compound I
Ipconazole


B-85
one individualized compound I
Metconazole


B-86
one individualized compound I
Myclobutanil


B-87
one individualized compound I
Oxpoconazol


B-88
one individualized compound I
Paclobutrazol


B-89
one individualized compound I
Penconazole


B-90
one individualized compound I
Propiconazole


B-91
one individualized compound I
Prothioconazole


B-92
one individualized compound I
Simeconazole


B-93
one individualized compound I
Tebuconazole


B-94
one individualized compound I
Tetraconazole


B-95
one individualized compound I
Triadimefon


B-96
one individualized compound I
Triadimenol


B-97
one individualized compound I
Triticonazole


B-98
one individualized compound I
Uniconazole


B-99
one individualized compound I
1-[rel-A(2S;3R)-3-(2-chlorophenyl)-




2-(2,4-difluorophenyl)-oxiranylmethyl]-




5-thiocyanato-1H-[1,2,4]triazole,


B-100
one individualized compound I
2-[rel-(2S;3R)-3-(2-chlorophenyl)-




2-(2,4-difluorophenyl)-oxiranylmethyl]-




2H-[1,2,4]triazole-3-thiol


B-101
one individualized compound I
Cyazofamid


B-102
one individualized compound I
Amisulbrom


B-103
one individualized compound I
Imazalil


B-104
one individualized compound I
Imazalil-sulfate


B-105
one individualized compound I
Pefurazoate


B-106
one individualized compound I
Prochloraz


B-107
one individualized compound I
Triflumizole


B-108
one individualized compound I
Benomyl


B-109
one individualized compound I
Carbendazim


B-110
one individualized compound I
Fuberidazole


B-111
one individualized compound I
Thiabendazole


B-112
one individualized compound I
Ethaboxam


B-113
one individualized compound I
Etridiazole


B-114
one individualized compound I
Hymexazole


B-115
one individualized compound I
2-(4-Chloro-phenyl)-N-[4-(3,4-dimethoxy-




phenyl)-isoxazol-5-yl]-2-prop-2-yn-




yloxy-acetamide


B-116
one individualized compound I
Fluazinam


B-117
one individualized compound I
Pyrifenox


B-118
one individualized compound I
3-[5-(4-Chloro-phenyl)-2,3-dimethyl-is-




oxazolidin-3-yl]-pyridine (Pyrisoxazole)


B-119
one individualized compound I
3-[5-(4-Methyl-phenyl)-2,3-dimethyl-




isoxazolidin-3-yl]-pyridine


B-120
one individualized compound I
Bupirimate


B-121
one individualized compound I
Cyprodinil


B-122
one individualized compound I
5-Fluorocytosine


B-123
one individualized compound I
5-Fluoro-2-(p-tolylmethoxy)pyrimidin-




4-amine


B-124
one individualized compound I
5-Fluoro-2-(4-fluorophenylmethoxy)py-




rimidin-4-amine


B-125
one individualized compound I
Diflumetorim


B-126
one individualized compound I
(5,8-Difluoroquinazolin-4-yl)-{2-[2-fluoro-




4-(4-trifluoromethyl-pyridin-2-yloxy)-




phenyl]-ethyl}-amine


B-127
one individualized compound I
Fenarimol


B-128
one individualized compound I
Ferimzone


B-129
one individualized compound I
Mepanipyrim


B-130
one individualized compound I
Nitrapyrin


B-131
one individualized compound I
Nuarimol


B-132
one individualized compound I
Pyrimethanil


B-133
one individualized compound I
Triforine


B-134
one individualized compound I
Fenpiclonil


B-135
one individualized compound I
Fludioxonil


B-136
one individualized compound I
Aldimorph


B-137
one individualized compound I
Dodemorph


B-138
one individualized compound I
Dodemorph-acetate


B-139
one individualized compound I
Fenpropimorph


B-140
one individualized compound I
Tridemorph


B-141
one individualized compound I
Fenpropidin


B-142
one individualized compound I
Fluoroimid


B-143
one individualized compound I
Iprodione


B-144
one individualized compound I
Procymidone


B-145
one individualized compound I
Vinclozolin


B-146
one individualized compound I
Famoxadone


B-147
one individualized compound I
Fenamidone


B-148
one individualized compound I
Flutianil


B-149
one individualized compound I
Octhilinone


B-150
one individualized compound I
Probenazole


B-151
one individualized compound I
Fenpyrazamine


B-152
one individualized compound I
Acibenzolar-S-methyl


B-153
one individualized compound I
Ametoctradin


B-154
one individualized compound I
Amisulbrom


B-155
one individualized compound I
[(3S,6S,7R,8R)-8-benzyl-3-[(3-iso-




butyryloxymethoxy-4-methoxypyridine-2-




carbonyl)amino]-6-methyl-4,9-dioxo-




[1,5]dioxonan-7-yl] 2-methylpropanoate


B-156
one individualized compound I
[(3S,6S,7R,8R)-8-benzyl-3-[(3-acetoxy-




4-methoxy-pyridine-2-carbonyl)amino]-




6-methyl-4,9-dioxo-1,5-dioxonan-7-yl]




2-methylpropanoate


B-157
one individualized compound I
[(3S,6S,7R,8R)-8-benzyl-3-[[3-




(acetoxymethoxy)-4-methoxy-pyridine-2-




carbonyl]amino]-6-methyl-4,9-dioxo-1,5-




dioxonan-7-yl] 2-methylpropanoate


B-158
one individualized compound I
[(3S,6S,7R,8R)-8-benzyl-3-[(3-iso-




butoxycarbonyloxy-4-methoxy-pyridine-




2-carbonyl)amino]-6-methyl-4,9-dioxo-




1,5-dioxonan-7-yl] 2-methylpropanoate


B-159
one individualized compound I
[(3S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-




benzodioxol-5-ylmethoxy)-4-methoxy-pyridine-




2-carbonyl]amino]-6-methyl-4,9-dioxo-




1,5-dioxonan-7-yl] 2-methylpropanoate


B-160
one individualized compound I
(3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-




2-pyridinyl)carbonyl]amino]-6-methyl-




4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl




2-methylpropanoate


B-161
one individualized compound I
Anilazin


B-162
one individualized compound I
Blasticidin-S


B-163
one individualized compound I
Captafol


B-164
one individualized compound I
Captan


B-165
one individualized compound I
Chinomethionat


B-166
one individualized compound I
Dazomet


B-167
one individualized compound I
Debacarb


B-168
one individualized compound I
Diclomezine


B-169
one individualized compound I
Difenzoquat,


B-170
one individualized compound I
Difenzoquat-methylsulfate


B-171
one individualized compound I
Fenoxanil


B-172
one individualized compound I
Folpet


B-173
one individualized compound I
Oxolinsäure


B-174
one individualized compound I
Piperalin


B-175
one individualized compound I
Proquinazid


B-176
one individualized compound I
Pyroquilon


B-177
one individualized compound I
Quinoxyfen


B-178
one individualized compound I
Triazoxid


B-179
one individualized compound I
Tricyclazole


B-180
one individualized compound I
2-Butoxy-6-iodo-3-propyl-chromen-4-one


B-181
one individualized compound I
5-Chloro-1-(4,6-dimethoxy-pyrimidin-2-




yl)-2-methyl-1H-benzoimidazole


B-182
one individualized compound I
5-Chloro-7-(4-methyl-piperidin-1-yl)-




6-(2,4,6-trifluoro-phenyl)-[1,2,4]tria-




zolo[1,5-a]pyrimidine


B-183
one individualized compound I
Ferbam


B-184
one individualized compound I
Mancozeb


B-185
one individualized compound I
Maneb


B-186
one individualized compound I
Metam


B-187
one individualized compound I
Methasulphocarb


B-188
one individualized compound I
Metiram


B-189
one individualized compound I
Propineb


B-190
one individualized compound I
Thiram


B-191
one individualized compound I
Zineb


B-192
one individualized compound I
Ziram


B-193
one individualized compound I
Diethofencarb


B-194
one individualized compound I
Benthiavalicarb


B-195
one individualized compound I
Iprovalicarb


B-196
one individualized compound I
Propamocarb


B-197
one individualized compound I
Propamocarb hydrochlorid


B-198
one individualized compound I
Valifenalate


B-199
one individualized compound I
N-(1-(1-(4-cyanophenyl)ethanesulfon-




yl)-but-2-yl) carbamic acid-(4-fluorophenyl)




ester


B-200
one individualized compound I
Dodine


B-201
one individualized compound I
Dodine free base


B-202
one individualized compound I
Guazatine


B-203
one individualized compound I
Guazatine-acetate


B-204
one individualized compound I
Iminoctadine


B-205
one individualized compound I
Iminoctadine-triacetate


B-206
one individualized compound I
Iminoctadine-tris(albesilate)


B-207
one individualized compound I
Kasugamycin


B-208
one individualized compound I
Kasugamycin-hydrochloride-hydrate


B-209
one individualized compound I
Polyoxine


B-210
one individualized compound I
Streptomycin


B-211
one individualized compound I
Validamycin A


B-212
one individualized compound I
Binapacryl


B-213
one individualized compound I
Dicloran


B-214
one individualized compound I
Dinobuton


B-215
one individualized compound I
Dinocap


B-216
one individualized compound I
Nitrothal-isopropyl


B-217
one individualized compound I
Tecnazen


B-218
one individualized compound I
Fentin salts


B-219
one individualized compound I
Dithianon


B-220
one individualized compound I
2,6-dimethyl-1H,5H-[1,4]dithiino




[2,3-c:5,6-c′]dipyrrole-




1,3,5,7(2H,6H)-tetraone


B-221
one individualized compound I
Isoprothiolane


B-222
one individualized compound I
Edifenphos


B-223
one individualized compound I
Fosetyl, Fosetyl-aluminium


B-224
one individualized compound I
Iprobenfos


B-225
one individualized compound I
Phosphorous acid (H3PO3) and derivatives


B-226
one individualized compound I
Pyrazophos


B-227
one individualized compound I
Tolclofos-methyl


B-228
one individualized compound I
Chlorothalonil


B-229
one individualized compound I
Dichlofluanid


B-230
one individualized compound I
Dichlorophen


B-231
one individualized compound I
Flusulfamide


B-232
one individualized compound I
Hexachlorbenzene


B-233
one individualized compound I
Pencycuron


B-234
one individualized compound I
Pentachlorophenol and salts


B-235
one individualized compound I
Phthalide


B-236
one individualized compound I
Quintozene


B-237
one individualized compound I
Thiophanate Methyl


B-238
one individualized compound I
Tolylfluanid


B-239
one individualized compound I
N-(4-chloro-2-nitro-phenyl)-N-ethyl-




4-methyl-benzenesulfonamide


B-240
one individualized compound I
Bordeaux mixture


B-241
one individualized compound I
Copper acetate


B-242
one individualized compound I
Copper hydroxide


B-243
one individualized compound I
Copper oxychloride


B-244
one individualized compound I
basic Copper sulfate


B-245
one individualized compound I
Sulfur


B-246
one individualized compound I
Biphenyl


B-247
one individualized compound I
Bronopol


B-248
one individualized compound I
Cyflufenamid


B-249
one individualized compound I
Cymoxanil


B-250
one individualized compound I
Diphenylamin


B-251
one individualized compound I
Metrafenone


B-252
one individualized compound I
Pyriofenone


B-253
one individualized compound I
Mildiomycin


B-254
one individualized compound I
Oxin-copper


B-255
one individualized compound I
Oxathiapiprolin


B-256
one individualized compound I
Prohexadione calcium


B-257
one individualized compound I
Spiroxamine


B-258
one individualized compound I
Tebufloquin


B-259
one individualized compound I
Tolylfluanid


B-260
one individualized compound I
N-(Cyclopropylmethoxyimino-(6-difluoro-




methoxy-2,3-difluoro-phenyl)-methyl)-




2-phenyl acetamide


B-261
one individualized compound I
N′-(4-(4-chloro-3-trifluoromethyl-




phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-




methyl formamidine


B-262
one individualized compound I
N′-(4-(4-fluoro-3-trifluoromethyl-




phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-




methyl formamidine


B-263
one individualized compound I
N′-(2-methyl-5-trifluoromethyl-4-(3-tri-




methylsilanyl-propoxy)-phenyl)-N-ethyl-




N-methyl formamidine


B-264
one individualized compound I
N'-(5-difluoromethyl-2-methyl-4-(3-tri-




methylsilanyl-propoxy)-phenyl)-N-ethyl-




N-methyl formamidine


B-265
one individualized compound I
Methoxy-acetic acid 6-tert-butyl-8-




fluoro-2,3-dimethyl-quinolin-4-yl ester


B-266
one individualized compound I

Bacillus subtilis NRRL No. B-21661



B-267
one individualized compound I

Bacillus pumilus NRRL No. B-30087



B-268
one individualized compound I

Ulocladium oudemansii



B-269
one individualized compound I
Carbaryl


B-270
one individualized compound I
Carbofuran


B-271
one individualized compound I
Carbosulfan


B-272
one individualized compound I
Methomylthiodicarb


B-273
one individualized compound I
Bifenthrin


B-274
one individualized compound I
Cyfluthrin


B-275
one individualized compound I
Cypermethrin


B-276
one individualized compound I
alpha-Cypermethrin


B-277
one individualized compound I
zeta-Cypermethrin


B-278
one individualized compound I
Deltamethrin


B-279
one individualized compound I
Esfenvalerate


B-280
one individualized compound I
Lambda-cyhalothrin


B-281
one individualized compound I
Permethrin


B-282
one individualized compound I
Tefluthrin


B-283
one individualized compound I
Diflubenzuron


B-284
one individualized compound I
Flufenoxuron


B-285
one individualized compound I
Lufenuron


B-286
one individualized compound I
Teflubenzuron


B-287
one individualized compound I
Spirotetramate


B-288
one individualized compound I
Clothianidin


B-289
one individualized compound I
Dinotefuran


B-290
one individualized compound I
Imidacloprid


B-291
one individualized compound I
Thiamethoxam


B-292
one individualized compound I
Flupyradifurone


B-293
one individualized compound I
Acetamiprid


B-294
one individualized compound I
Thiacloprid


B-295
one individualized compound I
Endosulfan


B-296
one individualized compound I
Fipronil


B-297
one individualized compound I
Abamectin


B-298
one individualized compound I
Emamectin


B-299
one individualized compound I
Spinosad


B-300
one individualized compound I
Spinetoram


B-301
one individualized compound I
Hydramethylnon


B-302
one individualized compound I
Chlorfenapyr


B-303
one individualized compound I
Fenbutatin oxide


B-304
one individualized compound I
Indoxacarb


B-305
one individualized compound I
Metaflumizone


B-306
one individualized compound I
Flonicamid


B-307
one individualized compound I
Lubendiamide


B-308
one individualized compound I
Chlorantraniliprole


B-309
one individualized compound I
Cyazypyr (HGW86)


B-310
one individualized compound I
Cyflumetofen


B-311
one individualized compound I
Acetochlor


B-312
one individualized compound I
Dimethenamid


B-313
one individualized compound I
metolachlor


B-314
one individualized compound I
Metazachlor


B-315
one individualized compound I
Glyphosate


B-316
one individualized compound I
Glufosinate


B-317
one individualized compound I
Sulfosate


B-318
one individualized compound I
Clodinafop


B-319
one individualized compound I
Fenoxaprop


B-320
one individualized compound I
Fluazifop


B-321
one individualized compound I
Haloxyfop


B-322
one individualized compound I
Paraquat


B-323
one individualized compound I
Phenmedipham


B-324
one individualized compound I
Clethodim


B-325
one individualized compound I
Cycloxydim


B-326
one individualized compound I
Profoxydim


B-327
one individualized compound I
Sethoxydim


B-328
one individualized compound I
Tepraloxydim


B-329
one individualized compound I
Pendimethalin


B-330
one individualized compound I
Prodiamine


B-331
one individualized compound I
Trifluralin


B-332
one individualized compound I
Acifluorfen


B-333
one individualized compound I
Bromoxynil


B-334
one individualized compound I
Imazamethabenz


B-335
one individualized compound I
Imazamox


B-336
one individualized compound I
Imazapic


B-337
one individualized compound I
Imazapyr


B-338
one individualized compound I
Imazaquin


B-339
one individualized compound I
Imazethapyr


B-340
one individualized compound I
2,4-Dichlorophenoxyacetic acid (2,4-D)


B-341
one individualized compound I
Chloridazon


B-342
one individualized compound I
Clopyralid


B-343
one individualized compound I
Fluroxypyr


B-344
one individualized compound I
Picloram


B-345
one individualized compound I
Picolinafen


B-346
one individualized compound I
Bensulfuron


B-347
one individualized compound I
Chlorimuron-ethyl


B-348
one individualized compound I
Cyclosulfamuron


B-349
one individualized compound I
Iodosulfuron


B-350
one individualized compound I
Mesosulfuron


B-351
one individualized compound I
Metsulfuron-methyl


B-352
one individualized compound I
Nicosulfuron


B-353
one individualized compound I
Rimsulfuron


B-354
one individualized compound I
Triflusulfuron


B-355
one individualized compound I
Atrazine


B-356
one individualized compound I
Hexazinone


B-357
one individualized compound I
Diuron


B-358
one individualized compound I
Florasulam


B-359
one individualized compound I
Pyroxasulfone


B-360
one individualized compound I
Bentazone


B-361
one individualized compound I
Cinidon-ethyl


B-362
one individualized compound I
Cinmethylin


B-363
one individualized compound I
Dicamba


B-364
one individualized compound I
Diflufenzopyr


B-365
one individualized compound I
Quinclorac


B-366
one individualized compound I
Quinmerac


B-367
one individualized compound I
Mesotrione


B-368
one individualized compound I
Saflufenacil


B-369
one individualized compound I
Topramezone









The active substances referred to as component 2, their preparation and their activity against harmful fungi is known (cf.: http://www.alanwood.net/pesticides/); these substances are commercially available. The compounds described by IUPAC nomenclature, their preparation and their fungicidal activity are also known (cf. Can. J. Plant Sci. 48(6), 587-94, 1968; EP-A 141 317; EP-A 152 031; EP-A 226 917; EP-A 243 970; EP-A 256 503; EP-A 428 941; EP-A 532 022; EP-A 1 028 125; EP-A 1 035 122; EP-A 1 201 648; EP-A 1 122 244, JP 2002316902; DE 19650197; DE 10021412; DE 102005009458; U.S. Pat. No. 3,296,272; U.S. Pat. No. 3,325,503; WO 98/46608; WO 99/14187; WO 99/24413; WO 99/27783; WO 00/29404; WO 00/46148; WO 00/65913; WO 01/54501; WO 01/56358; WO 02/22583; WO 02/40431; WO 03/10149; WO 03/11853; WO 03/14103; WO 03/16286; WO 03/53145; WO 03/61388; WO 03/66609; WO 03/74491; WO 04/49804; WO 04/83193; WO 05/120234; WO 05/123689; WO 05/123690; WO 05/63721; WO 05/87772; WO 05/87773; WO 06/15866; WO 06/87325; WO 06/87343; WO 07/82098; WO 07/90624, WO 11/028657).


The mixtures of active substances can be prepared as compositions comprising besides the active ingredients at least one inert ingredient by usual means, e. g. by the means given for the compositions of compounds I.


Concerning usual ingredients of such compositions reference is made to the explanations given for the compositions containing compounds I.


The mixtures of active substances according to the present invention are suitable as fungicides, as are the compounds of formula I. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, especially from the classes of the Ascomycetes, Basidiomycetes, Deuteromycetes and Peronosporomycetes (syn. Oomycetes). In addition, it is referred to the explanations regarding the fungicidal activity of the compounds and the compositions containing compounds I, respectively.


I. SYNTHESIS EXAMPLES

With due modification of the starting compounds, the procedures shown in the synthesis examples below were used to obtain further compounds I. The resulting compounds, together with physical data, are listed in Table I below.


I.1 Preparation of Strobilurin Type Compounds I
Example 1: Preparation of (Z)-5-[1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy]-2-[(E)-methoxyimino]-3-methyl-pent-3-enic Acid Methyl Amide (I-6)



embedded image


Ex. 1a: (Z)-3-Tributylstannanyl-but-2-en-1-ol (3)

To 156.9 ml (156.9 mmol) of a 1 molar solution of lithium-aluminum-hydride in THF 0.77 g (14.3 mmol) sodium methylate have been added and the temperature has been lowered to 0° C. afterwards. Then a solution of 10.0 g (142.7 mmol) 2-butin-1-ol in 108 ml THF has been added dropwise with stirring at this temperature. Stirring was continued for 36 h at 4° C. Thereafter, at about 0° C., 28.6 ml (292.5 mmol) ethyl acetate was-added slowly while stirring. A strongly exothermic reaction was observed. Stirring was continued for 10 min without cooling. After cooling to about 0° C., 45.8 g (142.7 mmol) tri(n-butyl)stannyl-methanolate have been added dropwise while stirring. Stirring was continued for 2 d at 4° C. After addition of 112.9 g methanol stirring was continued for 1 h at ambient temperature. The reaction mixture was poured into 250 ml of water, extracted thrice with 150 ml diethyl ether each, the combined extracts were washed twice with 80 ml of water each, then once with 40 ml saturated aqueous sodium chloride solution, dried with sodium sulfate and concentrated in vacuo. Yield 48.6 g oil, which have been purified by chromatography on 300 g silica gel with hexane/MTBE (10:1). Final yield 34.6 g (67%) oil. δ=0.90 (m); 1.30 (m); 1.50 m); 1.97 (s); 4.02 (t); 6.27 (t).


Ex. 1b: 1-(4-Chloro-phenyl)-3-((Z)-3-tributylstannanyl-but-2-enyloxy)-1H-pyrazole (5)

To 8.09 g (30.8 mmol) triphenylphosphine in 200 ml THF have been added with stirring at −75° C. 6.23 g (30.8 mmol) azodicarbonic acid diisopropyl ester. The mixture has been stirred at this temperature for 5 min. Then 10.39 g (28.8 mmol) (Z)-3-tributylstannanyl-but-2-en-1-ol have been added dropwise and stirred for 5 min at −75° C. After addition of 4.00 g (20.6 mmol) 1-(4-chlorophenyl)-3-hydroxypyrazole at −75° C. a red suspension was formed. The mixture was allowed to warm up to ambient temperature and stirred for 3 d. After removal of the solvents in vacuo 29 g oil have been collected and purified by chromatography on 120 g silica with MTBE/heptane. Yield 8.3 g (75%) oil. δ=0.85 (m); 0.95 (m); 1.30 (m); 1.50 m); 2.00 (s); 4.65 (d); 5.90 (d); 6.43 (t); 7.35 (d); 7.52 (d); 7.68 (d).


Ex. 1c: (Z)-5-[1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy]-2-[(E)-methoxyimino]-3-methyl-pent-3-enic Acid Methyl Ester (7)

3.00 g (5.58 mmol) 1-(4-Chloro-phenyl)-3-((Z)-3-tributylstannanyl-but-2-enyloxy)-1H-pyrazole, 1.15 g (5.86 mmol) hydroxamic acid bromide (6), 0.155 g (0.67 mmol) tri(2-furyl)phosphine and 96 mg (0.17 mmol) bis(dibenzylidenacetone)-palladium have been stirred in 10 ml 1,4-dioxane for 4 d at about 80° C. After removal of the solvents in vacuo 4.3 g oil have been collected and purified by chromatography on 70 g silica with MTBE/heptane/1% triethylamine. Yield 1.2 g (59%) oil. δ=1.95 (s); 3.85 (s); 4.07 (s); 4.58 (d); 5.85 (d); 5.93 (t); 7.35 (d); 7.52 (d); 7.65 (d).


Ex. 1 d: (Z)-5-[1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy]-2-[(E)-methoxyimino]-3-methyl-pent-3-enic Acid Methyl Amide (I-6)

120 mg (0.33 mmol) (Z)-5-[1-(4-chloro-phenyl)-1H-pyrazol-3-yloxy]-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl ester and 0.99 ml (1.98 mmol) of a 2-molar solution of methyl amine in THF have been stirred overnight at ambient temperature in 2.0 ml of THF and 0.5 ml of water. After removal of the solvent in vacuo the product (120 mg) was collected in quantitative yield and good purity. Melting point 129-130° C.


Example 2: (Z)-5-[1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy]-2-[1-methoxy-meth-(E)-ylidene]-3-methyl-pent-3-enoic Acid Methyl Ester (Compound I-7)



embedded image


1.50 g (2.79 mmol) 1-(4-Chloro-phenyl)-3-((Z)-3-tributylstannanyl-but-2-enyloxy)-1H-pyrazole (5), 0.81 g (3.35 mmol) of ester compound (8) [Chem Comm 4, 423-425, (2006)], 0.223 g (0.28 mmol) [(R)-(+)-2,2″-Bis(diphenylphosphino)-1,1″-bisnaphthyl]-palladium(II)chloride have been stirred in 14 ml 1,4-dioxane for 4.5 d at about 100° C. After removal of the solvents in vacuo the crude product has been collected, which has been purified by chromatography on 50 g silica with MTBE/hexane/2% triethylamine. Yield 0.12 g, melting point 123-125° C.


Example 3: Methyl N—[(Z)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-1-methyl-prop-1-enyl]-N-methyl-carbamate (I-10)



embedded image


Ex. 3a: 1-(4-chlorophenyl)-3-[(Z)-3-iodobut-2-enoxy]pyrazole (10)

To 10.0 g (18.6 mmol) 1-(4-chloro-phenyl)-3-((Z)-3-tributylstannanyl-but-2-enyloxy)-1H-pyrazole in 100 ml methylene chloride have been added 4.7 g (18.6 mmol) iodine at ambient temperature with stirring which was continued for 3 h. After removal of the solvents in vacuo the crude product was dissolved in 200 ml MTBE. 100 ml 20% aqueous potassium fluoride solution have been added and the mixture was stirred for 2 h at ambient temperature. The aqueous layer was separated and extracted with 20 ml methyltert.-butyl ether twice. The combined organic phases have been washed twice with 20 ml of water each, dried with sodium sulfate, and the solvents were removed in vacuo. The crude product (7.2 g) has been purified by chromatography on 50 g silica with methyl-tert.-butylether/hexane (1:20). Yield 5.9 g, melting point 75-77° C.


Ex. 3b: Methyl N—[(Z)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-1-methyl-prop-1-enyl]-N-methyl-carbamate

1.50 g (4.00 mmol) 1-(4-chlorophenyl)-3-[(Z)-3-iodobut-2-enoxy]pyrazole, 0.43 g (4.81 mmol) N-methylcarbamic acid methyl ester (9), 76 mg (0.4 mmol) copperiodide, 1.27 g (6.00 mmol) potassium phosphate and 71 mg (0.80 mmol) N,N′-dimethylethylene diamine in 14 ml toluene have been stirred for 1.5 d at 100° C. After removal of the solvents in vacuo the crude product has been purified by chromatography on 50 g silica with MTBE/hexane (1:3). Yield 0.67 g. 1H-NMR (CDCl3): δ=1.90 (s); 3.05 (s); 3.70 (s); 4.68 (m); 5.63 (m); 5.90 (d); 7.35 (m); 7.55 (m); 7.68 (d).


Example 4: (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,4-dimethyl-pent-3-enamide (Compound I-79)



embedded image


Ex. 4a: 1-[1-(4-Chlorophenyl)pyrazol-3-yl]oxypropan-2-one (11)

5.50 g (28.3 mmol) 1-(4-chlorophenyl)pyrazol-3-ol, 3.91 g (28.3 mmol) potassium carbonate and 50 mg sodium iodide in 30 ml DMF have been stirred for 5 min at ambient temperature. Then 2.62 g (28.3 mmol) chloroacetone have been added dropwise while stirring which was continued at 60° C. for 5 h. The mixture was poured into excess 10% aqueous lithium chloride solution and extracted with ethyl acetate three times. The combined extracts have been washed with 10% lithium chloride solution twice and dried with sodium sulfate. After removal of the solvent in vacuo the crude product has been purified by chromatography on silica. Yield 6.5 g. The product was used for the next step.


Ex. 4b: Methyl (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-4-methyl-pent-3-enoate and E-Isomer (13)

To 5.26 g (21.0 mmol) 1-[1-(4-chlorophenyl)pyrazol-3-yl]oxypropan-2-one and 7.20 g (26.9 mmol) methyl (2Z)-3-diethoxyphosphoryl-2-methoxyimino-propanoate (which can be prepared as described for the dimethoxy derivative [(Tetrahedron Let 29, 3361-3364 (1988)] in 100 ml THF have been added at ambient temperature with stirring 2.59 g (23.1 mmol) potassium tert.-butylate. Stirring was continued over night. After removal of the solvent in vacuo the mixture was purified by chromatography on silica with heptane/ethyl acetate. 1.07 g of a 80:20 E:Z-mixture have been collected. This has been used directly for the next step.


Ex. 4c: Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,4-dimethyl-pent-3-enamide

0.68 g (1.87 mmol) methyl (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-4-methyl-pent-3-enoate and E-isomer from the previous reaction have been dissolved in 3.0 ml THF. 2.0 ml 40% aqueous methylamine have been added at ambient temperature with stirring which was continued over night. After removal of the solvent in vacuo the mixture was purified by chromatography on silica with a heptane/ethyl acetate gradient. 90 mg of the desired Z-isomer have been collected.



1H-NMR (CDCl3): δ=2.03 (s); 2.85 (d); 3.97 (s); 4.64 (s); 5.87 (s); 6.02 (d); 6.65 (br); 7.35 (d); 7.50 (d); 7.67 (d).


Example 5: Methyl N—[(Z)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-1-methyl-prop-1-enyl]-N-methoxy-carbamate (I-1)



embedded image


Ex. 5a: Cis-3-methyloxiran-2-yl]methanol (15)

To 10.0 g (138.7 mmol) Z-but-2-en-1-ol in 140 ml dichloromethane (DCM) 37.6 g (152.6 mmol) 3-chloroperbenzoic acid (70% purity) have been added at 0-5° C. in small portions with stirring. Stirring was continued at 0° C. for 2 h. 35.0 g calcium hydroxide have been added at 0-5° C. with stirring which was continued for about 2 h at 0° C. The precipitate was filtered off, washed with DCM, and the filtrates dried with sodium sulfate. The solvent was largely removed at 380 mbar/30° C. The crude product (15.0 g, purity 75%) was used without further purification.


Ex. 5b: Racemic 1-(4-chlorophenyl)-3-[[(2R,3S)-3-methyloxiran-2-yl]methoxy]pyrazole (16)

To 28.3 g (107.9 mmol) triphenylphosphine and 15.0 g (127.7 mmol) cis-3-methyloxiran-2-yl]methanol (15) from the preceding experiment in 400 ml THF have been added with stirring at −75° C. 22.9 g (113.0 mmol) azodicarbonic acid diisopropyl ester. The mixture has been stirred at this temperature for 5 min. Then 20.0 g (102.8 mmol) 1-(4-chlorophenyl)-3-hydroxypyrazole have been added with stirring at −70° C. The mixture was allowed to warm up to ambient temperature and stirred for about 1 d. After removal of the solvents in vacuo the crude product was stirred with 200 ml of diisopropylether from which 42 g of a solid substance have been collected and further purified by chromatography on 330 g silica with MTBE/heptane. Yield 22.5 g (82%).


Ex. 5c: 5-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methoxy-4-methyl-oxazolidin-2-one (17)

To 1.08 g (10.0 mmol) methyl N-methoxycarbamate in 17 ml DMSO have been added with stirring at ambient temperature 1.00 g (8.9 mmol) potassium tert.-butylate. Stirring has been continued for 5 min before 2.00 g (7.56 mmol) 1-(4-chlorophenyl)-3-[[(2R,3S)-3-methyloxiran-2-yl]methoxy]pyrazole have been added. The mixture was stirred at 90° C. for 20 h. After cooling to ambient temperature the reaction mixture was poured into 150 ml of water, extracted thrice with 30 ml ethyl acetate each, the combined extracts have been dried with sodium sulfate and the solvent removed in vacuo. The crude product (2.5 g) was used without further purification.


Ex. 5d: Racemic (2S,3R-1-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-3-(methoxyamino)butan-2-ol (18)

To 10.0 g (30.0 mmol) 5-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methoxy-4-methyl-oxazolidin-2-one in 100 ml ethanol has been added at ambient temperature with stirring 14.6 g (40.0 mmol) 21% sodium ethylate solution (in ethanol) and stirred over night. The solvent was largely removed in vacuo and the remaining mixture poured into 250 ml aqueous sodium dihydrogenphosphate solution, extracted thrice with 150 ml ethyl acetate each, dried with sodium sulfate to yield 8.7 g of an oil after evaporation of the solvent in vacuo. Further purified by chromatography on 120 g silica with MTBE/heptane. Yield 4.0 g (43%). 1H-NMR (CDCl3): δ=1.22 (d); 3.17 (m); 3.57 (s); 3.91 (m); 4.33 (m); 4.47 (m); 5.93 (s); 7.35 (d); 7.52 (d); 7.68 (s).


Ex. 5e: Racemic methyl N-[(1R,2S)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-hydroxy-1-methyl-propyl]-N-methoxy-carbamate (19)

To 1.00 g (3.2 mmol) Racemic (2S,3R-1-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-3-(methoxyamino)butan-2-ol in 7 ml THF 0.28 g (3.5 mmol) sodium hydrogencarbonate has been added. Then 0.33 g (3.5 mmol) methyl chloroformate has been added dropwise with stirring at ambient temperature. Stirring has been continued over night. The reaction mixture was poured into 10 ml of water, extracted thrice with 10 ml MTBE each, the combined extracts dried with sodium sulfate, and the solvent removed in vacuo. The crude product (1.3 g) was used without further purification.


Ex. 5f: Methyl N—[(Z)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-1-methyl-prop-1-enyl]-N-methoxy-carbamate (I-1)

To 3.50 g (9.46 mmol) racemic methyl N-[(1R,2S)-3-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-hydroxy-1-methyl-propyl]-N-methoxy-carbamate in 13 ml THF 2.61 g (9.94 mmol) triphenylphoshin has been added with stirring at ambient temperature. The mixture was cooled to −15° C. Then 2.11 g (10.41 mmol) azodicarbonic acid diisopropyl ester has been added with stirring which was continued for 1 h at 0° C. and for about 1 d at ambient temperature. After removal of the solvents in vacuo the crude product was further purified by chromatography on 25 g silica with MTBE/heptane/1% triethylamine.



1H-NMR (CDCl3): δ=1.93 (s); 3.72 (s); 3.81 (s); 4.78 (d); 5.73 (t); 5.90 (d); 7.36 (d); 7.55 (d); 7.70 (d).









TABLE I







Compounds of formula I with physical data (melting point [° C.]; 1H-NMR (CDCl3)


(δ); HPLC/MS retention time [min])














No.
R1
R2
R3
R4
X
Y
m.p. [° C.]; 1H-NMR (δ); Rt [min]





I-1
CH3
H
R3-1
R4-4, R5 =
O
Y-1
δ = 1.93 (s); 3.72 (s); 3.81 (s);






OCH3


4.78 (d); 5.73 (t); 5.90 (d);









7.36 (d); 7.55 (d); 7.70 (d)


I-2
CH3
H
R3-1
R4-4, R5 =
NH
Y-1






OCH3


I-3
CH3
H
R3-1
R4-3
O
Y-1


I-4
CH3
H
R3-1
R4-3
NH
Y-1


I-5
CH3
H
R3-1
R4-1
O
Y-1
88-89° C.


I-6
CH3
H
R3-1
R4-1
NH
Y-1
130° C.


I-7
CH3
H
R3-1
R4-2
O
Y-1
123-125° C.


I-8
CH3
H
R3-1
R4-2
NH
Y-1


I-9
CH3
H
R3-1
R4-7

Y-1


I-10
CH3
H
R3-1
R4-4, R5 =
O
Y-1
δ = 1.90 (s); 3.05 (s); 3.70 (s);






CH3


4.68 (m); 5.63 (m); 5.90 (d);









7.35 (m); 7.55 (m); 7.68 (d)


I-11
CH3
H
R3-2
R4-1
NH
Y-1
δ = 1.95 (s); 2.85 (d); 3.95 (s);









4.55 (m); 5.87 (m); 5.95 (m);









6.70 (br); 6.95 (m); 7.73 (m); 7.80 (m)


I-12
CH3
H
R3-3
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.80 (d);









3.95 (s); 4.52 (m); 5.83 (d);









5.93 (m); 6.75 (br); 6.95 (m); 7.30 (m)


I-13
CH3
H
R3-4
R4-1
NH
Y-1
δ = 1.93 (s); 2.38 (s); 2.80 (d);









3.95 (s); 4.55 (m); 5.88 (d);









5.95 (m); 6.75 (br); 7.13 (m); 7.28 (m);









7.41 (d); 7.64 (d)


I-14
CH3
H
R3-5
R4-1
NH
Y-1
125-127° C.


I-15
CH3
H
R3-6
R4-1
NH
Y-1
δ = 1.95 (s); 2.85 (d); 3.95 (s);









4.55 (m); 5.90 (d); 5.95 (m);









6.70 (br); 7.32 (m); 7.50 (s); 7.54 (d);









7.70 (d)


I-16
CH3
H
R3-7
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.97 (s);









4.56 (m); 5.88 (d); 5.94 (m);









6.70 (br); 7.45 (m); 7.64 (s); 7.72 (d)


I-17
CH3
H
R3-8
R4-1
NH
Y-1


I-18
CH3
H
R3-9
R4-1
NH
Y-1
δ = 1.95 (s); 2.33 (s); 2.88 (d);









3.97 (s); 4.56 (m); 5.85 (m);









5.95 (m); 6.70 (br); 7.03 (t); 7.30 (m);









7.44 (m); 7.62 (m)


I-19
CH3
H
R3-10
R4-1
NH
Y-1


I-20
CH3
H
R3-11
R4-1
NH
Y-1
δ = 1.95 (s); 2.25 (s); 2.30 (s);









2.87 (d); 3.97 (s); 4.56 (m);









5.85 (d); 5.95 (m); 6.73 (br); 7.15 (d);









7.27 (m); 7.35 (d); 7.63 (d)


I-21
CH3
H
R3-12
R4-1
NH
Y-1


I-22
CH3
H
R3-13
R4-1
NH
Y-1


I-23
CH3
H
R3-14
R4-1
NH
Y-1


I-24
CH3
H
R3-15
R4-1
NH
Y-1


I-25
CH3
H
R3-16
R4-1
NH
Y-1


I-26
CH3
H
R3-17
R4-1
NH
Y-1


I-27
CH3
H
R3-14
R4-1
NH
Y-1


I-28
CH3
H
R3-18
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.97 (s);









4.57 (m); 5.87 (m); 5.95 (m);









6.70 (br); 7.07 (m); 7.33 (m); 7.55 (m);









7.64 (m)


I-29
CH3
H
R3-19
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.97 (s);









4.58 (m); 5.88 (d); 5.94 (m);









6.70 (br); 7.15 (m); 7.30 (m); 7.43 (m);









7.64 (s); 7.70 (d)


I-30
CH3
H
R3-20
R4-1
NH
Y-1


I-31
CH3
H
R3-21
R4-1
NH
Y-1


I-32
CH3
H
R3-22
R4-1
NH
Y-1
δ = 1.95 (s); 2.37 (s); 2.87 (d);









3.95 (s); 4.55 (m); 5.86 (d);









5.93 (m); 6.70 (br); 7.20 (m); 7.45 (m);









7.65 (d)


I-33
CH3
H
R3-23
R4-1
NH
Y-1
δ = 1.23 (m); 1.95 (s); 2.64 (m);









2.87 (d); 3.95 (s); 4.58 (m);









5.87 (d); 5.95 (m); 6.70 (br); 7.25 (m);









7.48 (m); 7.67 (d)


I-34
CH3
H
R3-24
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.97 (s);









4.58 (m); 5.92 (m); 6.70 (br);









7.67 (m); 7.75 (d)


I-35
CH3
H
R3-25
R4-1
NH
Y-1


I-36
CH3
H
R3-26
R4-1
NH
Y-1


I-37
CH3
H
R3-58
R4-1
NH
Y-1


I-38
CH3
H
R3-28
R4-1
NH
Y-1


I-39
CH3
H
R3-29
R4-1
NH
Y-1


I-40
CH3
H
R3-30
R4-1
NH
Y-1


I-41
CH3
H
R3-31
R4-1
NH
Y-1


I-42
CH3
H
R3-32
R4-1
NH
Y-1


I-43
CH3
H
R3-33
R4-1
NH
Y-1


I-44
CH3
H
R3-34
R4-1
NH
Y-1


I-45
CH3
H
R3-35
R4-1
NH
Y-1


I-46
CH3
H
R3-36
R4-1
NH
Y-1


I-47
CH3
H
R3-37
R4-1
NH
Y-1


I-48
CH3
H
R3-38
R4-1
NH
Y-1


I-49
CH3
H
R3-39
R4-1
NH
Y-1


I-50
CH3
H
R3-40
R4-1
NH
Y-1


I-51
CH3
H
R3-41
R4-1
NH
Y-1


I-52
CH3
H
R3-42
R4-1
NH
Y-1


I-53
CH3
H
R3-43
R4-1
NH
Y-1


I-54
CH3
H
R3-44
R4-1
NH
Y-1


I-55
CH3
H
R3-45
R4-1
NH
Y-1


I-56
CH3
H
R3-46
R4-1
NH
Y-1


I-57
CH3
H
R3-47
R4-1
NH
Y-1


I-58
CH3
H
R3-45
R4-1
NH
Y-1


I-59
CH3
H
R3-49
R4-1
NH
Y-1


I-60
CH3
H
R3-50
R4-1
NH
Y-1


I-61
CH3
H
R3-51
R4-1
NH
Y-1


I-62
CH3
H
R3-52
R4-1
NH
Y-1


I-63
CH3
H
R3-53
R4-1
NH
Y-1


I-64
CH3
H
R3-54
R4-1
NH
Y-1


I-65
CH3
H
R3-55
R4-1
NH
Y-1


I-66
CH3
H
R3-56
R4-1
NH
Y-1


I-67
CH3
H
R3-57
R4-1
NH
Y-1


I-68
CH3
H
R3-58
R4-4, R5 =
O
Y-1






OCH3


I-69
CH3
H
R3-58
R4-4, R5 =
NH
Y-1






OCH3


I-70
CH3
H
R3-58
R4-3
O
Y-1


I-71
CH3
H
R3-58
R4-3
NH
Y-1


I-72
CH3
H
R3-27
R4-1
O
Y-1


I-73
CH3
H
R3-58
R4-2
O
Y-1


I-74
CH3
H
R3-58
R4-2
NH
Y-1


I-75
CH3
H
R3-58
R4-7

Y-1


I-76
C2H5
H
R3-1
R4-1
NH
Y-1


I-77
C2H5
H
R3-2
R4-1
NH
Y-1


I-78
C2H5
H
R3-58
R4-1
NH
Y-1


I-79
H
CH3
R3-1
R4-1
NH
Y-1
δ = 2.03 (s); 2.85 (d); 3.97 (s);









4.64 (s); 5.87 (s); 6.02 (d);









6.65 (br); 7.35 (d); 7.50 (d); 7.67 (d)


I-80
H
CH3
R3-1
R4-1
O
Y-1


I-81
CH3
H
R3-1
R4-1
NH
Y-3


I-82
CH3
H
R3-59
R4-1
NH
Y-1
δ = 1.95 (s); 2.16 (s); 2.18 (s);









2.30 (s); 2.90 (s); 3.97 (s);









4.33 (m); 4.65 (m); 5.30 (m); 5.87 (m);









6.07 (m); 6.55 (s); 6.65 (br);









6.96 (s)


I-83
CH3
H
R3-60
R4-1
NH
Y-1
δ = 1.95 (s); 2.22 (s); 2.90 (d);









3.95 (s); 4.35 (m); 4.67 (m);









5.30 (m); 5.88 (m); 6.07 (m); 6.65 (br);









6.73 (d); 7.35 (d); 7.43 (s)


I-84
CH3
H
R3-61
R4-1
NH
Y-1
δ = 1.95 (s); 2.15 (s); 2.18 (s);









2.28 (s); 2.90 (d); 3.95 (s);









4.33 (m); 4.67 (s); 5.39 (d); 5.43 (d);









5.88 (m); 6.57 (s); 6.65 (br);









6.95 (s)


I-85
CH3
H
R3-62
R4-1
NH
Y-1
δ = 1.95 (s); 2.21 (s); 2.25 (s);









2.89 (d); 3.95 (s); 4.35 (m);









4.70 (s); 5.39 (d); 5.44 (d); 5.90 (m);









6.65 (br); 6.73 (d); 7.40 (d);









7.45 (s)


I-86
CH3
H
R3-63
R4-1
O
Y-1
δ = 1.73 (m); 1.93 (s); 2.15 (s);









2.30 (s); 3.85 (s); 4.05 (s);









4.33 (m); 4.60 (m); 5.75 (m); 5.85 (m);









6.55 (s); 6.95 (s)


I-87
CH3
H
R3-64
R4-1
O
Y-1
δ = 1.95 (s); 2.12 (s); 2.14 (s);









2.30 (s); 3.85 (s); 4.07 (s);









4.35 (m); 4.63 (m); 5.85 (m); 6.15 (m);









6.27 (m); 6.55 (s); 6.97 (s)


I-88
CH3
H
R3-65
R4-1
O
Y-1
δ = 1.95 (s); 2.17 (s); 2.19 (s);









3.85 (s); 4.05 (s); 4.35 (m);









4.65 (m); 5.87 (m); 6.17 (m); 6.31 (m);









6.72 (d); 7.35 (d); 7.43 (s).


I-89
CH3
H
R3-66
R4-1
NH
Y-1
δ = 1.95 (s); 2.12 (s); 2.14 (s);









2.30 (s); 2.90 (d); 3.95 (s);









3.97 (s); 4.32 (m); 5.87 (m); 6.57 (s);









6.65 (br); 6.97 (s)


I-90
CH3
H
R3-63
R4-1
NH
Y-1
δ = 1.73 (m); 1.93 (s); 2.15 (s);









2.30 (s); 2.90 (d); 3.95 (s);









4.33 (m); 4.55 (m); 5.75 (m); 5.90 (m);









6.57 (s); 6.65 (br); 6.95 (s)


I-91
CH3
H
R3-67
R4-1
NH
Y-1
δ = 1.73 (m); 1.93 (s); 2.18 (s);









2.20 (s); 2.90 (d); 3.95 (s);









4.35 (m); 4.60 (m); 5.75 (m); 5.90 (m);









6.55 (br); 6.73 (m); 7.35 (m);









7.43 (s)


I-92
CH3
H
R3-64
R4-1
NH
Y-1
δ = 1.95 (s); 2.15 (s); 2.30 (s);









2.90 (d); 3.95 (s); 4.33 (m);









4.60 (m); 5.87 (m); 6.15 (m); 6.27 (m);









6.57 (s); 6.65 (br); 6.95 (s)


I-93
CH3
H
R3-65
R4-1
NH
Y-1
δ = 1.95 (s); 2.19 (s); 2.21 (s);









2.90 (d); 3.95 (s); 4.35 (m);









4.65 (m); 5.90 (m); 6.17 (m); 6.31 (m);









6.65 (br); 6.75 (d); 7.35 (m);









7.43 (s)


I-94
CH3
H
R3-59
R4-1
O
Y-1
δ = 1.95 (s); 2.15 (s); 2.30 (s);









3.85 (s); 4.07 (s); 4.33 (m);









4.63 (m); 5.30 (m); 5.87 (m); 6.07 (m);









6.53 (s); 6.97 (s)


I-95
CH3
H
R3-60
R4-1
O
Y-1
δ = 1.93 (s); 2.22 (s); 3.85 (s);









4.07 (s); 4.37 (m); 4.67 (m);









5.30 (m); 5.87 (m); 6.07 (m); 6.70 (d);









7.37 (m); 7.45 (s)


I-96
CH3
H
R3-61
R4-1
O
Y-1
δ = 1.95 (s); 2.15 (s); 2.17 (s);









2.28 (s); 3.87 (s); 4.07 (s);









4.33 (m); 4.67 (s); 5.40 (d); 5.43 (d);









5.87 (m); 6.53 (s); 6.95 (s)


I-97
CH3
H
R3-62
R4-1
O
Y-1
δ = 1.95 (s); 2.21 (s); 2.23 (s);









3.85 (s); 4.05 (s); 4.37 (m);









4.70 (s); 5.39 (d); 5.42 (d); 5.87 (m);









6.70 (d); 7.38 (m); 7.45 (s)


I-98
CH3
H
R3-68
R4-1
O
Y-1
δ = 1.23 (t); 1.87 (s); 2.08 (s);









2.27 (s); 3.70 (s); 3.95 (s);









4.10 (d); 4.30 (m); 5.90 (m); 6.65 (s);









7.00 (s)


I-99
CH3
H
R3-69
R4-1
O
Y-1


I-100
CH3
H
R3-69
R4-1
NH
Y-1


I-101
CH3
H
R3-69
R4-4, R5 =
O
Y-1






OCH3


I-102
CH3
H
R3-70
R4-1
O
Y-6


I-103
CH3
H
R3-70
R4-1
NH
Y-6


I-104
CH3
H
R3-70
R4-4, R5 =
O
Y-6






OCH3


I-105
CH3
H
R3-71
R4-1
O
Y-4


I-106
CH3
H
R3-71
R4-1
NH
Y-4


I-107
CH3
H
R3-71
R4-4, R5 =
O
Y-4






OCH3


I-108
CH3
H
R3-72
R4-1
NH
Y-1


I-109
CH3
H
R3-72
R4-1
O
Y-1


I-110
CH3
H
R3-72
R4-4, R5 =
O
Y-1






OCH3


I-111
CH3
H
R3-72
R4-1
NH
Y-2


I-112
CH3
H
R3-72
R4-1
O
Y-2


I-113
CH3
H
R3-72
R4-4, R5 =
O
Y-2






OCH3


I-114
CH3
H
R3-1
R4-4, R5 =
O
Y-2






OCH3


I-115
CH3
H
R3-1
R4-4, R5 =
NH
Y-2






OCH3


I-116
CH3
H
R3-1
R4-3
O
Y-2


I-117
CH3
H
R3-1
R4-3
NH
Y-2


I-118
CH3
H
R3-1
R4-1
O
Y-2


I-119
CH3
H
R3-1
R4-1
NH
Y-2


I-120
CH3
H
R3-1
R4-2
O
Y-2


I-121
CH3
H
R3-1
R4-2
NH
Y-2


I-122
CH3
H
R3-1
R4-7

Y-2


I-123
CH3
H
R3-1
R4-4, R5 =
O
Y-2






CH3


I-124
CH3
H
R3-73
R4-1
NH
Y-1


I-125
CH3
H
R3-74
R4-1
NH
Y-1


I-126
CH3
H
R3-75
R4-1
NH
Y-1


I-127
CH3
H
R3-76
R4-1
NH
Y-1


I-128
CH3
H
R3-77
R4-1
NH
Y-1


I-129
CH3
H
R3-78
R4-1
NH
Y-1


I-130
CH3
H
R3-78
R4-1
NH
Y-1


I-131
CH3
H
R3-80
R4-1
NH
Y-1


I-132
CH3
H
R3-81
R4-1
NH
Y-1


I-133
CH3
H
R3-82
R4-1
NH
Y-1


I-134
CH3
H
R3-83
R4-1
NH
Y-1


I-135
CH3
H
R3-84
R4-1
NH
Y-1


I-136
CH3
H
R3-85
R4-1
NH
Y-1


I-137
CH3
H
R3-86
R4-1
NH
Y-1


I-138
CH3
H
R3-87
R4-1
NH
Y-1


I-139
CH3
H
R3-88
R4-1
NH
Y-1


I-140
CH3
H
R3-89
R4-1
NH
Y-1


I-141
CH3
H
R3-90
R4-1
NH
Y-1


I-142
CH3
H
R3-91
R4-1
NH
Y-1


I-143
CH3
H
R3-92
R4-1
NH
Y-1


I-144
CH3
H
R3-93
R4-1
NH
Y-1


I-145
CH3
H
R3-94
R4-1
NH
Y-1


I-146
CH3
H
R3-95
R4-1
NH
Y-1


I-147
CH3
H
R3-96
R4-1
NH
Y-1


I-148
CH3
H
R3-97
R4-1
NH
Y-1


I-149
CH3
H
R3-98
R4-1
NH
Y-1


I-150
CH3
H
R3-99
R4-1
NH
Y-1


I-151
CH3
H
R3-
R4-1
NH
Y-1





100


I-152
CH3
H
R3-
R4-1
NH
Y-1





101


I-153
CH3
H
R3-
R4-1
NH
Y-1





102


I-154
CH3
H
R3-
R4-1
NH
Y-1





103


I-155
CH3
H
R3-
R4-1
NH
Y-1





104


I-156
CH3
H
R3-
R4-1
NH
Y-1





105


I-157
CH3
H
R3-
R4-1
NH
Y-1





106


I-158
CH3
H
R3-
R4-1
NH
Y-1





107


I-159
CH3
H
R3-
R4-1
NH
Y-1





108


I-160
CH3
H
R3-
R4-1
NH
Y-1





109


I-161
CH3
H
R3-
R4-1
NH
Y-1





110


I-162
CH3
H
R3-
R4-1
NH
Y-1





111


I-163
CH3
H
R3-
R4-1
NH
Y-1





112


I-164
CH3
H
R3-
R4-1
NH
Y-1





113


I-165
CH3
H
R3-
R4-1
NH
Y-1





114


I-166
CH3
H
R3-
R4-1
NH
Y-1





115


I-167
CH3
H
R3-
R4-1
NH
Y-1





116


I-168
CH3
H
R3-
R4-1
NH
Y-1





117


I-169
CH3
H
R3-
R4-1
NH
Y-4





118


I-170
CH3
H
R3-
R4-1
NH
Y-4





119


I-171
CH3
H
R3-
R4-1
NH
Y-4





120


I-172
CH3
H
R3-
R4-1
NH
Y-4





121


I-173
CH3
H
R3-
R4-1
NH
Y-4





122


I-174
CH3
H
R3-
R4-1
NH
Y-4





123


I-175
CH3
H
R3-
R4-1
NH
Y-4





124


I-176
CH3
H
R3-
R4-1
NH
Y-4





125


I-177
CH3
H
R3-
R4-1
NH
Y-1





126


I-178
CH3
OCH3
R3-1
R4-4, R5 =
O
Y-1






OCH3


I-179
CH3
OCH3
R3-1
R4-4, R5 =
O
Y-1






OCH3


I-180
CH3
OCH3
R3-1
R4-4, R5 =
O
Y-1






OCH3


I-181
CH3
H
R3-1
R4-4, R5 =
O
Y-1






OCH3


I-182
CH3
H
R3-1
R4-1
NH
Y-1


I-183
CH3
H
R3-1
R4-1
O
Y-1


I-184
CH3
H
R3-1
R4-2
NH
Y-1


I-185
CH3
H
R3-1
R4-2
O
Y-1


I-186
CH3
H
R3-
R4-1
O
Y-1
79-81° C.





127


I-187
CH3
H
R3-
R4-1
NH
Y-1
δ = 1.95 (s); 2.12 (s); 2.18 (s);





127



2.87 (d); 3.97 (s); 3.98 (s);









4.35 (m); 5.90 (m); 6.65 (br); 7.35 (d);









7.43 (s)


I-188
C2H5
H
R3-1
R4-1
O
Y-1
δ = 1.05 (m); 2.30 (m); 3.85 (s);









4.05 (s); 4.62 (m); 5.90 (m);









7.35 (m); 7.52 (m); 7.70 (d)


I-189
CH3
H
R3-
R4-4, R5 =
O
Y-1
δ = 1.90 (s); 2.22 (s); 2.24 (s);





127
CH3


3.02 (s); 3.70 (s); 3.98 (s);









4.48 (m); 5.57 (m); 6.75 (m); 7.40 (m);









7.45 (s)


I-190
CH3
H
R3-66
R4-1
O
Y-1
δ = 1.95 (s); 2.10 (s); 2.13 (s);









2.30 (s); 3.85 (s); 3.92 (s);









4.05 (s); 4.35 (m); 5.87 (m); 6.53 (s);









6.97 (s)


I-191
CH3
H
R3-
R4-1
O
Y-1
δ = 1.30 (t); 1.95 (s); 2.20 (s);





128



2.22 (s); 3.85 (s); 4.06 (s);









4.20 (q); 4.37 (m); 5.87 (m); 6.71 (d);









7.37 (m); 7.45 (s)


I-192
CH3
H
R3-
R4-1
NH
Y-1
δ = 1.30 (t); 1.95 (s); 2.20 (s);





128



2.21 (s); 2.92 (d); 3.95 (s);









4.22 (m); 4.37 (m); 5.90 (m); 6.65 (br);









6.73 (m); 7.37 (m); 7.45 (s)


I-193
CH3
H
R3-68
R4-1
NH
Y-1
δ = 1.32 (t); 1.95 (s); 2.16 (s);









2.17 (s); 2.32 (s); 2.92 (d);









3.97 (s); 4.20 (q); 4.33 (m); 5.90 (m);









6.57 (s); 6.65 (br); 7.97 (s)


I-194
CH3
H
R3-5
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.05 (s);









4.53 (m); 5.87 (d); 5.93 (m);









7.07 (m); 7.25 (m); 7.55 (m); 7.63 (d)


I-195
CH3
H
R3-6
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.05 (s);









4.55 (m); 5.88 (d); 5.93 (m);









7.33 (m); 7.48 (s); 7.53 (d); 7.70 (d)


I-196
CH3
H
R3-2
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.55 (m); 5.87 (d); 5.92 (m);









6.95 (m); 7.73 (d); 7.80 (m)


I-197
CH3
H
R3-4
R4-1
O
Y-1
δ = 1.95 (s); 2.37 (s); 3.85 (s);









4.07 (s); 4.55 (m); 5.85 (d);









5.92 (m); 7.12 (m); 7.28 (m); 7.43 (d);









7.67 (d)


I-198
CH3
H
R3-22
R4-1
O
Y-1
δ = 1.95 (s); 2.35 (s); 3.85 (s);









4.05 (s); 4.57 (m); 5.83 (d);









5.93 (m); 7.20 (d); 7.47 (d); 7.66 (d)


I-199
CH3
H
R3-24
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.60 (m); 5.95 (m); 7.67 (m);









7.77 (d)


I-200
CH3
H
R3-22
R4-1
O
Y-1
δ = 1.25 (m); 1.95 (s); 2.65 (m);









3.85 (s); 4.05 (s); 4.58 (m);









5.83 (d); 5.93 (m); 7.25 (m); 7.48 (m);









7.67 (d


I-201
CH3
H
R3-19
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.58 (m); 5.87 (d); 5.93 (m);









7.15 (m); 7.30 (m); 7.45 (m); 7.63 (s);









7.70 (d)


I-202
CH3
H
R3-7
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.58 (m); 5.90 (d); 5.95 (m);









7.45 (m); 7.67 (d); 7.73 (d)


I-203
CH3
H
R3-129
R4-1
O
Y-1
δ = 1.35 (d); 1.95 (s); 3.85 (s);









4.07 (s); 4.55 (m); 5.84 (d);









5.93 (m); 6.92 (m); 7.45 (m); 7.60 (d)


I-204
CH3
H
R3-11
R4-1
O
Y-1
δ = 1.95 (s); 2.27 (s); 2.32 (s);









3.85 (s); 4.07 (s); 4.58 (m);









5.85 (d); 5.95 (m); 7.15 (d); 7.30 (m);









7.37 (s); 7.66 (d)


I-205
CH3
H
R3-3
R4-1
O
Y-1
δ = 1.95 (s); 2.25 (s); 3.83 (s);









4.05 (s); 4.54 (m); 5.82 (d);









5.92 (m); 6.95 (m); 7.25 (m); 7.32 (d)


I-206
CH3
H
R3-9
R4-1
O
Y-1
δ = 1.93 (s); 2.31 (s); 3.85 (s);









4.07 (s); 4.56 (m); 5.85 (m);









5.95 (m); 7.03 (m); 7.33 (m); 7.43 (m);









7.64 (m).


I-207
CH3
H
R3-18
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.58 (m); 5.85 (d); 5.95 (m);









7.05 (m); 7.33 (m); 7.55 (m); 7.65 (d)


I-208
CH3
H
R3-129
R4-1
NH
Y-1
δ = 1.33 (d); 1.95 (s); 2.87 (d);









3.97 (s); 4.55 (m); 5.84 (m);









5.95 (m); 6.73 (br); 6.92 (d); 7.45 (d);









7.62 (m)


I-209
CH3
H
R3-58
R4-1
O
Y-1
δ = 1.95 (s); 3.83 (s); 4.05 (s);









4.65 (m); 5.95 (m); 7.43 (d);









7.55 (d); 8.23 (s)


I-210
Cl
CH3
R3-1
R4-1
NH
Y-1
δ = 2.10 (s); 2.65 (d); 4.01 (s);









4.95 (s); 5.97 (d); 6.85 (br);









7.37 (d); 7.50 (d); 7.67 (d)


I-211
phenyl ring*

R3-1
R4-7

Y-1
90° C.






R6 = CH3


I-212
phenyl ring*

R3-98
R4-7

Y-1
151° C.






R6 = CH3


I-213
phenyl ring*

R3-130
R4-7

Y-4






R6 = CH3


I-214
phenyl ring*

R3-131
R4-7

Y-4
139-142° C.






R6 = CH3


I-215
phenyl ring*

R3-132
R4-7

Y-4
58-63° C.






R6 = CH3


I-216
phenyl ring*

R3-133
R4-7

Y-1
111-113° C.






R6 = CH3


I-217
phenyl ring*

R3-65
R4-7

Y-1
78-88° C.






R6 = CH3


I-218
phenyl ring*

R3-60
R4-7

Y-1
83-88° C.






R6 = CH3


I-219
phenyl ring*

R3-67
R4-7

Y-1
87-89° C.






R6 = CH3


I-220
phenyl ring*

R3-62
R4-7

Y-1
82-88° C.






R6 = CH3


I-221
phenyl ring*

R3-134
R4-7

Y-1
92-98° C.






R6 = CH3


I-222
phenyl ring*

R3-135
R4-7

Y-1
141-145° C.






R6 = CH3


I-223
phenyl ring*

R3-64
R4-7

Y-1
88-91° C.






R6 = CH3


I-224
phenyl ring*

R3-59
R4-7

Y-1
82-86° C.






R6 = CH3


I-225
phenyl ring*

R3-63
R4-7

Y-1
64-70° C.






R6 = CH3


I-226
phenyl ring*

R3-136
R4-7

Y-1
101-108° C.






R6 = CH3


I-227
phenyl ring*

R3-137
R4-7

Y-1
98-102° C.






R6 = CH3


I-228
phenyl ring*

R3-138
R4-7

Y-1
71-75° C.






R6 = CH3


I-229
phenyl ring*

R3-139
R4-7

Y-7
72-74° C.






R6 = CH3


I-230
phenyl ring*

R3-140
R4-7

Y-7
δ = 1.65 (s); 3.32 (s); 3.67 (s);






R6 = CH3


5.20 (s); 7.07 (m); 7.27 (m);









7.47 (m)


I-231
phenyl ring*

R3-141
R4-7

Y-1
136-138° C.






R6 = CH3


I-232
phenyl ring*

R3-142
R4-7

Y-7
δ = 1.65 (s); 3.43 (s); 3.70 (s);






R6 = CH3


5.20 (s); 7.30-7.65 (m)


I-233
phenyl ring*

R3-127
R4-7

Y-1
Rt = 3.678 min






R6 = CH3


I-234
phenyl ring*

R3-143
R4-7

Y-1
Rt = 4.092 min






R6 = CH3


I-235
phenyl ring*

R3-144
R4-7

Y-1
Rt = 4.065 min






R6 = CH3


I-236
phenyl ring*

R3-145
R4-7

Y-1
Rt = 3.947 min






R6 = CH3


I-237
phenyl ring*

R3-146
R4-7

Y-1
Rt = 3.875 min






R6 = CH3


I-238
phenyl ring*

R3-147
R4-7

Y-1
Rt = 4.100 min






R6 = CH3


I-239
phenyl ring*

R3-68
R4-7

Y-1
Rt = 3.933 min






R6 = CH3


I-240
phenyl ring*

R3-148
R4-7

Y-4
Rt = 3.496 min






R6 = CH3


I-241
phenyl ring*

R3-149
R4-7

Y-4
Rt = 4.075 min






R6 = CH3


I-242
phenyl ring*

R3-150
R4-7

Y-1
Rt = 4.128 min






R6 = CH3


I-243
phenyl ring*

R3-151
R4-7

Y-1
Rt = 3.894 min






R6 = CH3


I-244
phenyl ring*

R3-152
R4-7

Y-1
Rt = 3.875 min






R6 = CH3


I-245
phenyl ring*

R3-153
R4-7

Y-1
Rt = 3.995 min






R6 = CH3


I-246
phenyl ring*

R3-154
R4-7

Y-1
Rt = 4.115 min






R6 = CH3


I-247
phenyl ring*

R3-20
R4-7

Y-1
Rt = 3.715 min






R6 = CH3


I-248
phenyl ring*

R3-157
R4-7

Y-1
Rt = 3.714 min






R6 = CH3


I-249
phenyl ring*

R3-128
R4-7

Y-1
Rt = 3.861 min






R6 = CH3


I-250
phenyl ring*

R3-158
R4-7

Y-1
Rt = 4.251 min






R6 = CH3


I-251
phenyl ring*

R3-159
R4-7

Y-1
105-107° C.






R6 = CH3


I-252
phenyl ring*

R3-151
R4-7

Y-1
102-104° C.






R6 = Ethyl


I-253
phenyl ring*

R3-1
R4-7

Y-1
96-97° C.






R6 = CHF2


I-254
phenyl ring*

R3-128
R4-7

Y-1
Rt = 4.219 min






R6 = Ethyl


I-255
phenyl ring*

R3-68
R4-7

Y-1
Rt = 4.239 min






R6 = Ethyl


I-256
phenyl ring*

R3-146
R4-7

Y-1
Rt = 4.176 min






R6 = Ethyl


I-257
phenyl ring*

R3-66
R4-7

Y-1
Rt = 4.013 min






R6 = Ethyl


I-258
phenyl ring*

R3-160
R4-7

Y-1
δ = 2.15 (s); 3.67 (s); 3.95 (s);






R6 = CH3


5.28 (s); 6.85 (m); 7.45 (m);









7.50 (m); 7.70 (m)


I-259
phenyl ring*

R3-161
R4-7

Y-1
δ = 1.33 (t); 2.17 (s); 3.68 (s);






R6 = CH3


4.22 (q); 5.28 (s); 6.87 (d);









7.45 (m); 7.52 (m); 7.73 (m)


I-260
phenyl ring*

R3-162
R4-7

Y-1
Rt = 3.924 min






R6 = CH3


I-261
phenyl ring*

R3-163
R4-7

Y-1
Rt = 4.131 min






R6 = CH3


I-262
phenyl ring*

R3-164
R4-7

Y-1
Rt = 4.141 min






R6 = CH3


I-263
phenyl ring*

R3-165
R4-7

Y-1
Rt = 3.916 min






R6 = CH3


I-264
phenyl ring*

R3-166
R4-7

Y-1
Rt = 4.220 min






R6 = CH3


I-265
phenyl ring*

R3-167
R4-7

Y-1
Rt = 4.050 min






R6 = CH3


I-266
phenyl ring*

R3-149
R4-7

Y-8
δ = 2.03 (s); 3.71 (s);






R6 = CH3


7.45-7.62 (m)


I-267
phenyl ring*

R3-168
R4-7

Y-1
δ = 2.20 (s); 2.40 (s); 3.69 (s);






R6 = CH3


5.20 (s); 6.70 (s); 7.12 (s);









7.42 (s); 7.53 (m); 7.72 (m); 7.91 (s)


I-268
phenyl ring*

R3-169
R4-7

Y-1
δ = 2.11 (s); 2.18 (s); 3.62 (s);






R6 = CH3


3.72 (s); 5.21 (s); 6.77 (s);









6.96 (s); 7.25 (s); 7.53 (m); 7.72 (m);









8.91 (s)


I-269
phenyl ring*

R3-170
R4-7

Y-1
δ = 2.00 (s); 2.05 (s); 2.16 (s);






R6 = CH3


2.21 (s); 3.70 (s); 5.16 (s);









6.72 (s); 6.82 (s); 7.50 (m); 7.74 (m)


I-270
phenyl ring*

R3-171
R4-7

Y-1
δ = 2.16 (s); 2.39 (s); 2.53 (s);






R6 = CH3


3.70 (s); 5.19 (s); 6.70 (s);









7.53 (m); 7.72 (m)


I-271
phenyl ring*

R3-172
R4-7

Y-1
δ = 2.18 (s); 2.29 (s); 3.70 (s);






R6 = CH3


5.18 (s); 6.71 (s); 7.06 (s);









7.50 (m); 7.71 (m); 8.38 (s); 8.44 (s)


I-272
phenyl ring*

R3-173
R4-7

Y-1
δ = 1.28 (m); 2.12 (s);






R6 = CH3


3.00 (broad); 3.58 (m); 3.69 (s);









5.52 (s); 6.28 (s); 7.45 (m); 7.72 (m)


I-273
phenyl ring*

R3-174
R4-7

Y-1
δ = 0.97 (m); 1.02 (m); 1.20 (m);






R6 = CH3


1.90 (m); 2.05 (s); 2.62 (m);









3.68 (s); 5.51 (s); 5.84 (s); 7.50 (m);









7.73 (m)


I-274
phenyl ring*

R3-175
R4-7

Y-8
Rt = 3.715 min






R6 = CH3


I-275
CH3
H
R3-20
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.58 (m); 5.92 (m); 7.45 (m);









7.52 (m); 7.75 (m); 7.84 (d)


I-276
CH3
H
R3-12
R4-1
O
Y-1
72-74° C.


I-277
CH3
H
R3-15
R4-1
O
Y-1
73-75° C.


I-278
CH3
H
R3-176
R4-1
O
Y-1
δ = 1.97 (s); 3.85 (s); 4.07 (s);









4.58 (d); 5.90 (d); 5.95 (m);









7.17 (t); 7.43 (m); 7.65 (m)


I-279
CH3
H
R3-98
R4-1
O
Y-1
90-92° C.


I-280
CH3
H
R3-20
R4-1
NH
Y-1
101-103° C.


I-281
CH3
H
R3-12
R4-1
NH
Y-1
112-115° C.


I-282
CH3
H
R3-15
R4-1
NH
Y-1
93-95° C.


I-283
CH3
H
R3-176
R4-1
NH
Y-1
84-86° C.


I-284
CH3
H
R3-98
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.93 (d);









3.97 (s); 4.48 (m); 5.93 (m);









6.42 (m); 6.67 (broad); 6.80 (d);









7.37 (d); 7.45 (m); 7.68 (m); 7.83 (m)


I-285
CH3
H
R3-1
R4-4, R5 =
O
Y-1
δ = 1.93 (s); 3.72 (s); 3.81 (s);






OCH3


4.78 (d); 5.73 (t); 5.90 (d);









7.36 (d); 7.55 (d); 7.70 (d)


I-286
CH3
H
R3-51
R4-1
O
Y-1
δ = 1.93 (s); 2.45 (s); 3.82 (s);









4.05 (s); 4.60 (d); 5.92 (t);









7.25-7.50 (m)


I-287
C2H5
H
R3-1
R4-1
NH
Y-1
δ = 1.05 (t); 2.30 (q); 2.90 (d);









3.97 (s); 4.58 (m); 5.93 (m);









6.70 (broad); 7.35 (m); 7.53 (m);









7.68 (s)


I-288
CH3
H
R3-58
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.97 (s);









4.63 (m); 5.95 (m); 6.75 (broad);









7.43 (m); 7.55 (m); 8.23 (s)


I-289
CH3
H
R3-51
R4-1
NH
Y-1
δ = 1.93 (s); 2.45 (s); 2.83 (d);









3.95 (s); 4.58 (m); 5.92 (m);









6.73 (broad); 7.30-7.50 (m)


I-290
CH3
H
R3-1
R4-4, R5 =
O
Y-1
δ = 1.18 (m); 1.95 (s);






C2H5


3.45 (broad); 3.73 (s); 4.67 (m);









5.70 (m); 5.90 (m); 7.35 (m); 7.53 (m);









7.67 (m)


I-291
CH3
H
R3-39
R4-1
O
Y-1
72° C.


I-292
CH3
H
R3-44
R4-1
O
Y-1
106-110° C.


I-293
CH3
H
R3-44
R4-1
NH
Y-1
177° C.


I-294
CH3
H
R3-177
R4-1
O
Y-1
δ = 1.93 (s); 3.20 (m); 3.28 (m);









3.83 (s); 3.90 (m); 4.05 (s);









4.42 (m); 4.50 (m); 5.88 (m); 5.94 (s);









6.83 (m); 7.25 (m); 7.50 (s)


I-295
CH3
H
R3-39
R4-1
NH
Y-1
142° C.


I-296
Iso-
H
R3-1
R4-1
O
Y-1
δ = 0.93 (m); 1.60 (m); 2.15 (d);



butyl





3.84 (s); 4.07 (s); 4.62 (m);









5.89 (m); 7.35 (d); 7.53 (d); 7.67 (s)


I-297
CH3
H
R3-29
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.65 (m); 5.95 (m); 7.27 (m);









7.87 (m); 8.35 (s)


I-298
CH3
H
R3-36
R4-1
O
Y-1
δ = 1.95 (s); 3.85 (s); 4.07 (s);









4.65 (m); 5.95 (m); 7.63 (m);









7.67 (m); 7.93 (s); 8.37 (s)


I-299
Iso-
H
R3-1
R4-1
NH
Y-1
177° C.



butyl


I-300
C2H5
H
R3-58
R4-1
O
Y-1
87° C.


I-301
CH3
H
R3-29
R4-1
NH
Y-1
140° C.


I-302
CH3
H
R3-36
R4-1
NH
Y-1
125° C.


I-303
CH3
H
R3-33
R4-1
O
Y-1
δ = 1.95 (s); 3.83 (s); 4.05 (s);









4.65 (m); 5.95 (m); 7.37 (m);









7.57 (m); 8.27 (s)


I-304
CH3
H
R3-54
R4-1
O
Y-1
δ = 1.25 (m); 1.95 (s); 2.68 (m);









3.83 (s); 4.05 (s); 4.65 (m);









5.95 (m); 7.30 (m); 7.51 (m); 8.20 (s)


I-305
CH3
H
R3-33
R4-1
NH
Y-1
126° C.


I-306
CH3
H
R3-54
R4-1
NH
Y-1
128° C.


I-307
CH3
H
R3-178
R4-1
O
Y-1
δ = 1.95 (s); 2.27 (s); 3.82 (s);









4.07 (s); 4.62 (m); 5.95 (m);









7.28 (m); 7.36 (m); 7.93 (s)


I-308
CH3
H
R3-130
R4-1
O
Y-4
δ = 1.95 (s); 2.25 (s); 3.80 (s);









4.05 (s); 4.55 (m); 5.90 (m);









7.25-7.60 (m); 7.77 (m); 7.85 (s);









8.05 (s); 8.27 (s)


I-309
CH3
H
R3-130
R4-1
NH
—CH═N—O—CH2
δ = 1.95 (s); 2.88 (d); 3.96 (s);









4.50 (m); 5.92 (m); 6.70 (broad);









7.25-7.60 (m); 7.76 (m); 8.05 (s);









8.08 (s); 8.27 (s)


I-310
CH3
H
R3-42
R4-1
O
Y-1
116° C.


I-311
C2H5
H
R3-58
R4-1
NH
Y-1
154° C.


I-312
CH3
H
R3-30
R4-1
NH
Y-1
167° C.


I-313
CH3
H
R3-178
R4-1
NH
Y-1
143° C.


I-314
CH3
H
R3-42
R4-1
NH
Y-1
147° C.


I-315
CH3
H
R3-40
R4-1
NH
Y-1
153° C.


I-316
CH3
H
R3-177
R4-1
NH
Y-1
δ = 1.93 (s); 2.88 (d); 3.20 (m);









3.28 (m); 3.90 (m); 3.95 (s);









4.42 (m); 4.50 (m); 5.90 (m); 5.95 (s);









6.67 (broad); 6.86 (m); 7.25 (m);









7.50 (s)


I-317
CH3
H
R3-179
R4-1
NH
Y-1
δ = 1.83 (s); 1.93 (s); 2.18 (s);









2.42 (m); 2.70 (m); 2.88 (d);









3.83 (s); 3.95 (s); 4.35 (m); 5.90 (m);









6.65 (m); 6.93 (m)


I-318
CH3
H
R3-38
R4-1
O
Y-1
87° C.


I-319
CH3
H
R3-32
R4-1
O
Y-1
δ = 1.93 (s); 2.27 (s); 3.80 (s);









4.05 (s); 4.62 (m); 5.95 (m);









7.30 (m); 7.93 (s)


I-320
CH3
H
R3-34
R4-1
NH
Y-1
120° C.


I-321
CH3
H
R3-38
R4-1
NH
Y-1
143° C.


I-322
CH3
H
R3-37
R4-1
NH
Y-1
117° C.


I-323
CH3
H
R3-40
R4-1
O
Y-1
118° C.


I-324
CH3
H
R3-37
R4-1
O
Y-1
δ = 1.93 (s); 2.23 (s); 2.35 (s);









3.80 (s); 4.05 (s); 4.62 (m);









5.95 (m); 7.15 (m); 7.91 (s)


I-325
CH3
H
R3-43
R4-1
NH
Y-1
136° C.


I-326
CH3
H
R3-34
R4-1
O
Y-1
δ = 1.95 (s); 3.83 (s); 4.05 (s);









4.63 (m); 5.95 (m); 7.67 (m);









7.82 (m); 8.42 (s)


I-327
CH3
H
R3-32
R4-1
NH
Y-1
δ = 2.07 (s); 2.42 (s); 2.92 (d);









4.08 (s); 4.78 (m); 6.08 (m);









6.93 (broad); 7.45 (m); 8.08 (s)


I-328
CH3
H
R3-41
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.95 (s);









4.65 (m); 5.93 (m); 6.73 (broad);









7.30 (m); 7.55 (m); 8.23 (s)


I-329
CH3
H
R3-28
R4-1
NH
Y-1
94° C.


I-330
CH3
H
R3-50
R4-1
NH
Y-1
130° C.


I-331
CH3
H
R3-41
R4-1
O
Y-1
δ = 1.95 (s); 3.87 (s); 4.06 (s);









4.63 (m); 5.93 (m); 7.32 (m);









7.55 (m); 8.23 (s)


I-332
C2H5
H
R3-2
R4-1
O
Y-1
δ = 1.05 (t); 2.30 (m); 3.82 (s);









4.05 (s); 4.62 (d); 5.90 (m);









6.93 (m); 7.73 (m); 7.80 (m)


I-333
CH3
H
R3-180
R4-1
O
Y-1
δ = 1.95 (s); 2.27 (s); 3.85 (s);









4.07 (s); 4.40 (m); 5.88 (m);









6.66 (d); 6.78 (m); 7.37 (m); 7.45 (m);









7.83 (d)


I-334
CH3
H
R3-77
R4-1
O
Y-1
123-124° C.


I-335
CH3
H
R3-119
R4-1
O
Y-4
δ = 1.90 (s); 2.12 (s); 3.83 (s);









3.92 (s); 4.03 (s); 4.33 (m);









5.74 (m); 7.18-7.45 (m)


I-336
CH3
H
R3-80
R4-1
O
Y-1
133-134° C.


I-337
CH3
H
R3-180
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.90 (d);









3.97 (s); 4.40 (m); 5.88 (m);









6.66 (broad); 6.82 (m); 7.37 (m);









7.45 (m); 7.81 (d)


I-338
CH3
H
R3-79
R4-1
O
Y-1
94-97° C.


I-339
CH3
H
R3-119
R4-1
NH
Y-4
δ = 1.90 (s); 2.12 (s); 2.85 (d);









3.92 (s); 4.33 (m); 5.75 (m);









6.60 (broad); 7.18-7.45 (m)


I-340
CH3
H
R3-130
R4-1
O
—CH═N—O—CH2
δ = 1.95 (s); 3.82 (s); 4.05 (s);









4.52 (m); 5.87 (m); 7.25-7.60 (m);









7.75 (m); 7.80 (s); 8.05 (s);









8.26 (s)


I-341
CH3
H
R3-130
R4-1
NH
Y-4
δ = 1.95 (s); 2.25 (s); 2.83 (d);









3.97 (s); 4.54 (m); 5.93 (m);









6.75 (broad); 7.25-7.60 (m); 7.77 (m);









7.82 (s); 8.02 (s); 8.29 (s)


I-342
CH3
H
R3-181
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.88 (d);









3.97 (s); 4.39 (m); 5.93 (m);









6.67 (broad); 6.80 (m); 7.08 (m);









7.27 (m); 7.45 (m)


I-343
CH3
H
R3-182
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.91 (d);









3.98 (s); 4.41 (m); 5.93 (m);









6.70 (broad); 6.85 (m); 7.37 (m);









7.65 (m)


I-344
CH3
H
R3-183
R4-1
NH
Y-1
δ = 1.95 (s); 2.25 (s); 2.91 (d);









3.98 (s); 4.40 (m); 5.93 (m);









6.66 (broad); 6.83 (m); 7.25-7.46 (m)


I-345
CH3
H
R3-184
R4-1
NH
Y-1
δ = 1.95 (s); 2.25 (s); 2.90 (d);









3.85 (s); 3.98 (s); 4.38 (m);









5.93 (m); 6.66 (broad); 6.82 (m);









7.30 (m)


I-346
CH3
H
R3-185
R4-1
NH
Y-1
δ = 1.95 (s); 2.20 (s); 2.88 (d);









3.95 (s); 4.30 (m); 4.98 (s);









5.92 (m); 6.65 (m); 6.80 (m); 7.40 (m)


I-347
CH3
H
R3-69
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.95 (s);









4.65 (m); 5.92 (m); 6.67 (broad);









6.87 (m); 7.25 (m); 7.67 (m)


I-348
CH3
H
R3-186
R4-1
NH
Y-1
δ = 1.42 (m); 1.95 (s); 2.27 (s);









2.91 (d); 2.96 (m); 3.98 (s);









4.42 (m); 5.93 (m); 6.70 (broad);









6.83 (m); 7.87 (m)


I-349
C2H5
H
R3-5
R4-1
NH
Y-1
98° C.


I-350
CH3
H
R3-88
R4-1
O
Y-1
δ = 1.95 (s); 3.53 (s); 3.85 (s);









4.05 (s); 4.50 (m); 5.65 (s);









5.90 (m); 7.28 (m); 7.50 (s)


I-351
CH3
H
R3-88
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.50 (s);









3.97 (s); 4.48 (m); 5.65 (m);









5.93 (m); 6.70 (broad); 7.28 (m);









7.50 (s)


I-352
CH3
H
R3-76
R4-1
NH
Y-1
δ = 1.95 (s); 2.27 (s); 2.87 (d);









3.95 (s); 4.63 (m); 5.93 (m);









6.66 (broad); 7.35 (m); 7.77 (m)


I-353
CH3
H
R3-187
R4-1
NH
Y-1
δ = 1.95 (s); 2.87 (d); 3.97 (s);









4.63 (m); 5.90 (d); 5.95 (m);









6.70 (broad); 7.48 (m); 7.85 (m);









7.97 (d)


I-354
CH3
H
R3-188
R4-1
NH
Y-1
δ = 1.93 (s); 2.77 (d); 3.93 (s);









4.54 (m); 5.92 (m); 6.80 (broad);









7.33 (m); 7.45 (m)


I-355
CH3
H
R3-189
R4-1
NH
Y-1
δ = 1.95 (s); 2.85 (d); 3.95 (s);









4.55 (m); 5.92 (m); 6.70 (broad);









7.23 (m); 7.40 (m); 7.64 (s);









7.78 (d)


I-356
CH3
H
R3-193
R4-1
NH
Y-1
δ = 1.94 (s); 2.87 (d); 3.94 (s);









4.44 (m); 5.17 (s); 5.67 (d);









5.88 (m); 6.70 (broad); 6.86 (m);









7.20 (m); 7.37 (d)


I-357
CH3
H
R3-194
R4-1
NH
Y-1
δ = 1.95 (s); 2.80 (d); 3.95 (s);









4.55 (m); 5.87 (d); 5.93 (m);









6.75 (broad); 7.25 (m); 7.35 (m);









7.45 (m); 7.55 (m); 7.70 (d)


I-358
CH3
H
R3-83
R4-1
NH
Y-1
δ = 1.95 (s); 2.90 (d); 3.95 (s);









4.57 (m); 5.92 (m); 6.13 (s);









6.83 (broad); 7.45 (m); 7.35 (m);









7.70 (m)


I-359
CH3
H
R3-195
R4-1
NH
Y-1
δ = 1.95 (s); 2.50 (s); 2.88 (d);









3.95 (s); 4.57 (m); 5.85 (d);









5.95 (m); 6.70 (broad); 6.90 (m);









7.60 (m); 8.33 (d)





*“phenyl ring” denotes that R1 and R2 together with the two carbon atoms linking them form a phenyl ring.


Isobutyl = 2-methyl-1-propyl.


m.p. = melting point;


Rt = HPLC Retention time.


HPLC-data: RP-18 column (Chromolith Speed ROD 50 × 4.6 mm from Merck KgaA, Germany), 1.8 ml/min, injection volume 2 μl, column temperature 40° C.


Eluent: Acetonitrile + 0.1% trifluoroacetic acid (TFA)/water + 0.1% TFA (gradient %:95 to 95:5 within 5 min), 40° C. MS: Quadrupole electrospray ionisation, 80 V (pos. mode).






II. EXAMPLES OF THE ACTION AGAINST HARMFUL FUNGI

The fungicidal action of the compounds of the formula I was demonstrated by the following experiments:


II.1 Microtiter Tests

The active substances were formulated separately as a stock solution in dimethyl sulfoxide (DMSO) at a concentration of 10 000 ppm.


Use Example 1: Activity Against the Septoria Blotch Pathogen Caused by Septoria tritici in the Microtiter Test
Fungal Strains Used:

a) Septoria tritici (Qo-inhibitor sensitive, wild-type)


b) Septoria tritici (Qo-inhibitor-resistant, G143A mutant)


100 ml 2% Malt extract in water at pH6.8 were inoculated with microspores from 2 week old cultures grown on 2% malt extract+2% agar in Petri dishes and incubated for 3 days on a rotary shaker at 24° C. and 150 rpm. The culture was harvested, glycerol was added (15% (v/v) and kept frozen at −20° C. in aliquots of 1 ml.


1 ml stock suspension was thawed and suspended into 800 ml of 2% malt extract in water at pH 6.8. Compounds were diluted from stock solution in (dimethylsulfoxide) DMSO in 10 steps. The compound solutions were diluted ⅕ with sterile deionized water before use. 5 μl of the compound solutions were transferred into empty microplates. The plates were then filled with 195 μl of the microspore suspension of each strain.


The antifungal activity was determined by measuring the turbidity of a culture in 96-well microplates in the presence of test compounds. Fungal growth was measured by recording the optical density at 620 nm every 15 h for 150 h. The relative antifungal activity was calculated by comparison of the effect of the test compounds with the effect of a DMSO control and a standard fungicide.


IC50-values (concentration of test compound resulting in 50% inhibition of fungal growth) were calculated from the resulting dose-response for each compound and strain. The initial concentration of the test compounds and the 10 steps of dilution (1:4 each) allowed IC50-values from 0.001 to 100 μmol/l (μM) to be assessed.












TABLE II






Resistant Septoria
Sensitive Septoria
Resistance




tritici isolate


tritici isolate

factor



(G143A mutation)
(wild type)
RF = R-


Compound
(R-IC50) [μM]
(S-IC50) [μM]
IC50/S-IC50


















Azoxystrobin
>100
3.5
n.d.


Dimoxystrobin
>100
7.1
n.d.


Enestroburin
>100
4.5
n.d.


Kresoximmethyl
>100
0.76
n.d.


Metominostrobin
>100
>100
n.d.


Orysastrobin
>100
27
n.d.


Picoxystrobin
>100
2.3
n.d.


Pyrametostrobin
>100
>100
n.d.


Pyraoxystrobin
>100
1.6
n.d.


Pyraclostrobin
3.4
0.0012
2882


Trifloxystrobin
>100
0.52
n.d.


I-5
2.2
0.083
26


I-6
8.3
0.34
24


I-82
6.8
1.1
6


I-83
7.6
1.6
4.6


I-84
16.1
0.5
33


I-85
22
0.8
29


I-90
26
1.0
26


I-91
27
1.6
17


I-94
12
0.6
22


I-95
29
2.2
14


I-97
49
1.7
29


I-191
37
1.3
29


I-211
1.1
0.44
2.6


I-212
8.3
1.4
6


I-213
0.057
0.076
0.7


I-215
48
1.7
28


I-216
12.0
6.3
2.0


I-217
63
6.3
10


I-218
79
5.6
14


I-221
10
3.4
3


I-223
19
2.7
7


I-224
5.4
1.7
3.2


I-225
72
3.4
21


I-228
10
3.4
3.0


I-230
25
3.2
8


I-233
2.7
0.24
12


I-234
4
2.4
1.7


I-235
51
13
4


I-236
24
6
4


I-238
12
6
1.9


I-243
15
4.1
3.6


I-244
1.3
0.6
2.0


I-247
9
5
1.9


I-249
11
2.4
5


I-250
97
19
5


I-255
42
19
2.2


I-256
24
21
1.1


I-257
67
15
4.5


I-260
3.3
2.3
1.4


I-261
5
2.9
1.6


I-262
1.6
1
1.6


I-265
4
3.8
1.1


I-267
5
2.9
1.7


I-269
74
8
10


I-270
57
6
10


I-271
7
1.9
3.9


I-273
22
5
4


I-274
19
9
2.0


I-287
18
1.5
12


I-288
28
3.5
8.0


I-291
18
1.0
18.0


I-292
33
7.9
4.2


I-298
31
3.6
8.6


I-303
4.6
0.27
17.0


I-304
9.1
0.53
17.2


I-305
32
9.3
3.4


I-307
67
19.0
3.5


I-310
11
0.39
28.2


I-319
102
17.0
6.0


I-324
38
1.9
20.0


I-326
18
1.2
15.0


I-331
25
1.8
13.9


I-339
21
1.0
21.0









While commercial strobilurine type fungicides are do not show any activity against the resistant Septoria strain, containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors (G143A) while being active against sensitive wild type strains, compounds I have been active against both, the resistant and the wild-type strains. In general, the resistance factor ratio (RF) calculated from the IC50 values determined for both Septoria strains, was below 30 for the compounds I according to the invention. However, resistance factor ratios for commercial strobilurine type compounds are in most cases greater than 100 and usually greater than several hundreds (for details see e.g. FRAC, Mutations associated with QoI-resistance, December 2006; http://frac.info/frac/work/Mutations%20associated%20with%20QoI%20resistance.pdf and citations cited therein).


II.2 Comparative Examples
A) Field Trials
Compounds Used:

Compound I-6 was used as 50 g/l EC formulation. Pyraclostrobin was used as commercial product HEADLINE.


Compounds Used:




embedded image


Trial 1: Efficacy Against Septoria tritici on Winter Wheat


The trial was conducted under field conditions in Bohl-Iggelheim, Rhineland-palatinate,


Germany. Seeds of winter wheat (cv. Riband) were planted and grown under standard conditions with adequate supply of water and nutrients. At growing stage GS 32 (Apr. 14, 2011), a first compound treatment (200 g a.i. per ha) was made with a water volume of 400 L/ha, which was repeated 21 days later at growing stage GS 39. No further fungicide treatments were applied. Infection with fungal pathogens (e.g. Septoria tritici) occurred naturally. The evaluation of the disease incidences for Septoria tritici 20, 33 and 46 days after the last treatment (DAA) are shown in table III. In the last row, the evaluation of the percentage of Qo inhibitor-resistant Septoria tritici isolates with the G143A mutation after the treatments is given.












TABLE III










Percentage of



Disease (%)
G143A mutation













Concentration
20
33
46
(%) in Septoria


Treatment
(g a.i./ha)
DAA
DAA
DAA

tritici isolates
















Compound I-6
200
1
6
36
100


Pyraclostrobin
200
8
32
93
100


untreated

13
47
96
65









In this test, the fungal pathogen Septoria tritici has been completely selected towards Qo inhibitor-resistant isolates by each of the treatments with the strobilurin-analogue compounds Pyraclostrobin and Compound I-6. Due to this high resistance level, Pyraclostrobin showed insufficient control level although it has been used at commercial dose levels, whereas Compound I-6 was capable to control the Qo inhibitor-resistant isolates of Septoria tritici with the G143 mutation.


Trial 2: Efficacy Against Septoria tritici on Winter Wheat


This trial was conducted under field conditions in Limburgerhof, Rhineland-Palatinate, Germany. Seeds of winter wheat (cv. Riband) were planted and grown under standard conditions with adequate supply of water and nutrients. At growing stage GS 33 (Apr. 8, 2011), a first compound treatment (200 g a.i per ha) was made with a water volume of 400 L/ha, which was repeated 26 days later at growing stage GS 39. No further fungicide treatments were applied. Infection with fungal pathogens (e.g. Septoria tritici) occurred naturally. The evaluation of the disease incidences for Septoria tritici 19 and 34 days after the last treatment (DAA) are shown in Table IV. In the last row, the evaluation of the percentage of Qo inhibitor-resistant Septoria tritici isolates with the G143A mutation after the treatments is given.












TABLE IV









Disease (%)
Percentage of












Concentration
19
34
G143A mutation (%)


Treatment
(g a.i./ha)
DAA
DAA
in Septoria tritici isolates














Compound I-6
200
3
12
99


Pyraclostrobin
200
5
28
100


untreated

10
36
94









In this test, about the entire population of the fungal pathogen Septoria tritici has been Qo inhibitor-resistant (as evaluated at the end of the trial). Due to this high resistance level, Pyraclostrobin has shown antifungal activity only slightly above the untreated control although it has been used at commercial dose levels. However Compound I-6 was capable to reduce the infection by Qo inhibitor-resistant Septoria tritici with the G143 mutation significantly.


B) Glass House Trials

The spray solutions were prepared in several steps:


The stock solution was prepared as follows: 1.26 ml of a 1:1 mixture of cyclohexanone and dimethylsulfoxide was added to 8.4 mg of active ingredient. Next, 40.74 ml of a mixture of water, acetone (10%), the emulsifier Wettol (0.1%) and the wetting agent Silwet (0.05%) was added. This stock solution was then further diluted with the described solvent-emulsifier-water mixture to the desired concentrations.


Trial 3: Control of Leaf Blotch on Wheat Caused by Caused by Two Septoria tritici Isolates Containing the G143A in the Cytochrome b Gene for their Cytochrome bc1 Complex


Wheat plants were grown in pots. These plants were sprayed to run-off with an aqueous suspension, containing the desired concentration of active ingredient. The next day, the treated plants were inoculated with an aqueous suspension of Septoria tritici. After inoculation, the trial plants were covered with a lid and immediately transferred to a chamber with a relative humidity of about 83 to 85% and 19.5 to 20° C. After 4 days the lid was removed. Altogether, the trial plants were cultivated for about 28 days in that greenhouse chamber. The extent of fungal attack on the leaves was then visually assessed as % diseased leaf area.












TABLE VII







Resistant Septoria
Resistant Septoria





tritici isolate 1


tritici isolate 2




Conc.
(G143A mutation)
(G143A mutation)


Treatment
(ppm)
Disease level (%)
Disease level (%)


















I-7
200
3
0


I-7
100
3
1


I-7
50
20
5


I-7
25
80
15


I-7
12.5
100
90


I-211
200
1
0


I-211
100
3
1


I-211
50
10
5


I-211
25
60
10


I-211
12.5
80
30


I-14
200
3
1


I-14
100
15
5


I-14
50
70
15


I-14
25
80
70


I-14
12.5
100
90


I-6
200
1
0


I-6
100
3
3


I-6
50
3
3


I-6
25
10
15


I-6
12.5
50
20


I-11
200
1
1


I-11
100
3
5


I-11
50
30
30


I-11
25
90
50


I-11
12.5
100
70


Pyraclostrobin
200
30
15


Pyraclostrobin
100
90
25


Pyraclostrobin
50
100
40


Pyraclostrobin
25
100
60


Pyraclostrobin
12.5
100
60


Trifloxystrobin
200
90
60


Trifloxystrobin
100
90
70


Trifloxystrobin
50
90
70


Trifloxystrobin
25
100
70


Trifloxystrobin
12.5
100
80









III. MOLECULAR MODELING
III.1 Structural Models of Wild-Type and G143A Mutant Binding Site

Structural models of the binding site of wild-type and G143A cytochrome bc1 complex were generated based on the crystallographic structure of bovine cytochrome bc1 complex with azoxystrobin bound to the Qo-site (PDB: 1SQB: Esser et al. J Mol Biol 341, 281-302 (2004)).


The structure was imported into Schrödinger Maestro (version 9.0, Schrödinger, LLC, New York, N.Y., 2009).


Cytochrome b was isolated from the structure of the complex and treated with the Schrödinger Protein Preparation Wizard (Schrödinger Suite 2009 Protein Preparation Wizard; Epik version 2.0, Schrödinger, LLC, New York, N.Y., 2009; Impact version 5.5, Schrödinger, LLC, New York, N.Y., 2009, Prime version 2.1, Schrödinger, LLC, New York, N.Y., 2009).


This structure was used as the model for the wild-type binding site without further changes.


The model of the G143A mutant was generated by changing a hydrogen in Glycine 143 of the wild-type model into a methyl group, thereby generating S-Alanine, using Schrödinger Maestro. Amino acids in a sphere of 5 Å around the co-crystallized molecule of azoxystrobin were energy-minimized using Schrödinger MacroModel (version 9.7, Schrödinger, LLC, New York, N.Y., 2009).


III.2 Molecular Docking

Structures of inhibitors were prepared for docking with Schrödinger LigPrep (version 2.3, Schrödinger, LLC, New York, N.Y., 2009) and docked into the structural models using Schrödinger Glide (version 5.5, Schrödinger, LLC, New York, N.Y., 2009).


III.3 Graphics of Inhibitors Bound to Cytochrome bc1 Complex

Graphical representations of poses from the docking runs were generated using Molecular Operating Environment (MOE; 2010.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2010) and refined using the GNU Image Manipulation Program (GIMP, version 2.6.8, 2008).


As illustrated in FIG. 1 molecular modelling of an artificial Qo inhibitor-resistant cytochrome bc1 complex with the mutation G143A (see below for details) has been carried out. Docking of the commercial storbilurine analogue compound pyraclostrobin shows the steric clash resulting in impaired binding of this active ingredient in the G143A mutant cytochrome bc1 complex. The compounds of the present invention largely avoid this steric clash by either replacing the central phenyl ring of pyraclostrobin with a smaller and/or more flexible two carbon unit which may be suitably substituted or by replacing the well known pharmacophores with the smaller tetrazolinone moiety R4-7.


III.4 Number of Van-Der-Waals Clashes Between Inhibitors and Alanine G143A

The docked ligands were transferred to the G143A binding site model keeping the coordinates from docking into the wild-type model. Thereby, complexes between the G143A binding site and ligands were formed. Those were used as starting structures for the following energy minimization using Schrödinger MacroModel. During these simulations, only the ligand was allowed to move freely, the protein was considered “frozen”. The poses generated by this procedure were considered as the relaxed state of the inhibitors after introduction of the G143A mutation.


Two atoms are considered to be sterically clashing, if the distance between their centers is shorter than 0.9 times the sum of their Van-der-Waals radii. For the atoms pairs relevant for strobilurin interaction with Alanine 143 the respective distances are described in Table V.














TABLE V









vdW-S
Clash


Atom 1
vdW-Radius 1
Atom 2
vdW-Radius 2
um
Distance







C
1.70
C
1.70
3.40
3.06


C
1.70
N
1.55
3.25
2.93


C
1.70
O
1.52
3.22
2.90


C
1.70
H
1.20
2.90
2.61


H
1.20
N
1.55
2.75
2.48


H
1.20
O
1.52
2.72
2.45









After minimization in the G143A binding site as described above, the number of steric Van-der-Waals clashes with Alanine 143 was counted for each inhibitor. The results are given in the Table VI.












TABLE VI







Compound
No. of clashes









I-5
3



I-6
3



Pyrametostrobin
6



Metominostrobin
6



Azoxystrobin
7



Enestroburin
7



Pyraclostrobin
7



Dimoxystrobin
7



Orysastrobin
7



Pyraoxystrobin
8



Picoxystrobin
8



Trifloxystrobin
8



Kresoxim-Methyl
8










It was found that compounds I have a small number of steric Van-der-Waals clashes and also have unexpectedly high activity against Qo inhibitor-resistant fungal strains harboring said G143A mutation in microtiter titer tests as well as in field trials on sites which have a high portion of Qo inhibitor-resistant fungi strains harboring said G143A mutation (see below).

Claims
  • 1. (canceled)
  • 2. A compound of formula (I)
  • 3. The compound of claim 2, wherein R1 is selected from the group consisting of hydrogen, halogen, C1-C4-alkyl, C1-C4-chloroalkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl and C1-C4-haloalkoxy-C1-C4-alkyl.
  • 4. The compound of claim 3, wherein R1 is methyl or ethyl.
  • 5. The compound of claim 2, wherein R2 is hydrogen.
  • 6. The compound of claim 2, wherein Y is selected from the group consisting of —OCH2—, —CH2CH2—, —C(CH3)═N—O—CH2—, —O—N═C(CH3)—C(CH3)═N—O—CH2— and —C(═N—O—CH3)—C(CH3)═N—O—CH2—.
  • 7. The compound of claim 1, wherein Rb is phenyl, wherein said phenyl is optionally substituted by 1, 2, 3 or up to the maximum possible number of identical or different groups Rc, which may be the same or different to any other Rc, wherein Rc is selected from the group consisting of halogen, C1-C4-alkyl, C2-C4-alkenyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkoxyimino-C1-C4-alkyl, phenyl and a 5-membered saturated, partially unsaturated or aromatic heterocyclyl which, in addition to carbon atoms, contains one to three heteroatoms selected from the group consisting of N, O and S as ring members; and wherein the aforementioned heterocyclyl groups Rc are attached via a direct bond, an oxygen or sulfur atom and for their part may carry 1, 2, 3 or up to the maximum possible number of identical or different groups Rd.
  • 8. The compound of claim 2, wherein R4 is selected from the group consisting of —C(═NOCH3)—CONHCH3, —C(═NOCH3)—COOCH3, —C(═CHOCH3)COOCH3, —C(═CHOCH3)—CONHCH3, —N(OCH3)—COOCH3, —N(CH3)—COOCH3 and —N(CH2CH3)—COOCH3.
  • 9. The compound of claim 2, wherein R3 is
  • 10. An agrochemical composition comprising an auxiliary and at least one compound of formula I, as defined in claim 2, an N-oxide or an agriculturally acceptable salt thereof.
  • 11. The composition of claim 10 comprising at least one further active substance.
  • 12. The composition of claim 11, wherein the further active substance is selected from the classes A) to O): A) Respiration inhibitors Inhibitors of complex III at Qo site selected from azoxystrobin, coumethoxystrobin, coumoxystrobin, dimoxystrobin, enestroburin, fenaminstrobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, trifloxystrobin, 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneaminooxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, and fenamidone;inhibitors of complex III at Qi site selected from cyazofamid, amisulbrom, [(3 S,6 S, 7R, 8R)-8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[(3-isobutoxycarbonyloxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3 S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-benzodioxol-5-ylmethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, and (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate;inhibitors of complex II selected from: benodanil, benzovindiflupyr, bixafen, boscalid, carboxin, fenfuram, fluopyram, flutolanil, fluxapyroxad, furametpyr, isopyrazam, mepronil, oxycarboxin, penflufen, penthiopyrad, sedaxane, tecloftalam, thifluzamide, N-(4′-trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(2-(1,3,3-trimethyl-butyl)-phenyl)-1,3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(difluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, and 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide;other respiration inhibitors selected from diflumetorim, (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluoromethylpyridin-2-yloxy)-phenyl]-ethyl}-amine, binapacryl, dinobuton, dinocap, fluazinam, ferimzone, fentin salts, ametoctradin, and silthiofam;B) Sterol biosynthesis inhibitors C14 demethylase inhibitors selected from azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, diniconazole-M, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, 1-[rel-(2S; 3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-oxiranylmethyl]-5-thiocyanato-1H-[1,2,4]triazole, 2-[rel-(2S;3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-oxiranylmethyl]-2H-[1,2,4]triazole-3-thiol, imazalil, pefurazoate, prochloraz, triflumizol, fenarimol, nuarimol, pyrifenox, and triforine;Delta14-reductase inhibitors selected from aldimorph, dodemorph, dodemorph-acetate, fenpropimorph, tridemorph, fenpropidin, piperalin, and spiroxamine;Inhibitors of 3-keto reductase selected from fenhexamid;C) Nucleic acid synthesis inhibitors phenylamides or acyl amino acid fungicides selected from benalaxyl, benalaxyl-M, kiralaxyl, metalaxyl, metalaxyl-M, ofurace, and oxadixyl;other nucleic acid synthesis inhibitors selected from hymexazole, octhilinone, oxolinic acid, bupirimate, 5-fluorocytosine, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, and 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine;D) Inhibitors of cell division and cytoskeleton benzimidazole and thiophanate tubulin inhibitors selected from benomyl, carbendazim, fuberidazole, thiabendazole, and thiophanate-methyl;triazolopyrimidines selected from 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine;other cell division inhibitors selected from diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone, and pyriofenone;E) Inhibitors of amino acid and protein synthesis methionine synthesis inhibitors selected from cyprodinil, mepanipyrim, and pyrimethanil;protein synthesis inhibitors selected from blasticidin-S, kasugamycin, kasugamycin hydrochloride-hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, and validamycin A;F) Signal transduction inhibitors MAP/histidine kinase inhibitors selected from fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, and fludioxonil;G protein inhibitors selected from quinoxyfen;G) Lipid and membrane synthesis inhibitors Phospholipid biosynthesis inhibitors selected from edifenphos, iprobenfos, pyrazophos, and isoprothiolane;lipid peroxidation inhibitors selected from dicloran, quintozene, tecnazene, tolclofos-methyl, biphenyl, chloroneb, and etridiazole;phospholipid biosynthesis and cell wall deposition inhibitors selected from: dimethomorph, flumorph, mandipropamid, pyrimorph, benthiavalicarb, iprovalicarb, valifenalate and N-(1-(1-(4-cyano-phenyl)ethanesulfonyl)-but-2-yl), and carbamic acid-(4-fluorophenyl) ester;compounds affecting cell membrane permeability and fatty acids selected from propamocarb and propamocarb-hydrochlorid;fatty acid amide hydrolase inhibitor selected from 1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone;H) Inhibitors with Multi-site Action inorganic active substances selected from Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride, basic copper sulfate, sulfur;thio- and dithiocarbamates selected from ferbam, mancozeb, maneb, metam, metiram, propineb, thiram, zineb, and ziram;organochlorine compounds selected from anilazine, chlorothalonil, captafol, captan, folpet, dichlofluanid, dichlorophen, flusulfamide, hexachlorobenzene, pentachlorphenole and its salts, phthalide, tolylfluanid, and N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methyl-benzenesulfonamide;guanidines and other inhibitors with multi-site action selected from guanidine, dodine, dodine free base, guazatine, guazatine-acetate, iminoctadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), dithianon, and 2,6-dimethyl-1H,5H[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone;I) Cell wall synthesis inhibitors inhibitors of glucan synthesis selected from: validamycin and polyoxin B;melanin synthesis inhibitors selected from pyroquilon, tricyclazole, carpropamid, dicyclomet, and fenoxanil;J) Plant defence inducers selected from: acibenzolar-S-methyl, probenazole, isotianil, tiadinil, prohexadione-calcium; phosphonates: fosetyl, fosetyl-aluminum, and phosphorous acid and its salts;K) Active substances with unknown mode of actions selected from: bronopol, chinomethionat, cyflufenamid, cymoxanil, dazomet, debacarb, diclomezine, difenzoquat, difenzoquat-methylsulfate, diphenylamin, fenpyrazamine, flumetover, flusulfamide, flutianil, methasulfocarb, nitrapyrin, nitrothal-isopropyl, oxathiapiprolin, oxin-copper, proquinazid, tebufloquin, tecloftalam, triazoxide, 2-butoxy-6-iodo-3-propylchromen-4-one, N-(cyclopropylmethoxyimino-(6-difluoromethoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, N′-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, methoxy-acetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl ester, 3-[5-(4-methylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxylic acid amide, 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole, and 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxyphenyl)-isoxazol-5-yl]-2-prop-2-ynyloxy-acetamide;L) Antifungal biocontrol agents and plant bioactivators selected from: Ampelomyces quisqualis, Aspergillus flavus, Aureobasidium pullulans, Bacillus pumilus, Bacillus subtilis, Bacillus subtilis var. amyloliquefaciens FZB24, Candida oleophila I-82, Candida saitoana, Chitosan, Clonostachys rosea f. catenulata, Coniothyrium minitans, Cryphonectria parasitica, Cryptococcus albidus, Fusarium oxysporum, Metschnikowia fructicola, Microdochium dimerum, Phlebiopsis gigantea, Pseudozyma flocculosa, Pythium oligandrum DV74, Reynoutria sachlinensis, Talaromyces flavus V117b, Trichoderma asperellum SKT-1, T. atroviride LC52, T. harzianum T-22, T. harzianum TH 35, T. harzianum T-39, T. harzianum and T. viride, T. harzianum ICC012 and T. viride ICC080, T. polysporum and T. harzianum, T. stromaticum, T. virens GL-21, T. viride, T. viride TV1, and Ulocladium oudemansii HRU3;M) Growth regulators selected from: abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassinolide, butralin, chlormequat chloride, choline chloride, cyclanilide, daminozide, dikegulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat chloride, naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione-calcium, prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-iodobenzoic acid, and trinexapac-ethyl and uniconazole;N) Herbicides acetamides selected from acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, metolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, and thenylchlor;amino acid derivatives selected from bilanafos, glyphosate, glufosinate, and sulfosate;aryloxyphenoxypropionates selected from clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, haloxyfop, metamifop, propaquizafop, quizalofop, and quizalofop-P-tefuryl;Bipyridyls selected from diquat and paraquat;(thio)carbamates selected from asulam, butylate, carbetamide, desmedipham, dimepiperate, eptam, esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyributicarb, thiobencarb, and triallate;cyclohexanediones selected from butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, and tralkoxydim;dinitroanilines selected from benfluralin, ethalfluralin, oryzalin, pendimethalin, prodiamine, and trifluralin;diphenyl ethers selected from acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, and oxyfluorfen;hydroxybenzonitriles selected from bomoxynil, dichlobenil, and ioxynil;imidazolinones selected from imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, and imazethapyr;phenoxy acetic acids selected from clomeprop, 2,4-dichlorophenoxyacetic acid, 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, and Mecoprop;pyrazines selected from chloridazon, flufenpyr-ethyl, fluthiacet, norflurazon, and pyridate;pyridines selected from aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, picloram, picolinafen, and thiazopyr;sulfonyl ureas selected from amidosulfuron, azimsulfuron, bensulfuron, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metazosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, and 1-((2-chloro-6-propyl-imidazo[1,2-b]pyridazin-3-yl)sulfonyl)-3-(4,6-dimethoxy-pyrimidin-2-yl)urea;triazines selected from ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, metamitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, and triaziflam;ureas selected from chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, and tebuthiuron;other acetolactate synthase inhibitors selected from: bispyribac-sodium, cloransulam-methyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, penoxsulam, propoxycarbazone, pyribambenz-propyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, and pyroxsulam;other herbicides selected from amicarbazone, aminotriazole, anilofos, beflubutamid, benazolin, bencarbazone, benfluresate, benzofenap, bentazone, benzobicyclon, bicyclopyrone, bromacil, bromobutide, butafenacil, butamifos, cafenstrole, carfentrazone, cinidon-ethyl, chlorthal, cinmethylin, clomazone, cumyluron, cyprosulfamide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanid, fenoxasulfone, fentrazamide, flumiclorac-pentyl, flumioxazin, flupoxam, flurochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, quinclorac, quinmerac, mesotrione, methyl arsonic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefone, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazoxyfen, pyrazolynate, quinoclamine, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, topramezone, (3-[2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-phenoxy]-pyridin-2-yloxy)-acetic acid ethyl ester, 6-amino-5-chloro-2-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-chloro-3-(2-cyclopropyl-6-methylphenoxy)-pyridazin-4-ol, 4-amino-3-chloro-6-(4-chloro-phenyl)-5-fluoro-pyridine-2-carboxylic acid, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)pyridine-2-carboxylic acid methyl ester, and 4-amino-3-chloro-6-(4-chloro-3-dimethylamino-2-fluoro-phenyl)-pyridine-2-carboxylic acid methyl ester;O) Insecticides organo(thio)phosphates selected from acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phosphamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon;carbamates selected from: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, fenoxycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, and triazamate;pyrethroids selected from: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, and dimefluthrin;insect growth regulators selected from a) chitin synthesis inhibitors selected from benzoylureas: chlorfluazuron, cyramazin, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, and clofentazine; b) ecdysone antagonists selected from halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, and fenoxycarb; and d) lipid biosynthesis inhibitors selected from spirodiclofen, spiromesifen, and spirotetramat;nicotinic receptor agonists/antagonists compounds selected from clothianidin, dinotefuran, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, and 1-(2-chloro-thiazol-5-ylmethyl)-2-nitrimino-3,5-dimethyl-[1,3,5]triazinane;GABA antagonist compounds selected from endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, and 5-amino-1-(2,6-dichloro-4-methylphenyl)-4-sulfinamoyl-1H-pyrazole-3-carbothioic acid amide;macrocyclic lactone insecticides selected from abamectin, emamectin, milbemectin, lepimectin, spinosad, and spinetoram;mitochondrial electron transport inhibitor I acaricides selected from fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, and flufenerim;METI II and III compounds selected from acequinocyl, fluacyprim, and hydramethylnon;Uncouplers selected from chlorfenapyr;oxidative phosphorylation inhibitors selected from cyhexatin, diafenthiuron, fenbutatin oxide, and propargite;moulting disruptor compound selected from cryomazine;mixed function oxidase inhibitor selected from piperonyl butoxide;sodium channel blockers selected from indoxacarb and metaflumizone;other insecticides selected from benclothiaz, bifenazate, cartap, flonicamid, pyridalyl, pymetrozine, sulfur, thiocyclam, flubendiamide, chlorantraniliprole, cyazypyr, cyenopyrafen, flupyrazofos, cyflumetofen, amidoflumet, imicyafos, bistrifluron, and pyrifluquinazon.
  • 13. The composition of claim 10, wherein R1 in the compound of formula I is selected from the group consisting of hydrogen, C1-C4-alkyl, C1-C4-chloroalkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl and C1-C4-haloalkoxy-C1-C4-alkyl.
  • 14. The composition of claim 10, wherein R1 in the compound of formula I is methyl or ethyl.
  • 15. The composition of claim 10, wherein R2 in the compound of formula I is hydrogen.
  • 16. A method for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, wherein the mutation is G143A, comprising applying a pesticidally effective amount of compound of formula (I) according to claim 2.
  • 17. The method of claim 16, wherein the phytopathogenic fungi are selected from the group consisting of Alternaria alternata, Blumeria graminis, Pyricularia oryzae, Septoria tritici, Mycosphaerella fijiensis, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis and Plasmopara viticola.
  • 18. The method of claim 17, wherein the phytopathogenic fungus is Septoria tritici.
  • 19. The method of claim 16, comprising: treating the phytopathogenic fungi or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi with an effective amount of at least one compound of formula I, or a composition comprising it thereof.
  • 20. The method of claim 19, comprising: a) identifying the phytopathogenic fungi, or the materials, plants, the soil or seeds that are at risk of being diseased from phytopathogenic fungi, and
  • 21: Agrochemical compositions wherein said compositions comprise an auxiliary and at least one compound of formula (I): wherein:R1 and R2 together with the two carbon atoms linking them form a phenyl ring andR4 is 4-methyl-1,4-dihydro-tetrazol-5-one-1 yl, and wherein the abovementioned phenyl ring may carry 1, 2, 3 or up to the maximum number of identical or different groups Ra which independently of one another are selected from:Ra CN, nitro, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl and C1-C4-haloalkoxy;Y is a direct bond or a divalent group selected from —CH2—, —CH2CH2—, —C(Z)═N—O—CH2—, —CHZ—C(Z)═N—O—CH2—, —O—N═C(Z)—C(Z)═N—O—CH2—, —C(═O)—C(Z)═N—O—CH2— and —C(═N—O—Z)—C(Z)═N—O—CH2—,where the bond depicted on the left side of the divalent group Y is attached to R3, and the bond depicted on the right side is attached to the carbon atom being substituted by R2, andZ which may be the same or different to any other Z, is hydrogen, C1-C4-alkyl or C1-C4-haloalkyl;R3 is
  • 21: The agrochemical compositions of claim 20, wherein the further active substance is pyraclostrobin.
  • 22: The agrochemical compositions of claim 20, wherein the further active substance is selected from benzovindiflupyr, bixafen, boscalid, fluopyram, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane; ametoctradin and fluazinam.
  • 23: The agrochemical compositions of claim 8, wherein the further active substance is prothioconazole.
  • 24: The agrochemical compositions of claim 20, which comprise one compound of formula I as component 1) and one further active substance as component 2) and wherein the weight ratio of component 1) and component 2) is in the range of 1:20 to 20:1.
Priority Claims (2)
Number Date Country Kind
11195032.5 Dec 2011 EP regional
12190109.4 Oct 2012 EP regional
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/054,828, filed Feb. 26, 2016, the entire contents of which is hereby incorporated herein by reference. U.S. application Ser. No. 15/054,828, is a continuation of U.S. application Ser. No. 14/364,532, filed Jun. 11, 2014 (now U.S. Pat. No. 9,271,501), the entire contents of which is hereby incorporated herein by reference. U.S. application Ser. No. 14/364,532, is the National Stage application of International Application No. PCT/EP2012/074586, filed Dec. 6, 2012, the entire contents of which is hereby incorporated herein by reference. U.S. application Ser. No. 14/364,532, also claims priority under 35 U.S.C. § 119 to European Patent Application No. 11195032.5, filed Dec. 21, 2011, and to European Patent Application No. 12190109.4, filed Oct. 26, 2012, the entire contents of each are hereby incorporated herein by reference.

Continuations (2)
Number Date Country
Parent 15054828 Feb 2016 US
Child 16112176 US
Parent 14364532 Jun 2014 US
Child 15054828 US